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Food, by nature, is a biological substrate and is therefore capable of supporting the growth of
microbials that are potential producers of toxic compounds. Natural toxins include mycotoxins, marine
biotoxins, plant toxins, cyanogenic glycosides, and toxins occurring in poisonous mushrooms. Natural
toxins pose not only a risk to both human and animal health, but also impact food security and nutrition
by reducing people’s access to healthy food. The tracking and detection of natural toxins in foods
back to their source is a primary responsibility of food producers, distributors, handlers, and vendors.
National authorities should conduct monitoring and ensure that levels of the most relevant natural
toxins in food commodities comply with both national and international maximum levels or relevant
toxicological thresholds.
This Special Issue of Toxins includes some recent advances in analytical methodologies for the
detection of natural toxins in food commodities and biological fluids. The collected contributions
are relevant to two main analytical approaches, namely advanced liquid chromatography–tandem
mass spectrometry (LC-MS/MS) applications for the high sensitive and selective detection of emerging
contaminants, and approaches for rapid and cost effective toxin detection based on immunoassays and
cell-based assays.
The phytotherapeutic and nutritional use of plants and herbal-based products have increased in
popularity over the last few years, however the improper usage of plants or unawareness of plant
toxicity may lead to intoxication cases. Nowadays, highly sensitive and selective LC-MS/MS techniques
represent a relatively easy to access and powerful tool to target plant toxins at low levels, and as a
consequence, contaminants such as pyrrolizidine alkaloids and cardiac glycosides have surfaced as an
issue of relevance in food safety.
A method for the determination of pyrrolizidine alkaloids in honey has been set up by
Hungerford et al. [1]. The study includes the results of a large survey on honey samples from
Queensland (Australia), providing a picture of pyrrolizidine alkaloids incidence and levels and a
possible correlation with their plant origin. Malysheva et al. proposed a new LC-MS/MS method
for the quantification of cardiac glycosides in edible herbs and spices and, complementary to this,
in human urine [2]. The results of the validation indicated that the developed method is able to detect
and quantify the target cardiac glycosides at low levels making it suitable for application in food safety
controls and analysis of human biological fluids to unravel the level of exposure to plant toxins.
Among the readily available in vitro methods, the functional assay known as the cell-based assay,
which uses a neuroblastoma (N2a) cell line, is widely applied for routine surveillance of marine toxins.
In their study, Viallon et al. optimized several key parameters of the cell-based assay, improving
assay implementation and reliable toxin detection, making the final protocol suitable for future
standardization and interlaborarory comparisons [3].
The overall performances of immunoassays strongly depend on the quality of selected
immunoreagents, first of all, of the antibody. For this reason, the development and testing of
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new antibodies continues to warrant considerable efforts in current research. Maragos et al. proposed
a new competitive enzyme-linked immunosorbent assay (ELISA) to screen for citreoviridin and its
geometric isomer, iso-citreoviridin, in white rice based upon the isolation of two novel monoclonal
antibodies [4]. The developed assays were relatively tolerant to methanol and acetonitrile and provided
adequate analytical performances such as sensitivity, accuracy and precision, allowing for the screening
of citreoviridin and iso-citreoviridin at levels that are toxicologically relevant. Studies by Bever et al.
deal with the generation of novel monoclonal antibodies and their application in a competitive ELISA
and a lateral flow immunoassay (LFIA) for the detection of amatoxins, lethal toxins found in a variety
of mushroom species. The developed assays are intended for the screening of wild mushrooms
(ELISA) and urine samples (LFIA), thus providing complementary tools for evaluating amatoxins
occurrence and geographic distribution as well as directly determining amatoxin exposure of humans
and animals [5,6].
When applying rapid screening tests for compliance testing, their fitness for purpose needs to be
demonstrated through a validation study. The manuscript by Pecorelli et al. provides insights about
the process of evaluating and comparing the performance profile of rapid methods currently applied
for AFM1 screening in milk [7]. Addressing EU official guidelines, the analytical performances of the
strip test and ELISA-based methods were evaluated, including verification of method performances
through long-term quality control measurements and comparison with the AOAC reference method.
Antibodies as well as alternative receptors, such as aptamers, can be used in several biosensing
platforms. The review by Zhuheng Li et al. updates the construction strategies of electrochemical
biosensors such as immunosensors and aptasensors for the cost-effective determination of microbial
toxins including bacterial toxins, fungal toxins and algal toxins [8]. The paper summarizes the roles
of 2D nanomaterials and their nanocomposites in the configuration of electrochemical biosensors,
while also discussing advantages, major challenges and perspectives of these electrochemical biosensors
for future commercialization.
Overall, the papers included in this Special Issue have contributed to advance the state-of-art of
analytical methods for the detection of natural toxins. Furthermore, a part of the published studies
focused on emerging or less investigated toxins, thus providing the scientific community with new
tools and/or data supporting a better understanding of related food safety issues.
Funding: This research received no external funding.
Acknowledgments: The editor wishes to aknowledge all authors who contributed to this Special Issue and the
expert peer reviewers performing careful and rigorous evaluations. The valuable contribution and editorial
support of the MDPI management team and staff is also aknowledged.
Conflicts of Interest: The author declares no conflict of interest.
References
1. Hungerford, N.L.; Carter, S.J.; Anuj, S.R.; Tan, B.L.L.; Hnatko, D.; Martin, C.L.; Sharma, E.; Yin, M.;
Nguyen, T.T.P.; Melksham, K.J.; et al. Analysis of Pyrrolizidine Alkaloids in Queensland Honey: Using Low
Temperature Chromatography to Resolve Stereoisomers and Identify Botanical Sources by UHPLC-MS/MS.
Toxins 2019, 11, 726. [CrossRef] [PubMed]
2. Malysheva, S.V.; Mulder, P.P.J.; Masquelier, J. Development and Validation of a UHPLC-ESI-MS/MS Method
for Quantification of Oleandrin and Other Cardiac Glycosides and Evaluation of Their Levels in Herbs and
Spices from the Belgian Market. Toxins 2020, 12, 243. [CrossRef] [PubMed]
3. Viallon, J.; Chinain, M.; Taiana Darius, H. Revisiting the Neuroblastoma Cell-Based Assay (CBA-N2a) for
the Improved Detection of Marine Toxins Active on Voltage Gated Sodium Channels (VGSCs). Toxins 2020,
12, 281. [CrossRef] [PubMed]
4. Maragos, C.M.; Uchiyama, Y.; Kobayashi, N.; Kominato, F.; Sugita-Konishi, Y. Development and
Characterization of Monoclonal Antibodies for the Mycotoxin Citreoviridin. Toxins 2019, 11, 630. [CrossRef]
[PubMed]
2
Toxins 2020, 12, 467
5. Bever, C.S.; Hnasko, R.M.; Cheng, L.W.; Stanker, L.H. A Rapid Extraction Method Combined with a
Monoclonal Antibody-Based Immunoassay for the Detection of Amatoxins. Toxins 2019, 11, 724. [CrossRef]
[PubMed]
6. Bever, C.S.; Swanson, K.D.; Hamelin, E.I.; Filigenzi, M.; Poppenga, R.H.; Kaae, J.; Cheng, L.V.; Stanker, L.H.
Rapid, Sensitive, and Accurate Point-of-Care Detection of Lethal Amatoxins in Urine. Toxins 2020, 12, 123.
[CrossRef] [PubMed]
7. Pecorelli, I.; Guarducci, N.; von Holst, C.; Bibi, R.; Pascale, M.; Ciasca, B.; Logrieco, A.F.; Lattanzio, V.M.T.
Critical Comparison of Analytical Performances of Two Immunoassay Methods for Rapid Detection of
Aflatoxin M1 in Milk. Toxins 2020, 12, 270. [CrossRef] [PubMed]
8. Li, Z.; Li, X.; Jian, M.; Selale Geleta, G.; Wang, Z. Two-Dimensional Layered Nanomaterial-Based
Electrochemical Biosensors for Detecting Microbial Toxins. Toxins 2020, 12, 20. [CrossRef] [PubMed]
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Analysis of Pyrrolizidine Alkaloids in Queensland
Honey: Using Low Temperature Chromatography to
Resolve Stereoisomers and Identify Botanical Sources
by UHPLC-MS/MS
Natasha L. Hungerford 1,*, Steve J. Carter 2, Shalona R. Anuj 2, Benjamin L. L. Tan 2,
Darina Hnatko 2, Christopher L. Martin 1, Elipsha Sharma 1, Mukan Yin 1, Thao T. P. Nguyen 1,
Kevin J. Melksham 2 and Mary T. Fletcher 1,*
1 Queensland Alliance for Agriculture and Food Innovation (QAAFI), The University of Queensland,
Brisbane, QLD 4072, Australia; christopherlancemartin@gmail.com (C.L.M.); e.sharma@uq.net.au (E.S.);
mukan.yin@uq.net.au (M.Y.); tran.nguyen7@uq.net.au (T.T.P.N.)
2 Forensic and Scientific Services, Queensland Health, Brisbane, QLD 4108, Australia;
steve.carter@health.qld.gov.au (S.J.C.); shalona.anuj@health.qld.gov.au (S.R.A.);
benjamin.tan@health.qld.gov.au (B.L.L.T.); Darina.Hnatko@health.qld.gov.au (D.H.);
Kevin.Melksham@health.qld.gov.au (K.J.M.)
* Correspondence: n.hungerford@uq.edu.au (N.L.H.); mary.fletcher@uq.edu.au (M.T.F.)
Received: 25 October 2019; Accepted: 26 November 2019; Published: 11 December 2019
Abstract: Pyrrolizidine alkaloids (PAs) are a diverse group of plant secondary metabolites with
known varied toxicity. Consumption of 1,2-unsaturated PAs has been linked to acute and chronic
liver damage, carcinogenicity and death, in livestock and humans, making their presence in food of
concern to food regulators in Australia and internationally. In this survey, honey samples sourced
from markets and shops in Queensland (Australia), were analysed by high-resolution Orbitrap
UHPLC-MS/MS for 30 common PAs. Relationships between the occurrence of pyrrolizidine alkaloids
and the botanical origin of the honey are essential as pyrrolizidine alkaloid contamination at up
to 3300 ng/g were detected. In this study, the predominant alkaloids detected were isomeric PAs,
lycopsamine, indicine and intermedine, exhibiting identical MS/MS spectra, along with lesser amounts
of each of their N-oxides. Crucially, chromatographic UHPLC conditions were optimised by operation
at low temperature (5 ◦C) to resolve these key isomeric PAs. Such separation of these isomers by
UHPLC, enabled the relative proportions of these PAs present in honey to be compared to alkaloid
levels in suspect source plants. Overall plant pyrrolizidine alkaloid profiles were compared to
those found in honey samples to help identify the most important plants responsible for honey
contamination. The native Australian vines of Parsonsia spp. are proposed as a likely contributor to
high levels of lycopsamine in many of the honeys surveyed. Botanical origin information such as this,
gained via low temperature chromatographic resolution of isomeric PAs, will be very valuable in
identifying region of origin for honey samples.
Keywords: LC-MS; pyrrolizidine alkaloid; honey; Parsonsia straminea; lycopsamine; indicine;
Heliotropium amplexicaule
Key Contribution: This study demonstrated the occurrence of indicine and the isomeric lycopsamine
as predominant pyrrolizidine alkaloids in Australian honey; and established a HRAM LC-MS/MS
method that chromatographically separated these stereoisomers; enabling the investigation of
botanical origin of honey contamination by the respective alkaloids.
Toxins 2019, 11, 726; doi:10.3390/toxins11120726 www.mdpi.com/journal/toxins5
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1. Introduction
Pyrrolizidine alkaloids (PAs) are secondary metabolites that comprise more than 600 compounds,
typified by a pyrrolizidine base with one or more ester linkages. The 1,2-unsaturated PAs are
toxic to animals and humans, causing acute and chronic liver and lung damage or cancer and are
mainly produced by flowering plant species belonging to the families Asteracaeae (Compositae, tribes
Senecioneae and Eupatorieae), Fabaceae (Crotolaria, Chromolaena, Lotonis), Apocynaceae (Echiteae)
and Boraginaceae [1], estimated to represent 3% of the Earth’s flowering plants [2]. Plants containing
pyrrolizidine alkaloids are globally distributed and PAs provide a chemical defence for plants against
herbivores. PA biosynthesis has been found to be dependent on many factors, with implications for
plant/animal/insect interactions [3]. Various food products can contain toxic PAs either directly from
plant origin (certain herbs, herbal medicines) or indirectly through natural transfer from floral nectar
and pollen (e.g., some honey, pollen dietary supplements) or inadvertent cross-contamination (e.g.,
grains, herbs, teas) [4]. The Australian provisional tolerable daily intake of pyrrolizidine alkaloids is
1 μg/kg Bw/day [5], whilst the recommended European accepted intake is 150 times lower at 0.007
μg/kg Bw/day [6–8], although this has been recently revised [9,10].
Several studies have described the presence of toxic pyrrolizidine alkaloids (PAs) in honey
produced by Apis mellifera. Internationally it has been reported that such toxins can be found in
honey due to transfer by bees of pollen/nectar from certain flowers, including Heliotropium, Crotolaria,
Echium and Senecio species. Concern has been raised as to the extent of contamination in Australian
honey [11,12] but their presence in Queensland honey has not previously been examined. Previously,
investigations into the presence of PAs in Australian honey have concentrated on the introduced
pest plant Echium plantagineum L. (Paterson’s curse) as the major likely PA source [11–13]. However,
rigorous eradication and biological control programs in recent decades have decreased the prevalence
of this weed in Australia [14]. Diverse PA containing plant species occur in Australian pastures and
have intoxicated grazing horses, cattle, sheep or pigs and poultry fed contaminated grains [15,16] and
include both native and introduced Crotalaria, Heliotopium and Senecio species [17]. Additionally, native
Australian Parsonsia species grow in rainforests and on the margins of rainforest/eucalypt forest and
contain PAs known to be sequestered by butterflies [18–20]. Parsonsia species spread from tropical and
subtropical Asia to Australia and the south-west Pacific. Parsonsia straminea is native to Queensland
and New South Wales [21] but there have been no field reports of livestock poisonings [17]. The
distribution of these PA containing plants varies throughout the country and different alkaloids would
be expected in honey from tropical/sub-tropical Queensland regions as compared to honey originating
from southern temperate states. Given that honey represents a significant food source of human
exposure to PAs [10], identification of plant PA sources to reduce this exposure is crucial.
In this study of market honey, samples have been identified with alkaloid profiles that appeared to
be consistent with a number of PA containing plant species present within the Australian environment.
This study examines the presence of PAs in a market survey of honey purchased in Queensland with
the aim to assess any food safety concern for the consumer of honey and to correlate PAs identified
with previously unsuspected plant sources of these alkaloids.
2. Results and Discussion
2.1. Pyrrolizidine Analysis Method Validation
Pyrrolizidine alkaloid levels in honey/plant material were quantitated by HRAM UHPLC-MS/MS
analysis against 30 certified PA standards, through comparison of the precursor parent ion intensity
(Table 1) to the standard curves, with squared correlation coefficients (R2) typically in the range of
0.9932–0.9997. The honey analysis method was validated according to the National Association of
Testing Authorities (NATA) guidance document [22]. The method was validated in blank honey,
based on results for 10 spiked samples, giving Limits of Reporting (LORs) of 5 ng/g for individual
PAs (Table 2). The uncertainties given are at the 95% confidence level as required by NATA [22,23].
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Note that for multiresidue analyses at these levels, a default standard uncertainty of ±25% RSD at
the 95% confidence level is routinely applied by the authors and is used unless there is evidence that
the actual uncertainty is greater than this value. Erucifoline, erucifoline N-oxide, jacobine N-oxide
and seneciphylline N-oxide consistently gave low recoveries, resulting in high calculated standard
uncertainty (% RSD) for these PAs, but which are not unusual for analyses at these levels. The EU
recommends ±50% RSD unless it is demonstrated to be a bigger value [24]. The uncertainty values are
calculated at the LOR because it is expected that this level will be the worst case scenario. A small peak
was present in the blank for trichodesmine, explaining the higher LOD/LOR and increased uncertainty
for this compound.
Table 1. Details of pyrrolizidine alkaloids used in the Orbitrap analysis of PA containing plants and








Echimidine (7) C20H31NO7 12.86 398.2173 120.0809 83.0497 55.0550
Echimidine N-oxide C20H31NO8 12.80 414.2122 396.2004 352.1745 254.1379 220.1326 137.0833
Erucifoline C18H23NO6 6.23 350.1598 322.1642 220.1329 164.1066 138.0911 120.0807
Erucifoline N-oxide C18H23NO7 8.03 366.1547 278.1386 218.1172 164.1067 136.0756 119.0729
Europine C16H27NO6 6.97 330.1911 254.1385 156.1019 138.0914 120.0810 96.0812
Europine N-oxide C16H27NO7 7.86 346.1860 328.1743 270.1328 256.1172 172.0964 155.0937
Helioamplexine C16H27NO5 9.21 314.1962 156.1017 138.0913 120.0808 94.0655
Helioamplexine
N-oxide C16H27NO6 10.42 330.1911 172.0966 155.0938 138.0913 111.0913 94.0653
Heliotrine C16H27NO5 9.56 314.1962 156.1017 138.0913 120.0808 94.0655
Heliotrine N-oxide C16H27NO6 10.46 330.1911 172.0966 155.0938 138.0913 111.0913 94.0653
Indicine (2) C15H25NO5 6.67 300.1806 156.1019 138.0914 120.0810 94.0656 82.0657
Indicine N-oxide (5)
and intermedine
N-oxide (4) (n.r.) a
C15H25NO6 8.20 316.1755 226.1437 172.0968 155.0941 138.0914 111.0682 94.0656
Intermedine (1) C15H25NO5 6.26 300.1806 210.1488 156.1019 138.0914 120.0810 94.0656
Jacobine C18H25NO6 6.56 352.1755 308.1485 280.1539 262.1432 234.1483 155.1063
Jacobine N-oxide C18H25NO7 7.91 368.1704 296.1485 190.1222 139.0989 121.0885 120.0807
Lasiocarpine C21H33NO7 14.92 412.2330 238.1435 156.1020 138.0914 120.0810 94.0656
Lasiocarpine N-oxide C21H33NO8 16.14 428.2279 410.2168 352.1746 328.1753 254.1384 220.1333 137.0835
Lycopsamine (3) C15H25NO5 6.80 300.1806 156.1017 138.0914 120.0808 94.0655
Lycopsamine N-oxide
(6) C15H25NO6 8.65 316.1755 172.0964 155.0937 138.0911 136.0755 94.0654
Monocrotaline C16H23NO6 2.88 326.1598 280.1548 237.1354
Monocrotaline
N-oxide C16H23NO7 7.19 342.1547 314.1590 296.1487 236.1274 137.0833 119.0729
Retrorsine C18H25NO6 9.13 352.1755 324.1802 138.0913 120.0808 94.0655
Retrorsine N-oxide C18H25NO7 9.64 368.1704 220.1340 154.0862
Senecionine C18H25NO5 11.13 336.1806 308.1864 120.0809
Senecionine N-oxide C18H25NO6 11.83 352.1755 324.1825 220.1332
Seneciphylline C18H23NO5 9.52 334.1649 306.1706 120.0811
Seneciphylline
N-oxide C18H23NO6 10.46 350.1598 322.1656 246.1495
Senecivernine C18H25NO5 10.84 336.1806 308.1848 153.0907 138.0911 120.0807 94.0654
Senecivernine N-oxide C18H25NO6 11.45 352.1755 324.1795 220.1327 154.0859 136.0755 120.0807
Senkirkine C19H27NO6 13.62 366.1911 168.1020 150.0915
Trichodesmine C18H27NO6 8.79 354.1911 308.1857 223.1203 222.1489 164.1071 121.0889
a n.r. = not resolved.
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Echimidine (7) 5 0.7 2 5 ng/g 88 11
Echimidine N-oxide 5 0.5 2 5 ng/g 60 15
Erucifoline 5 0.7 2 5 ng/g 34 26
Erucifoline N-oxide 5 0.5 2 5 ng/g 26 31
Europine 5 1 2 5 ng/g 98 16
Europine N-oxide 5 0.5 1 5 ng/g 94 6
Heliotrine 5 0.5 0.7 5 ng/g 108 4
Heliotrine N-oxide 5 0.2 0.5 5 ng/g 83 2
Indicine 5 0.5 2 5 ng/g 98 8
Indicine N-oxide (5) and
intermedine N-oxide (4)
as indicine N-oxide (5)
5 0.5 1 5 ng/g 78 7
Intermedine (1) 5 0.5 2 5 ng/g 94 8
Jacobine 5 2 5 5 ng/g 61 30
Jacobine N-oxide 5 1 5 5 ng/g 36 51
Lasiocarpine 5 0.5 1 5 ng/g 82 6
Lasiocarpine N-oxide 5 0.5 0.7 5 ng/g 79 6
Lycopsamine (3) 5 0.2 0.7 5 ng/g 95 4
Lycopsamine N-oxide (6) 5 0.7 2 5 ng/g 81 14
Monocrotaline 5 2 5 5 ng/g 89 24
Monocrotaline N-oxide 5 0.7 2 5 ng/g 89 13
Retrorsine 5 1 2 5 ng/g 96 13
Retrorsine N-oxide 5 0.7 2 5 ng/g 58 22
Senecionine 5 0.7 2 5 ng/g 90 11
Senecionine N-oxide 5 0.5 2 5 ng/g 58 16
Seneciphylline 5 0.7 2 5 ng/g 70 15
Seneciphylline N-oxide 5 0.5 1 5 ng/g 16 36
Senecivernine 5 0.5 2 5 ng/g 86 9
Senecivernine N-oxide 5 0.7 2 5 ng/g 53 20
Senkirkine 5 0.5 0.7 5 ng/g 91 5
Trichodesmine 5 3 7 7 ng/g 78 69
2.2. Alkaloid Levels Measured in Honey
Honeys purchased in supermarkets, health food shops, and from individual
commercial/small-scale producers were analysed and calculated to contain pyrrolizidine alkaloids
levels between <LOR (i.e., below limit of reporting) to ≈3300 ng/g of honey.
Figure 1 summarises the results in a histogram, with single PA test results below the limit of
reporting (5 ng/g) set equal to zero. PAs were detected in 84% of the honey samples examined (n = 465).
Notably the mean total PA level of PA-positive samples (280 ng/g) was greater than the median (97 ng/g),
indicating that the distribution was skewed, with a prevalence of low values (Figure 1, histogram).
Whilst the prevalence of low values is reassuring, the overall distribution of total PA concentration is
wide, ranging from <LOR to ≈3300 ng/g.
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Figure 1. Histogram showing the frequency of total pyrrolizidine alkaloid concentrations in
honey samples (n = 465) analysed against all 30 pyrrolizidine alkaloid standards (and isolated
helioamplexine [25]).
2.3. LC-MS/MS Separation of Alkaloids
Analysis revealed that the individual PA pattern detected by the LC-MS/MS analysis of honeys
was characterised almost exclusively by lycopsamine-type PAs. In this study the lycopsamine-type
PAs were represented by standards intermedine (1), indicine (2) and lycopsamine (3) (Figure 2). These
diastereomeric PAs cannot be distinguished based on their MS/MS spectra [26], and Figure 3 shows
the identical mass spectra obtained for standards intermedine (1), indicine (2) and lycopsamine (3)
by our described HRAMS method. Given the diastereomeric nature of these alkaloids all parent
MH+ ions and fragment ions are identical, even with HRAMS. Separation based on retention time
(RT) was therefore necessary in order to ascertain the botanical origin of PA contamination in these
honeys. In most previous studies of PAs in honey, lycopsamine-type PAs were reported as the sum of
unresolved stereoisomers, (including indicine (2), intermedine (1) and/or lycopsamine (3), and even the
less common rinderine and echinatine) [27–30] or partially resolved stereoisomers [8,31–33]. Under our
initial UHPLC conditions, with a column oven temperature of 40 ◦C, intermedine (1) eluted separately
first, but indicine (2) and lycopsamine (3) co-eluted from the Kinetex XB-C18 UHPLC column. Notably
the combined indicine/lycopsamine (2/3) peak represented 75% of the alkaloids present in Queensland
honey. As these two alkaloids originate from distinctly different PA plant sources, our aim was to be
able to separately quantify the levels of each of these PAs in honey to enable the major plant source of
PA contamination to be identified.
9
Toxins 2019, 11, 726
Figure 2. Structures of predominant PAs (1–8) observed in honey (n = 465), together with structures of
minor components tentatively observed in Parsonsia straminea (9–10).
Figure 3. Stereoisomeric pyrrolizidine alkaloids (a) intermedine (1), (b) indicine (2), and (c) lycopsamine
(3), with identical high resolution accurate mass spectra.
Ultimately, separation of indicine/lycopsamine (2/3) was achieved by simply adjusting the column
temperature to 5 ◦C. A more complicated ‘multiple heart-cutting two dimensional chromatography’
method has previously been reported for the resolution of multiple PA isomer pairs [34], but in
our hands the simple gradient elution at 5 ◦C was sufficient to achieve our desired resolution of
indicine/lycopsamine (2/3). Under these conditions, of the 30 PAs and PA-NOs all were resolved based
on retention time or mass fragmentation of the MS/MS except for intermedine N-oxide (4) and indicine
N-oxide (5) which displayed identical RT and MS/MS (Figure 4). In plants where these N-oxides (4)
and (5) are prevalent, the N-oxides could be distinguished by reduction to the corresponding parent
alkaloid (2/3) which were resolved by RT under the described conditions.
10
Toxins 2019, 11, 726
Figure 4. Extracted ion chromatogram of the 30 pyrrolizidine alkaloid calibration standards, illustrating
the separation obtained under the UHPLC method, with column temperature of 5 ◦C.
2.4. Predominant Alkaloids Present in Queensland Honeys
Analysis of all 465 honeys under our optimised LC-MS/MS conditions revealed that the
predominant pyrrolizidine alkaloid present in our Queensland honey samples was lycopsamine
(3), which represented approximately 51% of the measured alkaloid content, followed by indicine (2) at
24%, lycopsamine N-oxide (6) at 9%, intermedine (1) at 6% and echimidine (7) at 3% (Figure 5). Even
though we did not resolve intermedine N-oxide (4) and indicine N-oxide (5), the identity of the minor
N-oxide in individual honey samples was inferred by the presence of the co-occurring parent alkaloid
(either intermedine (1) or indicine (2)).
In individual honeys, lycopsamine (3) was detected at up to ≈3100 ng/g, indicine (2) at up to
1700 ng/g, with the highest total PA content in any individual honey of ≈3300 ng/g which contained
mainly a mixture of lycopsamine (3) and lycopsamine N-oxide (6).
Figure 5. Total amount of each pyrrolizidine alkaloid detected against the 30 PA standards.
Figure 6 shows a Tukey box and whisker plot of the pyrrolizidine alkaloids detected in honeys
(n = 465), showing the distribution of each PA concentration, for positive samples only. The largest
variation was observed for lycopsamine (3), indicine (2) and lycopsamine N-oxide (6). In honeys where
lycopsamine (3) and its N-oxide (6) were abundant these were generally the dominant PAs (>90% of
PAs detected).
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Figure 6. Tukey box and whisker plot of distribution of each pyrrolizidine alkaloid detected in honey
(n = 465) (includes results >5 ng/g only).
Similarly, in honeys where indicine (2) and its N-oxide (5) were abundant these were generally
the dominant PAs (>68% of PAs detected). In order to explain the relative predominance of these
diastereomeric PAs in different honeys, it was clear that we had to identify two main and distinctly
different PA plant sources.
2.5. Plant Sources of Indicine (2) in Honey
An examination of the locally abundant weed Heliotropium amplexicaule (Blue heliotrope) by
our LC-MS/MS method revealed that indicine (2) and indicine N-oxide (5) were the predominant
pyrrolizidine alkaloids in this plant, and examination of more minor components including the newly
identified helioamplexine (8) provided a unique fingerprint in the HRAM LC-MS/MS profile [25].
Interrogation of the pyrrolizidine alkaloid profile from market honey samples with high amounts of
indicine (2), demonstrated that there was strong correlation between the honey PA profile and the H.
amplexicaule plant alkaloid profile. The presence of both major and minor H. amplexicaule alkaloids
in this honey provided strong evidence that this plant represented the floral source for this alkaloid
contamination [25].
2.6. Plant Sources of Lycopsamine (3) in Honey
We similarly sought to understand the source of lycopsamine (3) (and its N-oxide (6)), the major
PA observed in Queensland honey. Examination of the PAs co-occurring with lycospamine (3) and
lycopsamine N-oxide (6), in the source plant would enable us to establish a unique floral PA fingerprint
that could be correlated with PAs observed in honey. In past studies, Echium plantagineum L. (Paterson’s
curse) has been named as the source of lycopsamine (3) in Australian honey [35], despite the fact
lycopsamine (3) is usually only a minor alkaloid in Echium spp. [11,27,36,37]. In fact, a previous
European study noted the presence of high amounts of lycopsamine (3) (607 ng/g) compared to low
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amounts of echimidine (7) (15 ng/g) in imported Australian honeys, and postulated an unknown
plant source as a possible interpretation [27]. Indeed our analysis of E. plantagineum revealed that
after Zn reduction echimidine (7) and echiumine were the dominant PAs, with both lycopsamine
(3) and intermedine (1) present in much lower quantities. Clearly E. plantagineum is not the major
source of lycopsamine (3) seen in our Queensland honeys, which is also consistent with the more
temperate distribution of this species within Australia [38]. Other species/genera known internationally
to contain lycopsamine (3) (and intermedine (1)) include Anchusa off., Borago off., Lithospermum spp.,
and Symphytum spp., and Eupatorium spp. [39], and are generally not geographically distributed within
Australia [40]. They can logically be excluded as potential lycopsamine (3) floral sources.
When considering PA species which are known to be prevalent in Queensland, both Ageratum
and Aminscka spp. have been reported to contain lycopsamine (3). Ageratum conyzoides for
example has been reported to contain lycopsamine (3) and echinatine [41,42] or lycopsamine (3)
and 3′-O-acetyllycopsamine [43]. A targeted screen by Avula reported lycopsamine (3) and its N-oxide
(6) as the two major PAs, together with minor amounts of dihydrolycopsamine, dihydrolycopsamine
N-oxide and echinatine [1,44]. The closely related Ageratum houstonianum is locally abundant in
Queensland, and our analysis of Zn reduced plant extract revealed the predominance of retrohoustine,
heliohoustine and tentatively echinatine (ratio 2.7:1.7:1 respectively), with much lower amounts of
lycopsamine (3) and intermedine (1) (data not shown). This result is consistent with analysis of this same
species from Mexico that showed that lycopsamine (3) was not the predominant pyrrolizidine alkaloid
present with three other pyrrolizidine alkaloids (retrohoustine, heliohoustine and isoretrohoustine)
isolated in greater amounts than lycopsamine (3) [45]. Lycopsamine (3) and intermedine (1) have
also been identified in Amscinckia spp. [46], with NMR analysis revealing the relative proportion of
intermedine (1) to lycopsamine (3) varied from roughly 2:1 to 1:2 in A. intermedia, A. hispida, and A.
lycopsoides. Amsinckia spp. are however regionally controlled as noxious weeds in Australia, and not
likely to be a widely abundant PA sources in Queensland. The invasive aquatic weed Gymnocoronis
spilanthoides has been recently been shown [47] to contain predominantly lycopsamine (3) followed
by intermedine (1), however, this species is also controlled by government eradication programs.
None of these plant species matched either the predominant lycopsamine (3) profile observed in our
Queensland sourced honey or the regional abundance of plant species.
Historically lycopsamine (3) was identified in the hair pencil of Australian danaid butterflies
in Queensland in a region where Amsinckia plants are rare [48]. An examination of the native vines
Parsonsia straminea (family Apocynaceae) and Parsonsia eucalyptophylla, by these authors revealed
the presence of lycopsamine (3) and intermedine/indicine (1 or 2), and acetyl derivatives. As native
Parsonsia species occur widely in Queensland this species was deduced as the source of lycopsamine
(3) in danaid butterflies [49]. Lycopsamine-type PAs have been identified in a number of species in
Apocynaceae [50].
Interestingly, in a study of butterfly food plants, a comparison of Parsonsia straminea flowers
revealed the ratio of lycopsamine N-oxide (6) to intermedine N-oxide (4) to other alkaloids of 98:1:1.
By contrast, Ageratum sp. gave a predominance of two M+ 269 isomers compared to lycopsamine (3)
(45:48:1) [51]. Evidently, lycopsamine (3) and intermedine (1) and their N-oxides are present in a wide
variety of plant species, but we sought to identify an origin for the almost exclusive predominance of
lycopsamine (3) (and its N-oxide (6)) and these literature reports of Parsonsia provided the best clue.
2.7. Pyrrolizidine Alkaloids Determined in Parsonsia Vines
Local Parsonsia straminea (Qld Herbarium ID AQ522465) was collected and re-examined for PA
content using our described HRAM LC-MS/MS method. The plant pyrrolizidine alkaloids were present
primarily as the N-oxides (96% in the leaves and stems, 99% in the pods, 93% in the nectar and 80% in
the pollen). The plant pyrrolizidine alkaloids were analysed with and without reduction by Zn to enable
comparison with the honey alkaloids (primarily free alkaloids) as previously observed [25,52]. The SCX
SPE methodology was previously demonstrated to be suitable for plant extracts [36]. The investigations
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aimed to determine for the first time whether and to what extent PAs found in honey are sourced from
Parsonsia straminea (or closely-related Parsonsia species, a number of which are widespread in coastal
regions of eastern Australia [53]). High resolution accurate mass (HRAM) data, combined with RT
comparison with pyrrolizidine alkaloids standards enabled identification of the major pyrrolizidine
alkaloids in P. straminea (Table 3).
Table 3. High resolution accurate mass (HRAM) data for pyrrolizidine alkaloids in P. straminea identified










Mass Spectral Data (Rel. Int. %)
Intermedine (1) 6.27 [C15H25NO5 + H] + 300.1805 300.1804
300.1804 (6) 256.1539 (1) 156.1019
(53) 139.0992 (11) 138.0914 (31)
120.0809 (18) 112.0759 (2) 108.0811
(2) 96.0812 (4) 95.0733 (4) 94.0656
(100) 82.0657 (4)
Lycopsamine (3) 6.80 [C15H25NO5 + H] + 300.1805 300.1805
300.1805 (9) 256.1539 (0.3) 156.1020
(59) 139.0993 (13) 138.0915 (31)
120.0811 (19) 112.0760 (3) 108.0813
(1) 96.0813 (5) 95.0734 (5) 94.0656
(100) 82.0657 (6)
Intermedine
N-oxide (4) 8.19 [C15H25NO6 + H]
+ 316.1755 316.1752
316.1752 (41) 298.1631 (1) 272.1491
(2) 172.0967 (100) 155.0940 (18)
154.0862 (8) 138.0914 (55) 137.0837
(6) 136.0757 (15) 112.0759 (5)
111.0682 (12) 94.0655 (19) 93.0577
(13) 82.0419 (3)
Lycopsamine
N-oxide (6) 8.64 [C15H25NO6 + H]
+ 316.1755 316.1752
316.1752 (46) 298.1653 (1) 272.1491
(2) 172.0967 (100) 155.0940 (17)
154.0862 (10) 138.0913 (63)
137.0835 (6) 136.0758 (17) 112.0759
(5) 111.0681 (13) 94.0655 (22)
93.0577 (16) 82.0419 (4)
In the P. straminea nectar, the ratio of lycopsamine (3) and its N-oxide (6) to intermedine (1) and its
N-oxide (4) was >45–50:1, in the flowers it was 78:1, in anthers/pollen >50:1, in the pods it was >50:1,
whilst in the leaves, ~3:1.
Minor peaks after reduction were tentatively identified by analysis of the HRAM data
(Table 4) and corresponded to tessellatine (9) or isomer (a C7 isomer, found 300.1801, calculated
for C15H25NO5+H+: 300.1805), a further C9 lycopsamine isomer (found 300.1803, calculated for
C15H25NO5+H+: 300.1805), 3′-O-acetyllycopsamine (found 342.1905, calculated for C17H28NO6+H+:
342.1917), 3′-O-acetylintermedine (found 342.1924, calculated for C17H28NO6+H+: 342.1917) and two
helioamplexine isomers (found 314.1958 and 314.1958, calculated for C16H27NO5+H+: 314.1962). The
corresponding N-oxides were found in the non-reduced plant extract. Tessellatine (9) has the same
necic acid as lycopsamine (3) but is esterified at the C7 necine position rather than C9 as seen in
lycopsamine (3). The C7 esterification is evidenced in the predominant (base peak) fragment ion m/z
156.1019 (calculated for C8H14NO2+ 156.1019) characteristic of C7 monoesters [54,55], which display
much smaller peaks at m/z 138.0913, 120.0809 and 94.0656 than C9 monoesters lycopsamine (3)/indicine
(2)/intermedine (1). The diastereomeric 3′-O-acetyllycopsamine and 3′-O-acetylintermedine exhibited
a similar MS breakdown to that seen in 3′-O-angelylindicine [25], with a base peak of m/z 94.0655
and other typical peaks of C9 monoesters of retronecine, 156.1019, 138.0913 and 120.0809. In these
acetyl compounds, the lack of a peak at m/z 198.1125 and the lack of a base peak at m/z 214.1074 in
the corresponding N-oxides, excluded the 7-O-acetyl substitution pattern [1,56]. Similarly the two
helioamplexine isomers had identical MS to that seen in helioamplexine (8) (the C-6′ homoanalogue of
indicine) [25], and these components present in P. straminea which did not co-elute with helioamplexine
were deduced to be the corresponding C-6′ homoanalogues of lycopsamine and intermedine.
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Table 4. High resolution accurate mass (HRAM) data for pyrrolizidine alkaloids in P. straminea
identified by analysis of fragmentation patterns, together with those identified in honey samples high










Mass Spectral Data (Rel. Int. %)
* Tessellatine (9) or isomer 6.34 [C15H25NO5 + H] + 300.1805 300.1801
300.1801 (5) 156.1019 (100)
139.0990 (1) 138.0913 (6) 120.0809
(2) 112.0759 (4) 108.0810 (6)
96.0811 (1) 94.0656 (4) 82.0655 (1)
Lycopsamine isomer
(isomer of 3) 5.91 [C15H25NO5 + H]
+ 300.1805 300.1803
300.1803 (7) 210.1485 (1) 156.1019
(42) 139.0992 (14) 138.0914 (26)
120.0809 (18) 112.0759 (2) 108.0812
(2) 96.0813 (5) 95.0734 (6) 94.0656
(100) 82.0657 (5)
* Helioamplexine isomer I
(isomer of 8) 8.51 [C16H27NO5 + H]
+ 314.1962 314.1958
314.1958 (7) 270.1704 (0.5)
224.1643 (2) 156.1019 (44) 139.0992
(19) 138.0914 (25) 120.0810 (18)
112.0759 (2) 96.0812 (5) 95.0734 (8)
94.0656 (100) 82.0657 (7)
* Helioamplexine isomer II
(isomer of 8) 9.30 [C16H27NO5 + H]
+ 314.1962 314.1958
314.1960 (5) 270.1698 (0.5)
224.1643 (2) 156.1019 (33) 139.0992
(14) 138.0914 (25) 120.0809 (18)
112.0759 (2) 96.0812 (4) 95.0733 (7)
94.0656 (100) 82.0657 (6)
* Helioamplexine isomer
(C7-isomer of 8) 8.34 [C16H27NO5 + H]
+ 314.1962 314.1959
314.1959 (4) 156.1019 (100)
139.0992 (2) 138.0914 (6) 126.0916
(1) 120.0808 (2) 112.0759 (5)
108.0810 (10) 94.0655 (1) 86.0605
(2) 82.0656 (1) 80.0500 (1)
* 3′-O-Acetylintermedine 8.91 [C17H27NO6 + H] + 342.1911 342.1924
342.1924 (1) 282.1700 (4) 156.1019
(16) 139.0991 (7) 138.0913 (17)
120.0809 (20) 108.0812 (1) 96.0812
(2) 96.0450 (2) 95.0734 (3) 94.0655
(100) 82.0657 (3)
* 3′-O-Acetyllycopsamine 9.64 [C17H27NO6 + H] + 342.1911 342.1905
342.1905 (1) 282.1703 (2) 156.1019
(14) 139.0992 (3) 138.0913 (19)
120.0809 (19) 108.0812 (1) 96.0812
(2) 96.0448 (1) 95.0734 (2) 94.0655
(100) 82.0657 (3) 67.0549 (1)
Ideamine A (10) isomer I 2.43 [C14H23NO5 + H] + 286.1649 286.1648
286.1648 (11) 242.1392 (1) 196.1335
(2) 156.1019 (43) 139.0992 (11)
138.0914 (26) 120.0809 (18)
112.0758 (2) 108.0810 (2) 96.0813
(7) 95.0734 (5) 94.0656 (100)
82.0657 (5)
Ideamine A (10) isomer II 3.70 [C14H23NO5 + H] + 286.1649 286.1649
286.1649 (8) 156.1019 (35) 139.0992
(8) 138.0913 (30) 120.0808 (18)
96.0813 (4) 95.0734 (4) 94.0655
(100) 94.0593 (1) 82.0657 (3)
80.0500 (1) 67.0547 (1)
Ideamine A (10) isomer III 4.37 [C14H23NO5 + H] + 286.1649 286.1649
286.1649 (0) 156.1018 (46) 139.0992
(7) 138.0913 (26) 120.0807 (17)
98.2419 (3) 95.0733 (3) 94.0656
(100) 93.0705 (3) 82.0655 (4)
67.0549 (4)
Ideamine A (10) isomer IV 5.10 [C14H23NO5 + H] + 286.1649 286.1651
286.1651 (16) 258.9584 (3) 190.8082
(4) 188.1787 (3) 158.5305 (3)
156.1016 (48) 138.0913 (29)
124.0405 (3) 120.0807 (18) 94.0655
(100)
Ideamine A C7 isomer 1.72 [C14H23NO5 + H] + 286.1649 286.1656
286.1656 (10) 156.1019 (100)
138.0915 (5) 124.0757 (2) 120.0813
(1) 112.0760 (5) 108.0811 (7)
106.0656 (4) 94.0651 (2) 86.0603 (1)
Lycopsamine N-oxide
isomer 7.61 [C15H25NO6 + H]
+ 316.1755 316.1751
316.1754 (46) 172.0967 (100)
155.0940 (21) 154.0862 (13)
138.0914 (94) 137.0836 (8) 136.0757
(25) 112.0759 (8) 111.0681 (14)
108.0811 (6) 94.0656 (35) 93.0577
(24)
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Mass Spectral Data (Rel. Int. %)
7-Isomer of lycopsamine
N-oxide 7.19 [C15H25NO6 + H]
+ 316.1755 316.1751
316.1751 (5) 172.0968 (100)
155.0940 (6) 154.0863 (2) 138.0914
(3) 137.0836 (3) 136.0757 (2)
111.0681 (11) 106.0654 (6) 102.0555
(2) 94.0657 (1)
Helioamplexine N-oxide
isomer I 9.87 [C16H27NO6 + H]
+ 330.1911 330.1908
330.1908 (39) 286.1642 (4) 240.1594
(7) 172.0967 (100) 155.0940 (30)
154.0862 (11) 138.0914 (84)
136.0758 (22) 112.0760 (8) 111.0681
(18) 94.0655 (36) 93.0577 (20)
82.0419 (9)
Helioamplexine N-oxide
isomer II 10.63 [C16H27NO6 + H]
+ 330.1911 330.1909
330.1909 (46) 172.0967 (100)
155.0940 (30) 154.0862 (12)
138.0914 (91) 137.0835 (9) 136.0757
(23) 112.0759 (8) 111.0681 (20)
94.0655 (38) 93.0577 (26) 82.0419
(11)
3′-O-Acetyllycopsamine
N-oxide isomer I 10.25 [C17H27NO7+ H]
+ 358.1860 358.1856
358.1856 (15) 316.1758 (4) 298.1649
(40) 172.0968 (100) 155.0941 (23)
154.0863 (10) 138.0914 (73)
136.0758 (21) 111.0682 (19) 94.0656
(33) 93.0577 (21) 89.0602 (19)
87.0446 (14)
3′-O-Acetyllycopsamine
N-oxide isomer II 10.92 [C17H27NO7+ H]
+ 358.1860 358.1859
358.1859 (19) 316.1748 (4) 298.1648
(39) 172.0967 (100) 155.0940 (19)
154.0862 (14) 138.0914 (89)
137.0835 (8) 136.0758 (27) 112.0759
(7) 111.0681 (16) 94.0656 (44)
93.0577 (31)
7-O-Acetyllycopsamine
N-oxide 10.03 [C17H27NO7+ H]
+ 358.1860 358.1857
358.1857 (21) 214.1073 (100)
180.1019 (48) 178.0863 (14)
137.0836 (53) 136.0758 (17)
120.0810 (16) 119.0731 (14)
106.0654 (13) 101.0601 (25) 89.0602
(15) 73.0291 (20)
Ideamine A N-oxide
isomer I 4.87 [C14H23NO6+ H]
+ 302.1598 302.1595
302.1595 (67) 212.1275 (4) 172.0966
(91) 155.0939 (18) 154.0864 (10)
138.0913 (100) 137.0834 (7)
136.0757 (20) 112.0759 (7) 111.0681
(11) 108.0810 (6) 94.0655 (31)
93.0577 (23)
Ideamine A N-oxide
isomer II 6.27 [C14H23NO6+ H]
+ 302.1598 302.1596
302.1596 (65) 172.0968 (96)
158.1181 (7) 155.0941 (18) 154.0861
(12) 138.0913 (100) 137.0835 (10)
136.0757 (26) 112.0759 (9) 111.0680
(9) 94.0656 (31) 93.0577 (24)
* 3′-O-
Glucosyllycopsamine 8.94 [C21H35NO10 + H]
+ 462.2336 462.2336
300.1806 (12) 156.1021 (16)
139.0994 (4) 138.0915 (40) 120.0810
(16) 97.0289 (3) 96.0813 (2) 96.0451
(2) 94.0657 (100) 85.0290 (7)
* 3′-O-
Glucosylintermedine 7.41 [C21H35NO10 + H]
+ 462.2336 462.2335
300.1807 (17) 156.1019 (20)
139.0993 (5) 138.0914 (48) 120.0810
(19) 97.0289 (4) 96.0813 (2) 94.0656




9.89 [C21H35NO11 + H] + 478.2283 478.2286
316.1754 (100) 172.0968 (90)
155.0941 (15) 154.0860 (10)
138.0914 (74) 137.0837 (6) 136.0758
(19) 120.0809 (6) 112.0762 (5)





8.58 [C21H35NO11 + H] + 478.2283 478.2289
316.1758 (100) 172.0968 (76)
155.0943 (13) 154.0863 (9) 138.0916
(56) 137.0838 (7) 136.0757 (15)
120.0808 (7) 111.0681 (7) 94.0656
(29) 93.0578 (12)
Interestingly, PAs tentatively assigned as 3′-O-glucosyllycopsamine (found 462.2336, calculated
for C21H35NO10+H+: 462.2336) and 3′-O-glucosylintermedine (found 462.2335, calculated for
C21H35NO10+H+: 462.2336) and the corresponding N-oxides (found 478.2286 and 478.2289, calculated
for C21H35NO11+H+: 478.2283), were also identified in minor amounts in the pods and nectar
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(Table 4). The MS2 spectra exhibited virtually identical MS2 to the parent alkaloids 1 and 3, 4 and 6.
A 3′-glucopyranosyl 2,3-dihydro-1H-pyrrolizin-1-one derivative has previously been reported from
Cynoglossum gansuense [57]. Additionally, five isomeric components with MH+ 286.1649 were also
detected in P. straminea reduced extracts, with MS data consistent with these being desmethyl analogues
of lycopsamine, i.e ideamine A (10) isomers (four esterified at C9, one at C7). Ideamine A N-oxide
has previously been found in insects feeding on Parsonsia laevigata leaves [58,59]. Tessellatine (9),
3′-O-acetyl- and 7-O-acetyllycopsamine/intermedine and their N-oxides have been previously identified
in Amsinckia or Cryptantha species [54,55,60,61]. To positively identify the PAs in lycopsamine-rich
honey samples as originating from Parsonsia straminea, we sought to find some of these same minor PA
components of this plant in honey.
2.8. Honey PA Profiles Linked to P. straminea
The detection of minor alkaloids in Parsonsia straminea provides a distinctive PA fingerprint in its
HRAM LC-MS/MS profile, albeit in minor quantities compared to the major alkaloid lycopsamine (3).
By comparison with the PA profile observed in market honey samples, there is clear evidence that this
plant species is being used as a honey floral source by bees (Figure 7).
Figure 7. HRAM LC-MS/MS chromatograms (m/z 300.1805, m/z 316.1755) comparing the major
pyrrolizidine alkaloids in Parsonsia straminea and honey: (a) intermedine (1) and lycopsamine (3) in
Parsonsia straminea leaves (Zn reduced) (b) intermedine (1) and lycopsamine (3) in Parsonsia straminea
flowers (Zn reduced) (c) lycopsamine (3) and its N-oxide (6) in Parsonsia straminea flowers (unreduced)
(d) intermedine (1) and lycopsamine (3) in honey sample H-PA#146 (e) intermedine (1) and lycopsamine
(3) in honey sample H-PA#157.
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Honey samples such as H-PA#146 and H-PA#157 were independently purchased. When these
honey samples were analysed against the 30 PA standards in our screen (Table 1), only the major
alkaloid lycopsamine (3) and lesser intermedine (1) (and their N-oxides) were detected (Table 3).
Characteristic major/minor components present in certain honeys (Table 4) included in addition to
lycospamine and intermedine, the helioamplexine isomers at RT 8.20, 8.44 and 9.38 min (Figure 8) and
putative 3′-O-acetylintermedine (8.91 min) and 3′-O-acetyllycospamine (9.64 min). The tentatively
assigned 3′-O-glucosylintermedine and 3′-O-glucosyllycopsamine were also identified in these honey
samples with the MS2 spectra observed identical to that found in the plant pods and nectar. Non-toxic
dihydrolycopsamine isomers were also identified in the plant and honey. Due to the low levels of these
minor PAs in the plant, they were seen most readily in honey samples highest in lycopsamine (3) (eg.,
H-PA#19,157,146).
Figure 8. HRAM LC-MS/MS chromatograms (m/z 314.1911) comparing minor peaks in Parsonsia
straminea and honey (a) isomers of helioamplexine (8) in Parsonsia straminea leaves (Zn reduced)
(b) isomers of (8) in honey sample H-PA#146 (c) isomers of (8) in honey sample H-PA#157.
2.9. Plant Origins of PAs in Honeys Surveyed
Of the 30 PA standards utilised in our survey, fifteen PAs (50%) were not detected in any of
the market honey samples (Table 5). As shown in Table 5, based on profiles of alkaloids identified,
most of the honey PAs were likely sourced from Parsonsia straminea or Heliotropium amplexicaule, with
honey containing Parsonsia alkaloids being dominant in lycopsamine (3) (up to 3100 ng/g) and honey
containing Heliotropium amplexicaule alkaloids dominant in indicine (2) (up to 1700 ng/g). PAs sourced
from Echium plantagineum were much lower, with the dominant PA detected being echimidine (7) (up
to 260 ng/g) in agreement with previous studies [11,62]. Even lower levels of PAs from Heliotropium
europaeum (containing lasiocarpine, heliotrine and europine [11,62] (and their N-oxides)) and Senecio
species (most likely Senecio madagascariensis) [63] were detected (Table 5). Of course, many of the honey
samples are ascribed by their label to particular non-PA producing floral sources, so the observation of
PAs in these honeys is a product of either the natural foraging of bees on different available plants, or
the blending of honeys in the packaging process. This co-foraging/blending is also evident in honey
samples that show co-occurrence of pyrrolizidine alkaloids from multiple floral sources, for example,
honeys containing indicine (2) (from H. amplexicaule) and lycopsamine (3) (likely from P. straminea due
to lack of the dominant PA echimidine (7) as present in E. plantagineum). Both these sets of PAs were
present in significant levels in H-PA#11, 32, 216, 630 and 642. Geographically both the low-growing
heliotrope, H. amplexicaule, and the arboreal vine, P. straminea, can co-occur in sub-tropical coastal
regions of Queensland [53,64], so the co-occurrence of their respective alkaloids in honey would seem
logical if both plants are visited by foraging bees within the same landscape. The high abundance of
alkaloids from these quite different plant species in honey suggests that both are attractive to foraging
bees, and where possible both species should be avoided when siting honey hives. It is apparent
that the ‘standard set’ for PA/PANO testing of honeys varies depending on the natural flora of the
region, as well as the cultivated plants present. In this study erucifoline, jacobine, monocrotaline,
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senciphylline, or their corresponding N-oxides and senkirkine or trichodesmine were not found in the
honey tested, which is a considerably different result to those found recently in Schleswig-Holstein
region of Germany [28].
Table 5. Number of PA positive samples and PA concentration in honey samples (n = 465), grouped by
potential source of PA plant origin (mean and median are for positive samples only).







Parsonsia straminea (Monkey rope)
Lycopsamine 274 210 33 3100
Lycopsamine N-oxide 31 320 51 1900
Intermedine 217 b 32 18 290
Intermedine N-oxide a 30 c 86 21 660
Heliotropium amplexicaule (Blue heliotrope)
Indicine 221 120 31 1700
Indicine N-oxide/intermedine
N-oxide (n.r.) a 30
c 86 21 660
Intermedine 217 b 32 18 290
Helioamplexine d 78 23 13 130
Helioamplexine N-oxide e 5 28 35 51
Echium plantagineum (Paterson’s curse)





Heliotropium europaeum (Potato weed)
Europine 26 30 11 160
Europine N-oxide 4 11 7 24
Heliotrine 17 23 15 75
Heliotrine N-oxide 1 9 9 9
Lasiocarpine 10 20 14 59
Senecio species
Senecivernine 19 24 14 150
Senecionine 7 13 8 41

















a Not resolved–indicine N-oxide and intermedine N-oxide co-eluted. b,c Intermedine and intermedine N-oxide are
present in multiple plants, and prominent in both Parsonsia straminea and Heliotropium amplexicaule. d Helioamplexine
was quantified using heliotrine standard curve. e Helioamplexine N-oxide was quantified using heliotrine N-oxide
standard curve. f Lycopsamine observed in honey containing echimidine not necessarily attributed solely to E.
plantagineum, but of the 93 honey samples containing echimidine, the concentration of lycopsamine was lower than
echimidine in 76 honeys, which is consistent with the relative amounts observed in E. plantagineum. In the other 17
honeys which contain echimidine, it is likely that there is more than one source of lycopsamine. g Of the 76 honeys
in which lycopsamine was at a lower level than echimidine, 37 honey samples also contained intermedine.
2.10. Honey as a Dietary Source of Pyrrolizidine Alkaloids
Major supermarket honeys by comparison represent blended honeys from diverse locations, some
of which attributed the specific floral source and in general contained only low levels of PAs. It has
been observed previously that blended retail honeys had a lower PA content, but that PAs were present
19
Toxins 2019, 11, 726
in more samples [65]. In this study, for supermarket honeys (n = 129), PAs were detected in 84% of
honeys, and showed highest total PA levels of 1400 ng/g. For supermarket honeys, the mean total PA
level of PA-positive samples was 120 ng/g and the median level was 61 ng/g.
Certain small producer honeys displayed the highest levels of pyrrolizidine alkaloids, with the
PA content dependent on the location and attractiveness of PA containing plants to foraging honey
bees. Paradoxically, even though analysed PA content of small producer honeys range from <LOR to
an alarming 3000 ng/g, if equal amounts of each of these 205 small producer honeys were blended, the
hypothetical resultant mixed honey would have a PA content of only 240 ng/g (i.e., the average PA
content of all of these 465 honeys).
It has been observed previously in South American honeys that raw honeys showed greatest
variety due to the availability of PA containing plants near to hives [65].
The cumulative toxicity of the 1,2-unsaturated PAs have been demonstrated in animal studies
and genotoxicities/tumorigenicities were induced by hepatic metabolism of PAs [66]. Consequently,
provisional tolerable daily intakes (PTDI) have been recommended to control the human consumption
of PAs [5,10,39,67].
Using the Australian FSANZ provisional tolerable daily intake (PTDI) of 1 μg/kg BW/day, 0%
of honeys tested (total n = 465) exceeded the limit for a 70 kg adult consuming 20 g of honey per
day, but 19% of honeys tested exceeded the limit for a 15 kg child consuming 50 g of honey per day.
Applying the lowest recommended PTDI (EFSA, COT, BfR) of 0.007 μg/kg BW/day, 63% of honeys
tested exceeded the limit for a 70 kg adult consuming 20 g of honey per day and 84% of honeys tested
exceeded the limit for a 15 kg child consuming 50 g of honey per day.
The PA content of honey samples varies with geographical location and climate, determined by
the type and distribution of PA containing plants and by the propensity for bees to forage on these
plants [65,68]. Lycopsamine (3) and intermedine (1) are present in many PA-producing plants, with
the knowledge of the plants distributed in Australia and the ratio to other PAs present, it is likely that
Parsonsia straminea is a major contributor to the high PA levels observed in certain honeys in this study.
Of course, it is possible that there is more than one PA source of lycopsamine (3), with a small portion of
lycopsamine contamination of honey potentially originating from Echium plantagineum and Ageratum
houstonianium. Also, there are likely other PA containing plants that have not been considered. It is
also possible that not all PAs present in honey have been identified by comparison with standards
and by analysis of the top MSMS. Despite the observation that of the PAs tested in experimental rats,
lycopsamine (3) induced the lowest levels of liver DNA adducts (formed from PA derived reactive
pyrrolic metabolites), PA containing plants are the most common poisonous/carcinogenic plants
affecting livestock, wildlife and humans [69]. Beekeepers are advised to avoid these known plant
genera around the hive/apiary as much as possible to reduce PA contamination in honey.
3. Conclusions
The HRAM LC-MS/MS method for pyrrolizidine alkaloid analysis described here enables the
ready resolution of isomeric alkaloids of the lycopsamine-type. The described simple adjustment
of column conditions to a lower temperature was effective in resolving the problematic pairs of
indicine/lycopsamine alkaloids present in Australian honey. This resolution has enabled us to identify
Parsonsia vines as a previously unsuspected source of PA contamination in Australian honey. Low
temperature chromatographic resolution may have as yet unexplored application in resolving other
similar diastereomeric pyrrolizidine alkaloid isomers, of which there are many within the known
pyrrolizidine alkaloids, many of which do not have commercially available standards.
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4. Materials and Methods
4.1. Chemicals and Solvents
In total, 30 pyrrolizidine alkaloid standards were utilized in a high resolution accurate
mass (HRAM) LC-MS/MS screen. Echimidine, erucifoline, europine, heliotrine, indicine,
intermedine, jacobine, lasiocarpine lycopsamine, monocrotaline, retrorsine senecionine, seneciphylline,
senecivernine, and their respective N-oxides, were purchased together with senkirkine and
trichodesmine from Phytolab GmbH & Co. KG (Vestenbergsgreuth, Germany) and had a purity >89%.
All other chemicals and solvents were of analytical reagent or HPLC grade purity. Water used for
sample preparation and HPLC was Milli-Q purified (Merck Millipore, Darmstadt, Germany).
4.2. Honey Samples
Honey samples (465 in total) were purchased between September 2016 and December 2017 directly
from Queensland supermarkets, fruit shops, local markets, and producers.
4.3. Honey Alkaloid Extraction
Honey samples (1 g) were dissolved in aqueous H2SO4 (0.05 M, 10 mL) centrifuged and the
supernatant applied to preconditioned Agilent SPE Bond Elut 100 mg LRC-SCX columns (Agilent
Technologies, Folsom, CA, USA). SPE cartridges were washed with water (10 mL) and methanol
(10 mL), and pyrrolizidine alkaloids were then eluted with 3% ammonia in methanol (3 mL). The
eluate was evaporated to dryness under nitrogen, and the residue reconstituted in 5% methanol in
water (1 mL) for HRAM LC-MS/MS analysis.
4.4. Honey Method Validation
The validation of the method was conducted according to the National Association of Testing
Authorities (NATA) guidance document [22]. The method was validated in 3 blank honeys, and
based on results for 10 spiked samples at a spiking level of 5 ng/g (Table 2), 10 blank samples and
10 non-extracted spike samples and the recoveries determined. Limit of detection (LOD) was calculated
as 3s. Limit of quantitation was calculated as 9s. Limit of reporting was set at the levels the samples
were spiked, also the level of the lowest standard used for the calibration curve. The uncertainties given
are at the 95% confidence level as required by the NATA [22,23]. Replicate samples were prepared
for every tenth honey test sample to assess reproducibility. The difference between replicate samples
(coefficient of variance %) was typically 0.12–6.7%. High samples were diluted to levels within the
calibration curve and re-run. SPE wash steps and further elutions with 3% ammonia in methanol
(3 mL) were analysed for residual PAs and the extraction was found to be exhaustive. Table 2 shows
good recoveries for most PAs.
4.5. Plant Alkaloid Extraction
4.5.1. Plant Source
Parsonsia straminea was collected from a suburban area in the south of Brisbane and was
taxonomically identified by the Queensland Herbarium, with a voucher specimen (AQ522465)
incorporated into their collection. The Parsonsia straminea foliage sample was a collection of stems and
leaves, and was freeze dried, milled and stored frozen prior to analysis. Pods were collected separately
and freeze-dried, milled and frozen. Flowers were sampled as both intact flowers (freeze-dried, milled
and frozen) or utilized to provide nectar and pollen separately. Nectar was separated from flowers
using a microcap capillary, and anthers and pollen were separated from other flower plants with
tweezers and desiccated.
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4.5.2. Foliage and Seed Pod Extracts
Dried milled plant leaves and stems (1 g) and seed pods (1 g) were separately dissolved in
methanol (10 mL), vortexed (20 s), shaken (30 min) then centrifuged (4800 rpm, 10 min) and the
supernatants removed and concentrated to dryness under nitrogen. The residues were dissolved in
aqueous H2SO4 (0.05 M, 10 mL) centrifuged (4800 rpm, 10 min) and a portion of the supernatants
(0.1 mL) were applied to preconditioned Agilent SPE Bond Elut 500 mg LRC-SCX columns. SPE
cartridges were washed with water (10 mL) and methanol (10 mL), and pyrrolizidine alkaloids were
then eluted with 3% ammonia in methanol (10 mL). The eluate was evaporated to dryness under
nitrogen, and the residue reconstituted in 5% methanol in water (1 mL) for HRAM LC-MS/MS analysis.
4.5.3. Whole Flower Extracts
Dried and milled flowers (0.1 g) were dissolved in methanol (2 mL), vortexed (20 s), shaken
(30 min) then centrifuged (4800 rpm, 10 min) and the supernatant removed and concentrated to dryness
under nitrogen. The residue was dissolved in aqueous H2SO4 (0.05 M, 1 mL), centrifuged (4800 rpm,
10 min) and, for each sample, a portion of the supernatant (0.1 mL) was applied to a preconditioned
Agilent SPE Bond Elut 500 mg LRC-SCX column. Each SPE cartridge was washed with water (10 mL)
and methanol (10 mL), and pyrrolizidine alkaloids were then eluted with 3% ammonia in methanol
(10 mL). The eluate was evaporated to dryness under nitrogen, and the residue reconstituted in 5%
methanol in water (1 mL) for HRAM LC-MS/MS analysis.
4.5.4. Zinc Reduced Extracts
Another portion of each aqueous H2SO4 supernatant (0.5 mL) derived from leaves/stems, pods
and flowers was treated with Zn dust (100 mg) and stirred (2 h). After centrifugation (4800 rpm,
10 min), a portion of the supernatants (0.1 mL) was applied to a preconditioned Agilent SPE Bond Elut
500 mg LRC-SCX column. Each SPE cartridge was washed with water (10 mL) and methanol (10 mL),
and pyrrolizidine alkaloids were then eluted with 3% ammonia in methanol (10 mL). The eluate was
evaporated to dryness under nitrogen, and the residue reconstituted in 5% methanol in water (1 mL)
for HRAM LC-MS/MS analysis.
4.5.5. Floral Nectar Extract
Nectar (22.5 mg) was obtained from fresh flowers using a microcap capillary, dissolved in MeOH
(0.5 mL) and diluted 1 in 100 with 5% methanol in water (1 mL) for HRAM LC-MS/MS analysis.
4.5.6. Pollen Extract
Dessicated anthers and pollen were placed in hexane and shaken (1 min). The hexane containing
pollen was separated from the anthers and evaporated to dryness under nitrogen. The resulting pollen
(0.36 mg) was dissolved in 5% methanol in water and diluted as required for LCMS/MS analysis.
4.6. HRAM LC-MS/MS Analysis
Samples were analysed using a Vanquish UHPLC in combination with Q Exactive Orbitrap high
resolution accurate mass (HRAM) spectrometry system (Thermo Fisher Scientific, Bremen, Germany).
LC-MS/MS separation was achieved on a Kinetex XB-C18 analytical column (100 × 2.1 mm, 2.6 μm,
100 Å) at 5 ◦C. Analysis conditions: binary solvent system, solvent A (ammonium formate (5 mM)
and formic acid (0.1%) and solvent B (95% v/v methanol/water with ammonium formate (5 mM) and
formic acid (0.1%)). Compounds were eluted from the column at 0.3 mL min−1 with mobile phase B
held at 5% for 3 min followed by linear gradients of B from 5–50% (3–15 min), 50–80% (15–18.5 min),
80–100% (18.5–19 min), where it was held for 30 sec, before reducing from 100–5% over 6 sec, where
it was held until stop at 23.5 min. Instrument control, data acquisition and analysis were conducted
using Tracefinder 4.1 from Thermo Fisher Scientific. Alkaloid detection was performed by positive
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electrospray ionisation (ESI) with a spray voltage of 3500 V and a vaporiser temperature of 400 ◦C. MS
analysis run with arbitrary pressures of sheath gas 48, aux gas 11, sweep gas 2, spray voltage 3.5 kV,
capillary temperature of 320 ◦C, auxiliary gas heater at 350 ◦C and used full scan/dd-MS2 mode. Full
scans were conducted at a resolution of 70,000 FWHM (at m/z 200), with an AGC target of 1.00 × 106.
The maximum time of accumulating ions per scan event was 10 ms with a scan range of 75–1125 m/z.
Data dependent acquisition (dd-MS2) was conducted at a resolution of 17,500 with an AGC target of
1.00 × 106. The maximum time of accumulating ions per scan event was 50 ms. Normalized collision
energy (nce) was set to 50% and an isolation window of 1.0 m/z was utilized. Dynamic exclusion was
set to 3 s preventing subsequent triggering of the same ion in data dependent scans. A maximum of 5
most abundant precursors could be selected for dd-MS2 per scan event.
Pyrrolizidine alkaloid levels in honey/plant material were quantitated against certified PA
standards, with calibration curves obtained for each of the 30 pyrrolizidine alkaloid standards injected
at 5, 10, 20, 50 and 100 and 200 ppb (in duplicate/triplicate). Honey or plant extracts were analysed by
HRAM LC-MS/MS to detect pyrrolizidine alkaloids and their N-oxides by matching of retention time
with the corresponding standard and identified by their precursor parent ion (M+H+) and confirmed
by the detection of product ions (Table 1). The identity of these and further alkaloids was assigned by
use of the high resolution accurate mass data provided by the Q Exactive mass spectrometer, enabling
the determination of elemental composition of parent and fragment ions (Tables 3 and 4).
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Abstract: Cardiac glycosides (CGs) are naturally occurring plant secondary metabolites that can be toxic
to humans and animals. The aim of this work was to develop a targeted analytical method utilizing liquid
chromatography—tandem mass spectrometry (LC-MS/MS) for quantification of these plant toxins in a
herbal-based food and human urine. The method included oleandrin, digoxin, digitoxin, convallatoxin,
and ouabain. Samples of culinary herbs were extracted with acetonitrile and cleaned using Oasis® MAX
solid-phase extraction (SPE), while samples of urine were diluted with acidified water and purified on
Oasis® HLB SPE cartridges. Limits of quantification were in the range of 1.5–15 ng/g for herbs and
0.025–1 ng/mL for urine. The mean recovery of the method complied with the acceptable range of
70–120% for most CGs, and relative standard deviations were at maximum 14% and 19% for repeatability
and reproducibility, respectively. Method linearity was good with calculated R2 values above 0.997.
The expanded measurement uncertainty was estimated to be in the range of 7–37%. The LC-MS/MS
method was used to examine 65 samples of culinary herbs and herb and spice mixtures collected in
Belgium, from supermarkets and local stores. The samples were found to be free from the analyzed CGs.
Keywords: oleandrin; LC-MS/MS; plant toxins; validation; herbs; urine
Key Contribution: This work describes the development of a reliable analytical method for quantification
of poisonous cardiac glycosides in food, namely culinary herbs and spices, and in human urine. Such
methods are currently very scarce but paramount for investigation of accidental contamination with
toxic plants through the alimentary chain or intentional poisoning with raw plant parts.
1. Introduction
Cardiac glycosides (CGs) are secondary metabolites produced by plants belonging to, among
others, the genera Nerium (oleander), Convallaria (lily-of-the-valley), and Digitalis (foxglove). The core
structure of most CGs consists of lactone and steroid rings and a sugar moiety (Figure 1). CGs occur
in all parts of plants and can be poisonous to livestock and humans. Their primary mechanism of
action is inhibition of the membrane sodium-potassium pump that influences the intracellular sodium,
calcium, and potassium concentrations and, as a consequence, causes disruptions in the cardiovascular
system. However, other symptoms of toxicity may also include gastrointestinal, ocular, and neurologic
disorders. In a specific dose range, however, CGs such as digoxin (DIGO) and digitoxin (DIGI)
(Figure 1), have a long history of use as medications in treating various heart conditions [1–6].
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In the literature, numerous cases of human poisoning with plants containing CGs through
self-medication, accidental ingestion, suicide attempts, or criminal administration have been
documented [7–11]. These reports also included a remarkable case of intoxication with CGs through
food [8]. Superficial resemblance of the leaves of Nerium oleander, a plant producing toxic CG oleandrin
(OLE), to the leaves of olive and bay trees (Laurus nobilis) might contribute to misidentification of the
plant material and to accidental poisoning. Renal excretion is the main elimination route for some
CGs (e.g., DIGO), while the hepatic route is more common to other CGs, combined with a partial renal
elimination [12]. CGs excreted in urine are mainly unchanged [13–15] or partially metabolized [16].
A number of analytical, mostly single-analyte, methods for quantification of CGs in biological matrices
have been described [11,17–24]. As a detection technique, these methods utilized mass spectrometry
(MS) coupled to liquid chromatography (LC), which, thanks to its good selectivity and sensitivity, has
nowadays become the method of choice for many applications including toxin analysis. Other techniques,
such as immunoassay, (high-performance) thin-layer chromatography, and high-performance LC coupled
to a UV or fluorescence detector [25–29], have also been applied to the detection and quantification of CGs.
Analytical methods for determination of these plant toxins in other than clinical samples are
currently scarce. However, in case of a poisoning incident originating from the alimentary chain, the
availability of a reliable method for food products is essential to confirm or rule out the ingestion of
CG-containing plant material. Owing to the frequent use of herbal products as composite blends, and
the complexity of the CG compound class, more than one CG might be associated with the poisoning,
which points towards the significance of setting up multi-analyte methods. Therefore, the objective of
this work was the development and validation of an ultra-high-performance (UHPLC)-MS/MS method
for quantification of five plant toxins, namely OLE, DIGO, DIGI, convallatoxin (CON), and ouabain
(OUB) (Figure 1), in edible herbs and spices and, complementary, in human urine. The choice of the
target glycosides was dictated by their toxicity, known intoxication cases, occurrence of CG-producing
plants, and availability of commercial reference standards.
2. Results
2.1. Optimization of LC-MS/MS Conditions
In this study, basic (pH 9, 10 mM ammonium bicarbonate (NH4HCO3) with ammonia (NH3))
and acidic (pH 3, 10 mM ammonium formate (HCOONH4) with formic acid (HCOOH)) aqueous
mobile phases in combination with acetonitrile (ACN) as an organic phase were used to optimize
the MS ionization of target CGs. As the initial step of optimization, the flow injection analysis was
performed in electrospray ionization positive (ESI(+)) and negative (ESI(-)) modes. In the acidic mobile
phase, the presence of intense [M + Na]+ and [M + K]+ adducts, which did not further fragment, was
observed for all CGs; therefore, further optimizations were carried out with the basic mobile phase.
Figure 2a,b demonstrates a full ESI(+)-MS spectrum of CON in the mobile phase at pH 3, in which an
abundant presence of [M + Na]+ and [M + K]+ adducts can be clearly observed, and a full ESI(+)-MS
spectrum in the basic mobile phase, in which the abundant presence of the molecular ion is apparent.
As opposed to [M + Na]+ and [M + K]+ ions, fragmentation of the molecular ion provided several
abundant product ions (Figure 2c), usable for defining selected reaction monitoring (SRM) transitions.
While in the ESI(+) mode [M +H]+ or [M +NH4]+ ions were abundant in the spectrum, the full MS
scan in the ESI(-) mode revealed sufficient abundance of [M-H]- ions for all CGs. The final MS and
MS/MS conditions (Table 1) were optimized in ESI(+), because of the higher intensity of MS signals in
this mode.
For LC separation of the target analytes, the suitability of a UHPLC column with the C18 BEH
stationary phase in combination with the basic mobile phase consisting of ACN and 10 mM NH4HCO3
at pH 9, was tested. Using a gradient elution (see Section 5.2), good separation of the CGs was achieved
(Figure 3).
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Figure 2. Full ESI(+)-MS spectra obtained through the flow injection analysis of a 1 μg/mL solution
of convallatoxin (CON) in H2O + 10 mM HCOONH4 (pH 3):acetonitrile (ACN) (50:50, v/v) (a) and
H2O + 10 mM NH4HCO3 (pH 9):ACN (50:50, v/v) (b) and ESI(+)-MS/MS spectrum in H2O + 10 mM
NH4HCO3 (pH 9):ACN (50:50, v/v) (c). The vertical axes represent relative peak intensity (normalized
to 100%), while the horizontal axes display measured m/z (mass-to-charge ratio) values. The MS setup
is given in Section 5.3.
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Table 1. Electrospray ionization positive (ESI)(+)-MS/MS parameters for detection of cardiac glycosides.
Analyte
Precursor Ion
(m/z) Cone Voltage (V) Product Ions (m/z)
Collision Energy
(eV)





Digoxin 781.2 [M + H]+ 25 651.1391.1
10
15





Convallatoxin 551.1 [M + H]+ 20 369.2351.2
10
20
Ouabain 585.1 [M + H]+ 30 403.1385.1
15
20





1 Highlighted in bold: Most abundant product ion, 2 internal standard.
Figure 3. LC-MS/MS selected reaction monitoring (SRM) chromatograms of a single injection of
a standard mixture of DIGI (a), DIGO (c), CON (d), and ouabain (OUB) (e) at a concentration of
2.5 ng/mL and OLE (b) at a concentration of 0.25 ng/mL, dissolved in H2O:ACN (80:20, v/v). For each
cardiac glycoside (CG) the most abundant SRM transition is displayed. The vertical axes represent
relative peak intensity (normalized to 100%), while the horizontal axes display retention time (in min).
The chromatographic conditions applied are given in Section 5.2.
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2.2. Optimization of Sample Preparation
For the evaluation of extraction and clean-up recovery, analyte-free herbal and urine samples
spiked with the target CGs before and after extraction and/or clean-up step were prepared.
A herbal mixture (herbes de Provence) was used as a test mixture for the extraction experiments.
ACN, methanol (MeOH), and H2O, as single solvents or as mixtures, were tested. It was found that
good extraction recoveries (>70%) were obtained with ACN, MeOH, ACN:H2O (50:50, v/v), and
MeOH:H2O (50:50, v/v), with slightly better results for OUB if MeOH was used in the extraction
solvent. This method was aimed at achieving as low as possible limits of quantification (LOQs).
It was apparent that to accomplish that a further clean-up and concentration step of the extract was
necessary. The widely-used QuEChERS method [30], which combines extraction of a sample with
ACN, salting-out, and subsequent dispersive solid phase extraction (SPE) clean-up, was tried, however,
it demonstrated low extraction recoveries and poor clean-up efficiency. ENVI-Carb™ SPE with a
graphite sorbent, which is very suitable for elimination of pigments that are abundantly present in
herbs, resulted in no recovery of the target CGs. Other SPE cartridges, such as Discovery® DSC-18,
and Oasis® HLB, provided acceptable recoveries but matrix effects were pronounced, affecting the
sensitivity of the method. Oasis® MAX SPE was found to be the most suitable for clean-up of the
herb samples, as it showed reduced matrix effects, good recoveries, and improved estimated LOQs.
Among the tested extraction solvents, ACN was best compatible with the required setup of the Oasis®
MAX protocol. Other solvents in combination with the herb matrix caused blockage of SPE cartridges
or of the filter prior to the SPE. It should be mentioned that none of the tested protocols provided a
sufficiently low LOQ and reproducible results for OUB, therefore, this compound was not included in
the final method for herbal samples.
The sample preparation for urine was more straightforward and consisted of a sample dilution
with H2O containing 2% HCOOH and clean-up with Oasis® HLB SPE. The subsequent extract
concentration was necessary to achieve a higher method sensitivity. In urine, this protocol was able
to provide reproducible results for OUB and thus all selected plant toxins were included in the final
method for this matrix.
The detailed protocols for extraction and clean-up of herb and urine samples are given in
Section 5.4.
2.3. Method Validation
The method validation data for herbs and urine are summarized in Tables 2 and 3, respectively.
The method LOQs were calculated based on a signal-to-noise ratio (S/N) approach and are reported in
order to simplify the comparison with other methods for CGs described in the literature. The LOQs
were in the range from 1.5 to 15 ng/g for herbs and from 0.025 to 1 ng/mL for urine, with OLE showing
the highest sensitivity among the target CGs (Table S1). The analysis of blank herb and urine samples
demonstrated that no peak with a S/N of at least 3 was detected at the expected retention time of the
CGs, pointing out good specificity of the method. The matrix effect experiments revealed that the
calculated t-value for the target CGs in herbs and urine were much greater than the tabulated t-value
at the 95% confidence level indicating a significant difference between the slopes of calibration curves
in the solvent and matrix, i.e., the presence of matrix effects. All CGs in both matrices suffered from
a signal suppression, with the strongest suppression for OUB and the smallest effect for OLE and
DIGI. The calibration curves were prepared in matrix extracts (spiked post clean-up) by plotting the
concentration of the analyte in the calibration standards against the ratio of peak area of the analyte to
the internal standard, digoxin-d3 (DIGO-D), for all target CGs. Calibration curves for herb and urine
samples were linear over the validated concentration range with coefficients of determination (R2)
>0.997. The lowest calibration level (LCL) is used as a reporting limit for quantification of CGs in herbs
and urine. The mean (apparent) recovery data obtained for three concentration levels in herbs were
in the range from 83% to 115% for OLE, DIGO, and DIGI, and 55% for CON. The mean recoveries
for all CGs in urine ranged from 80% to 96%. The method precision was expressed as a relative
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standard deviation (RSD) of replicate measurements. For herbs, the repeatability (RSDr) of the method
ranged from 6% to 14% and the within-laboratory reproducibility (RSDwR) was from 7% to 17%, while
these parameters for urine ranged from 1% to 7% and from 5% to 19%, respectively. The expanded
measurement uncertainty (MU) was not higher than 28% and 37% at the lowest concentration levels
validated for herbs and urine, respectively. The uncertainty at higher concentration levels did not
exceed 31% and 16% for herbs and urine, respectively.
2.4. Method Application for Analysis of Culinary Herbs
The validated LC-MS/MS method was subsequently used to investigate the contamination of
culinary herbs and spices that are available on the Belgian food market. In total, 65 samples were
acquired in supermarkets and organic food shops and comprised the culinary herbs and herb/spice
mixtures containing bay leaves (Laurus nobilis). For the majority of samples, the country of production
was not specified. About 20% of samples originated from organic farming. The detailed information
on ingredients of the samples is given in Table S2.
Quality control samples, namely a standard mixture of CGs in a neat solvent and herb mixture
fortified with CGs at the concentrations corresponding to the middle validated level, were included in
each sample sequence. Identification of CGs in samples was completed following the Commission
Decision 2002/657/EC [31]. This implied the presence of a peak of the target analyte with a S/N ratio of
at least 3 for each ion transition, compliance of relative retention times, and conformity of deviations of
relative ion intensities with regards to the matrix-matched calibration standards. The most abundant
product ion was used for quantification, while the second product ion was used for confirmation of the
analytes. The analysis demonstrated that none of the collected samples contained CGs above the LCL.
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3. Discussion
Phytotherapeutic and nutritional use of plants and herbal-based products has (re)gained its
popularity in the last years. Due to improper usage of plants or unawareness of plant toxicity, several
intoxication cases with CG-containing plants have been reported recently [7,10,11]. Ingestion of toxic
plant (parts) may also be possible through the food chain. Plant misidentification and inadequate
control of harvesting or processing may lead to an unintentional mix of toxic plant material with the
raw plant material used for production. Since more analytical methods became available for screening
of organic molecules at low levels, several contaminants have surfaced as an issue of relevance in
food safety. That was the case for other plant toxins, such as tropane alkaloids and pyrrolizidine
alkaloids, which were found in herbal teas, herbs and spices, cereal-based food, and herbal food
supplements [32–35], sometimes at levels that can represent risk for human health [36,37]. The current
study aimed at developing a reliable analytical method for detection of CGs in plant-based food
products. As a complementary tool for control of poisoning incidents, the method was also validated
for the urine matrix. As opposed to some other human biological fluids that are used to study exposure
to contaminants, urine is easily accessible from individuals of all ages, can be obtained in larger
volumes, and its collection method is noninvasive.
As a detection technique, LC-MS/MS was chosen for this work, as it allows a high-throughput
simultaneous detection of structurally diverse molecules, including compounds of natural origin, at trace
levels and with high selectivity and specificity. In the proposed method, the SRM mode was used to
obtain increased sensitivity and specificity, the parameters that are of great importance in the analysis of
such complex matrices as herbs and urine. The selected ionization mode was ESI, the commonly used
interface in the LC-MS analysis of natural toxins. Though less frequent, atmospheric pressure chemical
ionization (APCI) is also used for the ionization of small molecules. Sugergat et al. [38] compared these
two ionization modes for the analysis of DIGO in human serum and observed a lower intensity of the
protonated molecule and a higher degree of fragmentation, resulting in lower sensitivity of the APCI
mode compared to ESI.
For some molecules, formation of alkali metal adducts can be observed in ESI-MS. This can
possibly be attributed to leaching from glass recipients or the presence of impurities in the mobile
phase [39]. Such adducts, as compared to the molecular ions, can be unstable and might not produce
fragment ions, jeopardizing the reliability of a quantitative LC-MS/MS method. The particular issue
of metal adduct formation has also been reported for CGs [18]. In this study, formation of metal
adducts, not prone to fragmentation, was observed when a mobile phase with HCOONH4 and HCOOH
(pH 3) was used for the LC. In order to generate a sensitive single precursor ion for the analysis in
the SRM mode, Bylda et al. investigated different mobile phase additives and finally selected the
[M + Li]+ adduct for the quantification of CGs [18]. In the absence of intense molecular ions, some
applications used [M + Na]+ or [M + K]+ adducts for quantification of CGs in a single or selected
ion monitoring (SIM) mode [38,40]. However, it has been noticed that SIM produced much higher
detection limits with biological samples compared to SRM, while the two modes were similar in
sensitivity if a standard mixture of CGs containing no matrix was injected [21]. In the current method,
under the applied LC-MS conditions (see Section 5.2) with a NH4HCO3-containing mobile phase
(pH 9), formation of a protonated molecular ion [M + H]+ for DIGO, OLE, OUB, and CON, and of an
[M + NH4]+ adduct for DIGI was achieved. Under mild fragmentation conditions, these precursor
ions underwent collision-induced dissociation in the quadrupole yielding usable intense product ions.
Of these fragments, the two most abundant ions were selected for the identification and quantification
of these plant toxins, thereby fulfilling the requirements of the Commission Decision 2002/657/EC,
which recommends the use of four identification points for confident identification of compounds in
the LC-MS/MS analysis [31]. Some of the observed abundant product ions corresponded to sequential
losses of the sugar moieties and elimination of hydroxyl groups from the steroid aglycones [41].
To optimize the sensitivity and selectivity of the LC-MS/MS method, SPE was used in the sample
preparation of CGs in herbs and urine, in order to reduce complexity of the matrix and to allow
36
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enrichment of the analytes. This approach has previously been used for purification of some CGs in
whole blood and plasma [17,24,42]. Compared to Oasis® HLB SPE devices, used for the clean-up of
urine samples in the current method, a significant reduction of matrix effects for herb samples was
noted with Oasis® MAX cartridges.
Currently, no maximum levels for CGs in food are set and analytical methods should preferably
achieve as low as possible LOQs. The results of validation indicated that the developed method is able
to detect and quantify the target CGs at low levels. In comparison to other existing methods for CGs in
biological matrices and herbal-based products (Table S1), the current method is able to reach lower or
similar LOQs. During the validation, matrix effects were observed for herbs and urine. The matrix
effect is in many occasions unavoidable in MS analysis of complex matrices. It could be caused by
co-eluting compounds that interfere with the ionization process of the target analytes leading to signal
suppression or enhancement. The CGs were differently affected by the matrix interferences. OUB,
being the most polar CG and eluting early in the chromatographic run, suffered from a greater matrix
suppression than OLE and DIGI, which eluted at the end of the run. This can be associated with the fact
that hydrophilic compounds of the biological or plant matrix also eluted early in the chromatographic
run giving rise to a more pronounced matrix effect in this region of the chromatogram. The addition of
stable isotope labeled analogues of the analyzed molecules is suggested for use as internal standards
to counteract the matrix effects. The use of commercially available or in-house synthesized labeled
internal standards have already been reported for the LC-MS analysis of a number of CGs [18,19].
Other structurally related molecules, such as methyldigoxin, digitoxigenin, and gitoxigenin, were
included as internal standards in some analytical methods [21,40,43]. In the current method DIGO-D,
the deuterated analogue of DIGO, was applied as an internal standard for all target CGs.
The method linearity was tested and found to be good exhibiting R2 >0.997, in most cases >0.999.
The mean recovery of the developed method was in agreement with the acceptable limit of 70–120%,
except for CON in herbs. A good precision of the method was demonstrated with repeatability and
within-laboratory reproducibility below 20% for both matrices. The accuracy and the precision of
the developed method were in the same range as for other methods, reported in the literature, for
quantification of CGs in biological matrices (Table S1). The obtained MU was below 50%, complying
with the SANTE/12682/2019 guidance document [44].
After completing the validation, the developed LC-MS/MS method was applied, to assess the CG
contamination of herbs and herbal/spice mixtures used for culinary purposes, available on the Belgian
food market. None of the target CGs were detected in these samples indicating that there is currently
no safety risk for the population with regards to contamination of culinary herbs and blends with CGs.
CGs are a large and diverse group of naturally occurring toxic compounds, and, upon necessity,
the LC-MS technique allows extension of the method to other plant toxins from this class. The presented
method can, on the one hand, be used in food control initiatives to ensure food safety and, on the other
hand, in population-wide survey studies that combine monitoring of food contamination and analysis
of human biological fluids to unravel the level of exposure to plant toxins.
4. Conclusions
This study describes the first detailed validated method for quantification of OLE and other
CGs in culinary herbs and human urine. The method displays good specificity, linearity, accuracy,
and expanded measurement uncertainty, thus enabling the accurate quantification of OLE, DIGO,
DIGI, and CON in culinary herbs and OLE, DIGO, DIGI, CON, and OUB in human urine. This new
method was applied to the analysis of more than 60 samples of culinary herbs and herb/spice mixtures
containing bay leaves present on the Belgian food market, showing that these products are safe for the
consumer. The UHPLC-ESI-MS/MS method described here could, therefore, become a useful tool to
determine these plant toxins in culinary herbs and also in urine.
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5. Materials and Methods
5.1. Standards, Reagents, and Consumables
Analytical standards of OLE, DIGO, DIGI, CON, and OUB octahydrate were purchased from
Sigma-Aldrich (Buchs, Switzerland). Individual stock solutions were prepared by dissolving the
crystalline standards in MeOH at a concentration of 1 mg/mL. A methanolic solution of DIGO-D
(1 mg/mL) was obtained from Cayman Chemicals (Ann Arbor, MI, USA). Intermediate solutions were
prepared by diluting the stock solutions in MeOH. The stock and the intermediate solutions were
stored at −20 ◦C.
The MeOH absolute ULC-MS, ACN ULC-MS, and HCOOH 99% ULC-MS were purchased
from Biosolve (Valkenswaard, the Netherlands). The ammonia solution 28–30% was obtained from
Merck (Darmstadt, Germany), while NH4HCO3 LC-MS and HCOONH4 LC-MS were supplied by
Sigma-Aldrich (Steinheim, Germany). H2O was purified by a Milli-Q purification system (Millipore
Corp., Bedford, MA, USA).
Oasis® MAX (3 cc, 60 mg) LP and Oasis® HLB (3 cc, 60 mg) extraction cartridges were provided
by Waters (Wexford, Ireland). Discovery® DSC-18 (6 mL, 500 mg) and Supelclean™ ENVI-Carb™
(6 mL, 500 mg) SPE cartridges were obtained from Sigma-Aldrich. VWR (Randor, PA, USA) was the
supplier of 15 and 50 mL centrifuge PP tubes and centrifugal filters (modified nylon, 0.2 μm, 500 μL).
5.2. UHPLC-MS/MS Conditions
The UHPLC-MS/MS system consisted of an ACQUITY UPLC H-class system coupled to a Xevo
TQ-S triple quadrupole mass spectrometer (Waters, Milford, MA, USA).
The mass spectrometer was operated in the ESI(+) mode. The MS parameters were set as follows:
Source and desolvation temperatures: 150 and 350 ◦C, respectively; capillary voltage: 1.50 kV; cone
and desolvation gas flows: 150 and 1000 L/h, respectively; collision gas flow: 0.15 mL/min; source
offset: 30 V. The SRM acquisition mode was used.
Chromatographic separation was achieved on an AQUITY UPLCTM BEH C18 column (2.1 × 100 mm;
1.7 μm) with an ACQUITY UPLCTM BEH C18 VanGuard precolumn (2.1 × 5 mm; 1.7 μm) (both from
Waters). The column temperature was maintained at 40 ◦C. The mobile phase was composed of phase A
(H2O containing 10 mM NH4HCO3 pH 9) and phase B (ACN). The flow rate used was 0.45 mL/min and
the applied gradient elution program was as follows: 0–1 min: 95% A, 1–6 min: 40% A, 6–7 min: 10% A,
7–7.1 min: 95% A, 7.1–10 min: 95% A. The injection volume was 10 μL.
5.3. Samples
The samples of culinary herbs were purchased from supermarkets and local (organic food) stores
in Belgium and included 14 single herbs and 51 herb/spice mixtures. More details on the samples are
provided in Table S2. Prior to the analysis, the herb samples were finely ground and homogenized.
The samples of human urine were provided by volunteers.
5.4. Sample Preparation
Two grams of the herb sample was weighed in a 50 mL PP tube. After addition of 25 mL of ACN,
the sample was vigorously shaken on an overhead shaker for 30 min and centrifuged for 10 min at
3180× g. Ten mL of supernatant was transferred in a 15 mL PP tube and evaporated at 45 ◦C under a
stream of nitrogen until a volume of approximately 1 mL. Subsequently, H2O containing 5% NH3 was
added to a total volume of 10 mL. After thorough vortexing and centrifugation (10 min at 3180× g) the
extract was subjected to further clean-up. Oasis® MAX SPE cartridges were conditioned with 3 mL
MeOH and 3 mL H2O. Three mL of supernatant was loaded onto the cartridge and washed with 3 mL
H2O containing 5% NH3. After a brief drying step, the target analytes were eluted with 3 mL MeOH
and collected in 15 mL PP tubes. The eluate was evaporated until dryness at 45 ◦C under a stream of
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nitrogen. The residue was reconstituted in 250 μL H2O:ACN (80:20, v/v) and filtered through filter
units for 5 min at 14,000× g.
Five mL of urine was transferred to a 15 mL PP tube, to which 5 mL H2O containing 2% HCOOH
was added. After vortexing, the sample was centrifuged for 10 min at 3180× g. For the clean-up, Oasis®
HLB cartridges were conditioned with 3 mL MeOH and 3 mL H2O. Six mL of supernatant was loaded
onto the cartridge and washed with 3 mL H2O. After a brief drying step, the target analytes were
eluted with 3 mL MeOH and collected in 15 mL PP tubes. The eluate was evaporated until dryness at
45 ◦C under a stream of nitrogen. The residue was reconstituted in 500 μL H2O:ACN (80:20, v/v) and
filtered through filter units for 5 min at 14,000× g.
5.5. Validation
The validation study was performed using spiked analyte-free representative sample materials.
The following method parameters were evaluated: LOQ, specificity, linearity, recovery, repeatability
(RSDr), reproducibility (RSDwR), matrix effects, and expanded measurement uncertainty (MU).
LOQ was defined as the minimum analyte concentration in the spiked samples that produced an
SRM transition with a minimum S/N of 10. Specificity of the method was assessed through the analysis
of blank matrix samples. The absence of a peak with a S/N ≥ 3 at the expected retention time of the
target CG indicated good method specificity. Linearity of the method was evaluated by fortifying blank
matrix samples with the target analytes at varying concentrations (minimum five levels). A logarithmic
transformation of the axes and a linear regression model were applied. (Apparent) recovery was
assessed by a spiking of blank matrix with the target analytes at three concentration levels in triplicate.
The measured concentrations were determined using a matrix-matched calibration curve and the
recovery was calculated as follows (Equation 1):
Recovery (%) =Measured concentration/Theoretical concentration × 100. (1)
For determination of the repeatability (RSDr), spiking experiments were performed at three
concentration levels in triplicate on the same day, while for within-laboratory reproducibility (RSDwR)
evaluation, the same experiments were carried out on three days. Matrix effects were assessed by
comparing the slopes of calibration curves prepared in the matrix extract and neat solvent. The t-test
was used for statistical evaluation of the matrix effect data. The expanded measurement uncertainty
(MU) (corresponding to a 95% confidence level and a coverage factor of 2) was estimated according
to [44].
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/12/4/243/s1,
Table S1: Comparison of performance characteristics of different LC-MS/MS methods for analysis of cardiac
glycosides; Table S2: Overview of culinary herbs and spices collected in Belgian food stores.
Author Contributions: Conceptualization, S.V.M. and J.M.; methodology, S.V.M., P.P.J.M., and J.M.; validation,
S.V.M. and J.M.; formal analysis, S.V.M. and J.M.; investigation, S.V.M., P.P.J.M., and J.M.; data curation, S.V.M.;
writing—original draft preparation, S.V.M., P.P.J.M., and J.M.; writing—review and editing, S.V.M., P.P.J.M., and
J.M.; visualization, S.V.M., P.P.J.M., and J.M.; supervision, J.M.; project administration, S.V.M. All authors have
read and agreed to the published version of the manuscript.
Funding: This research was funded by the Belgian National Reference Laboratory for Mycotoxins, Plant Toxins,
and Marine Biotoxins (contract number FAVV-NRL-GGO-TOX-2017, lot 2).
Acknowledgments: Benoît Guillaume and Céline Segers are acknowledged for their technical support, and
Séverine Goscinny is thanked for providing a part of the herb samples.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
39
Toxins 2020, 12, 243
References
1. Fozzard, H.A.; Sheets, M.F. Cellular mechanism of action of cardiac glycosides. J. Am. Coll. Cardiol. 1985, 5,
10A–15A. [CrossRef]
2. Hollman, A. Plants and cardiac glycosides. Br. Heart J. 1985, 54, 258–261. [CrossRef] [PubMed]
3. Melero, C.P.; Medarde, M.; San Feliciano, A. A short review on cardiotonic steroids and their aminoguanidine
analogues. Molecules 2000, 5, 51–81. [CrossRef]
4. Kanji, S.; MacLean, R.D. Cardiac glycoside toxicity More than 200 years and counting. Crit. Care Clin. 2012,
28, 527–535. [CrossRef]
5. Morsy, N. Cardiac glycosides in medicinal plants. In Aromatic and Medicinal Plants (Back to Nature);
El-Shemy, H.A., Ed.; InTechOpen: London, UK, 2017. [CrossRef]
6. Botelho, A.F.M.; Pierezan, F.; Soto-Blanco, B.; Melo, M.M. A review of cardiac glycosides: Structure,
toxicokinetics, clinical signs, diagnosis and antineoplastic potential. Toxicon 2019, 158, 63–68. [CrossRef]
7. Wasfi, I.A.; Zorod, O.; Al katheeri, N.A.; Al Awadhi, A.M. A fatal case of oleandrin poisoning. Forensic. Sci. Int.
2008, 179, e31–e36. [CrossRef]
8. Gechtman, C.; Guidugli, F.; Marocchi, A.; Masarin, A.; Zoppi, F. Unexpectedly dangerous escargot stew:
Oleandrin poisoning through the alimentary chain. J. Anal. Toxicol. 2006, 30, 683–686. [CrossRef]
9. Hugues, T.; Anoult, M.; Beaub, N.; Yaici, K.; Mélandri, P.; Saoudi, N.; Gibelin, P. Intoxication volontaire au
laurier rose; cas clinique et revue de la littérature. A non fatal Nerium oleander self-poisoning; case report and
discussion. Ann. Cardiol. Angeiol. 2012, 61, 128–131. [CrossRef]
10. Papi, L.; Luciani, A.B.; Forni, D.; Guisiani, M. Unexpected double lethal oleander poisoning. Am. J. Forensic.
Med. Pathol. 2012, 33, 93–97. [CrossRef]
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Abstract: The neuroblastoma cell-based assay (CBA-N2a) is widely used for the detection of marine
biotoxins in seafood products, yet a consensus protocol is still lacking. In this study, six key parameters
of CBA-N2a were revisited: cell seeding densities, cell layer viability after 26 h growth, MTT incubation
time, Ouabain and Veratridine treatment and solvent and matrix effects. A step-by-step protocol was
defined identifying five viability controls for the validation of CBA-N2a results. Specific detection of
two voltage gated sodium channel activators, pacific ciguatoxin (P-CTX3C) and brevetoxin (PbTx3)
and two inhibitors, saxitoxin (STX) and decarbamoylsaxitoxin (dc-STX) was achieved, with EC50
values of 1.7 ± 0.35 pg/mL, 5.8 ± 0.9 ng/mL, 3 ± 0.5 ng/mL and 15.8 ± 3 ng/mL, respectively.
When applied to the detection of ciguatoxin (CTX)-like toxicity in fish samples, limit of detection
(LOD) and limit of quantification (LOQ) values were 0.031 ± 0.008 and 0.064 ± 0.016 ng P-CTX3C
eq/g of flesh, respectively. Intra and inter-assays comparisons of viability controls, LOD, LOQ and
toxicity in fish samples gave coefficients of variation (CVs) ranging from 3% to 29%. This improved
test adaptable to either high throughput screening or composite toxicity estimation is a useful starting
point for a standardization of the CBA-N2a in the field of marine toxin detection.
Keywords: CBA-N2a; standardization; matrix effects; absorbance data; ciguatoxins; brevetoxins;
saxitoxins; biological sample; seafood safety
Key Contribution: The present work is a revisit of several parameters of the CBA-N2a that improved
assay implementation and reliable toxin detection. This study resulted in a practical guide accessible
to both supervised beginners and experienced users, provided in the Supplementary Materials.
This revisited CBA-N2a allowed for the improved detection of toxins acting on the voltage gated
sodium channels (ciguatoxin, brevetoxin and saxitoxin) as evidenced by CTX estimation data obtained
from fish samples of known toxic status.
1. Introduction
The bio-accumulation of marine biotoxins produced by phytoplankton in filter-feeding
invertebrates and finfish not only poses significant health threats to consumers but also has detrimental
effects on the economies of nations highly dependent on seafood consumption for their subsistence [1–3].
Among these potent marine biotoxins are neurotoxins acting on the voltage gated sodium channels
(VGSCs) of excitable cells, namely VGSC activators such as brevetoxins (PbTxs) and ciguatoxins
(CTXs), and VGSC inhibitors such as saxitoxins (STXs) and tetrodotoxins (TTXs) [1,2]. Detection and
quantification of these groups of marine toxins remain highly challenging due to the wide range of
congeners present in trace amounts in contaminated biological matrices [4]. In addition, an official
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reference method is still lacking for most of these toxins due to the poor availability of certified
reference standards [5]. Although the mouse bioassay has been recommended by the European
Food Safety Authority (EFSA) for years until 2015, the European Union now strongly advocates
the use of analytical techniques based on liquid chromatography coupled with mass spectrometry
in tandem (LC-MS/MS) and high performance liquid chromatography with fluorescence detection
(HPLC-FLD) for the detection of lipophilic and hydrophilic toxins, respectively [6–10]. However,
the need for alternative high throughput methods for toxin screening and quantification purposes
remains [8,11]. Among the readily available and most widely used in vitro methods, the functional
assay known as the cell-based assay (CBA) that uses a neuroblastoma (N2a) cell line appears as the
most promising one [2,12].
Based on the mode of action of VGSC toxins, the CBA-N2a was initially developed to detect two
VGSC inhibitors, STXs and TTXs [13]. Those marine toxins have no cytotoxic effect on N2a cells and
their detection requires the addition of the sodium/potassium (Na+/K+) ATPase pump blocker ouabain
(O), together with the sodium-channel activator veratridine (V), which induces permanent activation
of the VGSCs [14]. Under this O/V treatment (OV+ conditions), sodium influx resulted in the cellular
swelling and subsequent death of N2a cells [13]. Following the addition of STX or TTX, an increase of
cell viability is observed as the two inhibitors counteract the effect of ouabain and veratridine. At that
time, viability measure was achieved by a visual estimation of the morphological changes of N2a
cells and the enumeration of viable cells under an inverted microscope. This assay performed in a
96-well microplate format has been applied to the detection of Paralytic Shellfish Poisoning (PSP) toxin
standards [13] and to assess the presence of PSP toxins in biological extracts [15,16]. Standardization
was also achieved using a certified STX standard for the detection of PSP toxins in shellfish and
dinoflagellate cell extracts using automated endpoint determination with final readout based on
crystal violet staining [17]. Further, this CBA-N2a was applied to detect VGSC inhibitors in marine
bacterial supernatants using neutral red for final estimation of toxicity [18] and was subsequently
extended to the detection of PbTxs and CTXs [19,20]. Contrary to VGSC inhibitors, these two VGSC
activators induce a decrease in N2a cell viability in OV+ conditions [19,20], whereas no cytotoxic
effect is observed in the absence of O/V treatment [21]. These same authors also introduced a more
workable measure of cell viability using the 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium
bromide (methylthiazolyldiphenyl-tetrazolium bromide) colorimetric assay (known as MTT assay),
as modified from previous protocols aiming at assessing either cellular growth and survival [22] or
chemosensitivity in established cell lines [23]. The MTT assay is widely used to measure cell viability
and proliferation [24–27], and is based on the capacity of mitochondrial dehydrogenase enzymes
present in living cells to reduce tetrazolium salts into an insoluble purple formazan product [28]
localized in lipids droplets [29]. The readout step was first established using dimethyl-sulfoxide
(DMSO) to dissolve formazan products [23], the amount of the formazan produced is directly linked to
the number of viable cells remaining at the end of the assay. This estimation is achieved by means of
an automated readout. Two patents describing an improved and simplified CBA-N2a were eventually
filed, leading to great expectations among the scientific community that this bioassay could soon be
routinely used to detect both activators and inhibitors of sodium channels [30,31]. However, neither
commercial kit nor detailed protocol is available to date.
Briefly, the CBA-N2a originally set by Manger et al. [19,20] consists of three major steps; (i) cell
seeding of 100,000 cells/200 μL/well in a 96-well microplate left to grown for ≈ 24 h, (ii) O/V treatment
followed by cell layer exposure to toxin standards and/or biological samples during 24 to 48 h,
depending on the targeted toxin activity (final reaction volume of 230 μL/well) and (iii) N2a cell
viability readout at 570 nm using the MTT colorimetric assay. Practically, the detection of VGSC
activators and inhibitors by CBA-N2a requires 3 and 4 days, respectively.
Since 1993, the CBA-N2a has been widely used in a number of studies for the detection
of VGSC toxins and related toxin families. However, a comprehensive review of the literature
shows that the protocol initially defined by Manger et al. [19,20] has undergone numerous
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changes: for instance, (i) up to 13 different cell seeding densities have been tested, ranging
from 10,000 to 250,000 cells/well [32–88] suggesting that cell confluence likely varied substantially
between studies, especially when estimated by eye measurement; (ii) the culture medium
established for cell layer implementation, which formerly used 10% of fetal bovine serum (FBS),
was often reduced to 5% in many studies [32,33,36–39,42,46,48,54,59,69,70,74,77,78,81–83,85,86,89];
(iii) the confluence level reached by N2a cells after 24 h growth varied from non-confluent
cells [66] to >90% confluence [48,59,63–65,72,73,77,78,83] or even was not specified in some
studies [33–38,40–43,47,49–58,61,66,67,69,70,74–76,79–82,85,87–90].
Other steps of the CBA-N2a have also been the subject of substantial modifications. For instance,
although many studies used a 500/50 μM (1:10 ratio) for O/V treatment [32–49,76,89,91,92]
as initially defined by Manger et al. [19,20,30,31], numerous changes in O/V
concentrations [54–57,59,61,63–65,71–75,77–83,85,87,93–95], O/V ratios [50–52,69,86] and reaction
volumes [32,33,35,36,49,51,53,59,61,63,64,69,73,75,77–80,84,86–90] were further proposed. Interestingly,
in many of these studies, the effects on cell viability resulting from all these modifications were rarely
addressed but, when reported, showed incongruent results. For instance, O/V treatment at 500/50 μM
was shown to induce highly variable effects between 20–92% [34,45,68,96]. Conversely, similar
effects (10–56%) were reportedly obtained at lower O/V concentrations [50,86]. The most significant
modification was the use of two different O/V treatments, i.e., 100/10 and 300/30 μM, in order to induce
20% and 80% of cell mortality, respectively, for a more reliable assessment of the effects of VGSC toxin
activators and inhibitors on N2a cells [83]. Several changes were also made to the final reaction volume
(230 μL) at the last step of the CBA-N2a, i.e., cell exposure to toxin standards or biological samples,
with volumes varying from 100 to 210 μL [32–36,45,49,51,53,59,61,63,64,69,73,75,77–80,84,86–90,95].
Moreover, measuring cell viability by means of the MTT colorimetric assay is classically performed
at 570 nm, however, different wavelengths were also tested that ranged from 490 to 595
nm [33,35,36,38–42,45,50,56,57,61,64,67–69,71,75,76,79,80,84,85,87,88,90,93,97]. Finally, water-soluble
tetrazolium reagents were sometimes preferred to the former water insoluble formazan product, with
the use of WST-8 [49,60] or commercial kits such as CellTiter 96® Aqueous One solution [33,38,69,86],
Cell Counting Kit-8 [47] or XTT Cell Proliferation Assay kit [98].
This wide range of “in-house” methods described in the literature highlights the present lack of a
consensus, standardized protocol for CBA-N2a, making any attempt to compare CBA data between
assays and/or laboratories difficult or impossible. It also greatly hampers all current efforts to establish
the CBA-N2a tool as a potential alternative reference method to LC-MS/MS. In this context, the present
work aims at a comprehensive revisit of the CBA-N2a by evaluating the effects of six key parameters
that are critical in obtaining reliable toxicity results, i.e., cell seeding densities, cell layer viability after
26 h growth, MTT incubation time, O/V treatment and solvent and matrix effects. To evaluate its
robustness, the newly improved protocol thus established was further applied to the detection of
toxins active on VGSC families (activators vs. inhibitors), and the estimation of CTX-like toxicity in
fish samples of known ciguatoxic status.
2. Results
2.1. Characterization of N2a Cell Growth and Initial Viability
The N2a CLL 131 cell line used in this study displayed a typical growth curve characterized by
a short lag phase (slow cell growth), followed by a log phase (exponential proliferation of cells and
consumption of nutrients of the culture medium) until a maximum density of ≈ 100,000 cells/well is
reached, and a late stationary/senescence phase (reduced cell proliferation) (Figure 1).
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Figure 1. Characteristic growth pattern of the neuroblastoma (N2a) cell line used in this study. Densities
in 96-well microplates were extrapolated from growth experiments conducted over a 4 days period
in 25 cm2 culture flasks using a 10% fetal bovine serum (FBS) culture medium. Data represent the
mean ± standard deviation (SD) of one experiment (N2a cells at 383 passages (P)), with n = 10 counts
for each point. Coefficients of variation (CV) ranged from 10.8% to 26.3%.
The linearization of the log phase of the growth curve was defined by the following equation:
Y = 0.0578X + 7.7948 (r2 = 0.9974) (1)
in which X is the culture time (hours) and Y is the Ln-transformed cell number. Based on this equation,
it was concluded that the N2a growth curve was characterized by a 9.8 h lag phase (Y = Ln (4288))
and that the cell number increased by two-fold after an additional 12 h. Moreover, a cell seeding
density of 50,000 ± 10,000 cells/well allowed reaching a maximum cell density of ≈ 100,000 cells/well
after 22 h culture time. For more convenience, a culture time of 26 h post-seeding was selected in all
further experiments.
Next, the N2a cell initial viability after 26 h growth was compared at ten different cell seeding
densities ranging from 10,000 to 100,000 cells/well and in two culture conditions (5% and 10% FBS
growth medium) (Figure 2). Results showed that (i) the highest absorbance value is consistently
obtained at a cell seeding density around the maximum number of cells supported by microplate wells,
and (ii) absorbance values increase in proportion with MTT incubation times (Figure 2). For instance,
the maximum absorbance value measured after 26 h culture time and 45 min MTT incubation time was
1.4 while selecting a cell seeding density of 50,000 ± 10,000 cells/well (vertical dotted lines, Figure 2)
allowed to reach absorbance values comprised between 1 and 1.25 (horizontal dotted lines, Figure 2).
This absorbance range was considered optimal when the detection of a decrease in cell viability is
sought. Finally, no differences were observed when using either 5% or 10% FBS growth medium,
which indicates possible saving opportunities on this expensive reagent at this step of the CBA-N2a.
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Figure 2. Initial viability of N2a cells observed in 96-well microplates after 26 h growth in 5% FBS
(full line) and 10% FBS (dotted line) culture medium, at different cell seeding density. Six distinct
MTT incubation times were also tested: 15 min (blue); 25 min (green); 35 min (orange); 45 min (black);
55 min (pink); 65 min (red). Data represent the mean ± SD of one microplate (N2a cells at 536 P),
each point tested in six wells. Mean CVs were <3%. Absorbance values were measured at 570 nm via
the MTT assay.
Based on these results, all further CBA-N2a experiments were conducted as follows:
• Implement cell layer in microplates using a cell seeding density of 50,000± 10,000 cells/well in 200μL
of a 5% FBS culture medium, in order to reach a maximum cell density of 100,000 ± 20,000 cells/well
after ≥22 h of culture.
• Conduct the MTT assay at an incubation time of 45 min, in order to reach an absorbance value
≥1.0 that is used to define N2a “initial viability”.
• For each experiment, dedicate a separate microplate to measure the N2a cell initial viability after
26 h of growth defined as the “Reference Cell Viability” control (RCV control).
2.2. Characterization of N2a Cell Final Viability
The second step of CBA-N2a is the exposure of N2a cells to VGSC activators or inhibitors, in OV−
or OV+ conditions. Following an additional culture time of 19 h overnight, the final viability of N2a
cells was assessed as previously described.
2.2.1. N2a Cell Final Viability in OV− Conditions
A final cell viability lower than the initial cell viability (as measured in the RCV control) was
observed only with 1% FBS growth medium at cell seeding density > 40,000 cells/well (Figure 3).
Conversely, all other growth media allowed to reach a final viability higher than the one displayed by
the RCV control, regardless of the cell seeding density (Figure 3), suggesting a complete renewal of the
culture medium with 2% FBS growth medium is sufficient to ensure a stable cell viability during 19 h
additional culture of the toxin exposure. A better stability of cell viability was consistently achieved
at cell seeding densities > 40,000 cells/well. In other words, working at a cell seeding density of
50,000 ± 10,000 cells/well will allow to reach an absorbance value ≥1, close to the one measured in the
RCV control (Figure 3).
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Figure 3. Final viability of N2a cells observed at different seeding densities when cultured 26 h in
5% FBS culture medium followed by 19 h in fresh growth medium supplemented with 1% FBS (red),
2% FBS (green), 3% FBS (orange), 4% FBS (pink) and 5% FBS (black). The initial viability measured
in the Reference Cell Viability (RCV) control microplate after 26 h of growth is represented by the
blue dotted curve. Data represent the mean ± SD of one microplate (N2a cells at 537 P), each point
tested in six wells. Absorbance values were measured at 570 nm via the MTT assay, after a 45 min MTT
incubation time.
Based on these results, the following procedure was selected to ensure that, at this step of the
CBA-N2a, a final cell viability close to the initial cell viability is obtained in OV− conditions:
• After cell layer implementation (26 h after seeding), remove the used culture medium from
microplates (except for the RCV control plate which is sacrificed to get the initial N2a cell viability
via the MTT assay).
• Replace with 200 μL of fresh 2% FBS growth medium prior to an additional culture time of 19 h.
• Measure the absorbance data in control wells (n = 3) in the absence of O/V treatment (COV−) to
characterize the N2a cell final viability in OV− conditions.
• Compare absorbance data in COV− control vs. RCV control to verify cell viability is maintained
in OV− conditions.
2.2.2. N2a cell Final Viability in OV+ Conditions
As expected, absorbance data measured at 0/0 μM (OV− conditions) was close to the one of the
RCV control (Figure 4). At O/V concentrations ranging from 10/1 to 80/8 μM, a “protective effect”
was observed as evidenced by an increase in cell viability of ≈ 20% above the RCV control (Figure 4).
Between 80/8 and ≈ 110/11 μM, although a slight decrease in absorbance data was observed, these
values were consistently found above the RCV control (Figure 4), suggesting a slightly toxic effect,
although regarded as “non-destructive effect” of O/V treatment on N2a cells (Figure 4). At higher
concentrations, however, cell viability decreased in a dose-dependent manner down to the level
observed for DMSO control, which was indicative of a “destructive effect” of O/V treatment on N2a
cells (Figure 4). Above 300/30 μM, the effect of O/V on cell viability was considered “lethal” with
the complete elimination of cell viability (Figure 4). Concerning the variability of O/V treatment
obtained across a wide range of N2a cell passages from 384 to 804 P, the CVs were below 12.4% for
the “non-destructive” O/V treatment between 80/8 and 100/10 μM selected for the detection of VGSC
activators. When seeking to detect VGSC inhibitors, the absorbance values were close to 0 showing
non significative CVs above 45% for the “destructive” O/V treatment between 270/27 and 300/30 μM.
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Figure 4. Dose-response curve of N2a cells when exposed to increasing concentrations of Ouabain
and Veratridine (O/V) treatments ranging from 0/0 to 360/36 μM. Data represent the mean ± SD of one
microplate in six independent experiments corresponding to cell passage numbers of 384, 542, 800,
801, 803 and 804 P, each point run in triplicate. The mean absorbance ± SD values corresponding to
the RCV control (horizontal green line and dotted green lines) and DMSO control (horizontal red line)
were determined at 1.105 ± 0.096 and 0.042 ± 0.001, respectively. Absorbance values were measured at
570 nm via the MTT assay, after a 45 min MTT incubation time. The four different effects induced by
increasing concentrations of O/V treatment on N2a cells, i.e., protective, non-destructive, destructive
and lethal are also represented.
Based on these results, the O/V treatment conditions best adapted to the type of activity we seek
to detect on target cells (e.g., activation or inhibition of VGSCs on N2a cells) were defined as follows:
• Select non-destructive O/V treatment conditions (between 80/8 and 100/10 μM) in order to induce
a final cell viability slightly above the one observed in the RCV control, so that any loss in cell
viability can be assigned to the specific activity of VGSCs activators. In the following experiments
(Sections 2.4.2 and 2.4.3), 100/10 and 85.7/8.57 μM (final concentrations) were used.
• Select destructive O/V treatment conditions close to the lethal effect (between 270/27 and 300/30μM)
in order to induce a final cell viability slightly above the one observed in the DMSO control, so that
any increase in cell viability can be assigned to the specific activity of VGSC inhibitors. In the
following experiments (Section 2.4.2), 270/27 μM (final concentrations) were used.
• Measure the absorbance data in control wells (n = 3) in the presence of O/V treatment (COV+) to
characterize the N2a cell final viability in OV+ conditions.
• Compare absorbance data in COV+ control vs. RCV control to verify the efficiency of the O/V
treatment conditions applied in the experiment.
2.3. Characterization of the Unspecific Effects of Solvent and Dry Extract on N2a Cell Viability
The issue of potential solvent toxicity and sample extract matrix effects on N2a cell viability was
also taken into consideration.
2.3.1. Solvent Effects
Using methanol (MeOH), a progressive loss in N2a cell viability is observed in 100/10 μM OV+
conditions at solvent concentrations ≥0.8%, giving a mean absorbance value ≈ 25% lower than the
one measured in the RCV control at the highest concentration tested (Figure 5a). In OV− conditions,
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an opposite effect is observed as evidenced by an increase in cell viability also at concentrations ≥0.8%
(Figure 5a). Conversely, regardless of the OV conditions, DMSO consistently induced an abrupt
decrease in cell viability at concentrations ≥1% until the complete elimination of viable N2a cells
(Figure 5b). These findings indicate that both solvents can be used provided a concentration <0.8%
is selected and that the maximum concentration of solvent can start at 0.5%. Practically, the use of
non-volatile DMSO was preferred for the preparation of stock solutions (especially for toxin standards)
as it is non-hazardous and likely to ensure stable toxin concentration over long periods of storage.
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Figure 5. Dose-response curves of N2a cells when exposed to increasing concentrations of two solvents,
in OV− (open symbols) and OV+ (solid symbols) conditions at 100/10 μM (final concentrations);
(a) MeOH (/) and (b) DMSO (Δ/) were tested using N2a cells at 551 and 549 P, respectively.
Data represent the mean ± SD of one microplate, with each point run in triplicate. Absorbance values
were measured at 570 nm via the MTT assay, after a 45 min MTT incubation time. The initial cell
viability in the RCV control was 1.139 ± 0.021 and 0.995 ± 0.031 and the final cell viability in the absence
of O/V treatment (COV−) control was 1.217 ± 0.025 and 1.047 ± 0.023 for (a,b), respectively. The dotted
vertical line corresponds to the maximum solvent concentration 0.5% for solvent interferences.
Consequently, a dilution of at least 1:200 giving the first final concentration (C1) of the toxin
standard/sample extract stock solutions in MeOH or DMSO was achieved in all further CBA-N2a
experiments, as follows:
• Initial dilution of at least 1:10 in 2% FBS culture medium,
• Final dilution at 1:21 by direct addition of 10 μL of initial dilution in 200 μL of growth medium.
This will ensure the final solvent concentration in wells does not exceed 0.5%.
2.3.2. Biological Matrix effects
In this study, the dry extract weights (DEW) obtained from 10 g of fish flesh ranged from 2.7 to
4.3 mg (Section 5.2), but they have been shown to sometimes vary up to ten-fold in other studies (data
not shown). When tested at similar concentrations in OV− conditions, all extracts induced a final cell
viability slightly above the one observed in the RCV control at concentrations ≥1500 pg/μL, whereas cell
viability could increase up to 70% as observed for sample Emer05 at 10,000 pg/μL (or 30.08 ± 5.92 μg
fish flesh equivalent/μL) (Figure 6). Above this concentration, a decrease in cell viability rapidly
occurred, suggesting an unspecific cytotoxicity on N2a cells likely due to matrix effects (Figure 6).
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Figure 6. Dose-response curves of N2a cells in OV− conditions when exposed to increasing
concentrations of LF90/10 dry extracts prepared from Chlorurus microrhinos Cmic02 (blue), Cmic19
(red), Epinephelus merra Emer13 (black) and Emer05 (green) fish samples. Data represent the mean
± SD of three independent microplates (N2a cells at 800, 801 and 803 P), each point run in triplicate.
Absorbance values were measured at 570 nm via the MTT assay, after a 45 min MTT incubation time.
The cell viability in the RCV control was determined at 1.143 ± 0.009, while the final cell viability in
COV− control was 1.037 ± 0.053. The dotted vertical line corresponds to the maximum concentration of
dry extract (MCE = 10,000 pg/μL) for matrix interferences.
Based on these results, the MCE for LF90/10 fractions was set at 10,000 pg/μL for this study in all
further experiments. Prior to CBA-N2a toxicity analysis, dry extract solutions of fish samples were
thus prepared as follows:
• For all fish samples, resuspend LF90/10 dry extract in MeOH or DMSO at 10 mg/mL, then proceed
with an intermediate 1:50 dilution of this previous stock solution.
• Add 10 μL of the solution thus obtained in 200 μL of growth medium to test the highest
final concentration below the MCE, i.e., 9524 pg/μL, in the absence vs. under non-destructive
O/V treatment.
This revisited CBA-N2a resulted in a practical guide that is presented in the
Supplementary Materials.
2.4. Application to the Detection of VGSC Activators and Inhibitors
2.4.1. N2a Cell Initial Viability
To test the relevance of the six parameters revisited in Sections 2.1–2.3, this improved protocol
was further applied to the detection of different toxin standards acting on VGSCs.
First, the initial viability of N2a cells prior to toxin exposure was assessed by measuring
absorbance values in RCV control using the MTT colorimetric assay in three independent experiments.
The metabolization of MTT into formazan by N2a viable cells resulted in a uniform blue color visible
in all wells, proof that a high cell layer confluence was attained. Following the addition of DMSO and
cell lysis, a dark purple color was released in each well (Figure S1).
The net absorbance data obtained for RCV controls in all three experiments were indicative of
a high viability of N2a cells (mean value between 1 and 1.25) and were also highly reproducible,
with CVs below 5% (Table 1).
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Table 1. Initial viability of N2a cells as assessed in RCV controls (cell layer ≈ 100,000 cell/well obtained











Inter-assay * 3 1.170 ± 0.050 0.043 ±0.0001 1.127 ± 0.050 4.4
* Data represent the mean ± SD of one microplate in three independent experiments (N2a cells at 662, 663 and 666 P).
2.4.2. Detection of VGSC Activators and Inhibitors
In OV− conditions (upper half of the microplates), the same dark purple color was observed for
COV− control and all concentrations tested regardless of the toxin standard (Figure S1). Conversely,
in OV+ conditions (bottom half of the microplate), a progressive fading of this dark purple color
was observed with increasing concentrations of P-CTX3C and PbTx3, until complete discoloration,
signing the total death of N2a cells (Figure S1). Otherwise, a progressive darkening of the pale color
observed at low concentrations occurred with increasing concentrations of STX and dc-STX, signing a
progressive restoration of N2a cell viability (Figure S1).
For VGSC activators, net absorbance values showed that COV− and COV+ control absorbance
data were close to that of the RVC control. The same observation applies to VGSC inhibitors except in
OV+ conditions where absorbance data of COV+ controls were in the range of 0.1.
Inter-assay comparison in three independent experiments showed that net absorbance data are
reproducible with CVs of 6.1% and 5.4% for COV− controls, and 1.6% and 4.5% for COV+ controls of
P-CTX3C and PbTx3, respectively. Likewise, net absorbance data of COV− controls showed CVs of 6%
and 3.9% of STX and dc-STX, respectively, but 41.4% and 37.5% for COV+ controls, these latter values
being close to 0 absorbance.
In the presence of the two VGSC activators, net absorbance data of all nine concentrations obtained
in OV− conditions remained close to the ones measured in COV−, COV+ and RCV controls regardless
of the toxin concentrations tested, whereas in OV+ conditions, a sigmoidal dose-response curve was
obtained for both P-CTX3C and PbTx3 (Figure 7a,b). In the presence of the two VGSC inhibitors,
net absorbance data of all nine concentrations obtained in OV− conditions remained close to the ones
measured in COV− and RCV controls regardless of the toxin concentrations tested, whereas in OV+
conditions, a sigmoidal dose-response curve was obtained for both STX and dc-STX (Figure 7c,d).
Table 2 details several characteristic parameters of CBA-N2a curves. The EC50 values roughly
corresponded to twice that of EC80 for VGSC activators and to 2.5-fold higher than that of EC20 for
VGSC inhibitors. Overall, high reproducibility was found for top and bottom absorbances as well
as negative Hillslopes with CVs < 5% for P-CTX3C and PbTx3, and CVs < 10% for STX and dc-STX
(Table 2). Regarding VGSC activators, CVs were ≈ 19% and between 17% and 21% for EC80 and EC50
values, respectively. For VGSC inhibitors, CVs of EC20 and EC50 varied between 10.3% and 17.5% for
STX, and between 19.2% and 26.3% for dc-STX. Comparing the potency within VGSC acting toxin
family, P-CTX3C was approximately 3300-fold more potent than PbTx3 and STX was approximately
4-fold more potent than dc-STX (Table 2).
All these findings showed that this newly improved CBA-N2a allowed for specific and sensitive
detection of VGSC activators and inhibitors.
Based on these results, quality check (QC) controls were defined as follows:
• The “QCOV−” is the quality control that serves to check for the final viability of N2a cells after 19h
of additional culture in the absence of O/V treatment and in the presence of VGSC acting toxins.
• The “QCOV+” is the quality control that serves to check for the final viability of N2a cells after
19h of additional culture under O/V treatment and in the presence of VGSC acting toxins.
The QC controls are used to verify the specific action of VGSC acting toxins (Figure S2) and their
concentration is selected at the EC50 of a given standard toxin.
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Figure 7. Dose-response curves displayed by N2a cells when exposed to nine increasing concentrations
of toxin standards after 19 h exposure time, in OV− (open symbols) and OV+ (solid symbols) conditions
at 100/10 μM for voltage gated sodium channels (VGSC) activators and 270/27 μM for VGSC inhibitors
(plain symbols): (a) P-CTX3C (/•); (b) PbTx3 (/); (c) (STX) (♦/); (d) dc-STX (Δ/). Data represent
the mean ± SD of one microplate in three independent experiments (N2a cells at 662, 663 and 666 P),
with each concentration run in triplicate. Net absorbance values were 1.101 ± 0.067 and 1.077 ± 0.058
in COV− controls (n = 3), and 1.209 ± 0.014 and 1.226 ± 0.055 in COV+ controls (n = 3) for (a,b),
respectively, for VGSC activators. Net absorbance values were 1.170 ± 0.046 and 1.113 ± 0.067 in COV−
controls (n = 3), and 0.136 ± 0.051 and 0.145 ± 0.060 in COV+ controls (n = 3) for (c,d), respectively.
Table 2. Dose-response curve parameters of cell-based assay (CBA)-N2a when detecting VGSC
activators or inhibitors.
Parameters P-CTX3C ** PbTx3 ** STX ** dc-STX **
Top absorbance 1.149 ± 0.028 1.182 ± 0.060 0.917 ± 0.017 0.990 ± 0.038
Bottom absorbance −0.017 ± 0.028 0.057 ± 0.013 0.149 ± 0.073 0.130 ± 0.049
Hillslope −1.802 ± 0.074 −2.052 ± 0.102 1.545 ± 0.127 1.290 ± 0.126
EC80 * (fg/μL) 0.787 ± 0.155 2950 ± 537 ND ND
EC50 * (fg/μL) 1.700 ± 0.354 5800 ± 926 2982 ± 523 15851 ± 3050
EC20 * (fg/μL) ND ND 1195 ± 123 5456 ± 1434
* Data represent the mean ± SD of one microplate in three independent experiments (N2a cells at 662, 663 and 666 P).
** OV+ conditions: 100/10 and 270/27 μM final concentrations for VGSC activators and inhibitors, respectively.
ND = not determined.
2.4.3. Composite Toxicity Estimation of VGSC Activators in Fish Samples
Four fish samples were analyzed: two steephead parrot-fish (Chlorurus microrhinos, Scaridae,
Cmic02 and Cmic19) and two honeycomb groupers (Epinephelus merra, Serranidae, Emer05 and Emer13).
To evaluate the composite CTX-like toxicity, a set of standards must be run in parallel with samples
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in order to calibrate an experiment properly. For this purpose, P-CTX3C standard was tested in
parallel with fish matrix, in the absence vs. under non-destructive O/V treatment at 85.7/8.57 μM (final
concentrations), as the EC50 of standards are further needed to infer toxin content in biological samples.
A high repeatability and reproducibility of viability data were obtained for RCV, COV−, COV+
controls as well as QCOV− (Table 3), with CVs < 7%, whereas a lower reproducibility was observed for
QCOV+ absorbance data with a CV of 17.3% inherent to the cytotoxicity of PbTx3 at EC50 (Section 2.4.2).
Table 3. Assessment of five viability controls useful to validate the detection of VGSC activators in fish
matrix using the revisited CBA-N2a.
Variability RCV Control COV− COV+ QCOV− QCOV+
Intra-assay * 1.122 ± 0.046 1.264 ± 0.068 1.130 ± 0.029 1.257 ± 0.067 0.448 ± 0.038
Inter-assay ** 1.132 ± 0.052 1.165 ± 0.074 1.129 ± 0.078 1.174 ± 0.074 0.409 ± 0.071
* Data represent the mean ± SD of three microplates in one experiment (N2a cells at 810 P). ** Data represent the
mean ± SD of one microplate in three independent experiments (N2a cells at 795, 797 and 798 P).
Moreover, statistical analyses by means of the Wilcoxon test showed no significant difference
between RCV control and COV+, and between QCOV− and COV− for both intra- and inter-assay
(Table S1). Conversely, significant differences were observed between QCOV+ and all other controls.
In addition, the comparison between intra- and inter-assay values showed no significant differences
for COV+ values, nor between RCV control and COV+ values showing that final viability was similar
to initial viability under non destructive O/V treatment (Table S1).
The dose-response curves thus obtained for P-CTX3C (data not shown) allowed to establish
another set of EC80 and EC50 (Table 4) which were compared to those of Table 2 (Section 2.4.2).
Statistical comparison by means of the Wilcoxon test showed no significant differences between
EC80 and EC50 values obtained under two distinct O/V treatments, i.e., 100/10 and 85.7/8.57 μM with
p-values > 0.4 (Table S2).
Table 4. Variabilities of EC80 and EC50 for two VGSC activators (P-CTX3C and PbTx3) using the
revisited CBA-N2a as assessed under non-destructive O/V treatment conditions.
Variability O/V Treatment
P-CTX3C PbTx3
EC80 (fg/μL) EC50 (fg/μL) EC80 (fg/μL) EC50 (fg/μL)
Inter-assay * 100/10 μM 0.787 ± 0.155 1.700 ± 0.354 2950 ± 538 5800 ± 929
Intra-assay ** 85.7/8.57 μM 0.964 ± 0.055 2.004 ± 0.190 3230 ± 270 6241 ± 388
Inter-assay *** 85.7/8.57 μM 0.825 ± 0.236 1.730 ± 0.414 3015 ± 347 5946 ± 788
* Data represent the mean ± SD of one microplate in three independent experiments (N2a cells at 662, 663 and 666 P).
** Data represent the mean ± SD of three microplates in one experiment (N2a cells at 810 P). *** Data represent the
mean ± SD of one microplate in three independent experiments (N2a cells at 795, 797 and 798 P).
Further, the limit of detection (LOD) and the limit of quantification (LOQ) of the CTX-like toxicity
in fish were determined using the MCE of 10,000 pg dry extract/μL and EC80 and EC50 values obtained
for P-CTX3C exclusively run in parallel with fish samples under 85.7/8.57 μM OV treatment. The LOD
and LOQ showed high repeatability with CVs < 9.5% (intra-assay), whereas a lower reproducibility
was noticed with CVs > 23.9% (Table 5). The Wilcoxon test also confirmed no significant differences
between intra- and inter-assay data with p-values of 0.7 and 0.4 for LOD and LOQ, respectively.
Hence, a mean LOD value was established at 0.089 ± 0.017 ng/mg of dry extract for P-CTX3C, with LOQ
values about twice that of LOD.
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Table 5. Estimation of limit of detection (LOD) and limit of quantification (LOQ) of the CTX-like toxicity
in fish flesh using the revisited CBA-N2a under non-destructive O/V treatment at 85.7/8.75 μM.
Variability Sample ID
ng P-CTX3C eq/mg Dry Extract ng P-CTX3C eq/g Fish Flesh
LOD LOQ LOD LOQ
Intra-assay **
Cmic02
0.096 ± 0.006 0.200 ± 0.019
0.035 ± 0.002 0.072 ± 0.007
Cmic19 0.041 ± 0.002 0.086 ± 0.008
Emer05 0.030 ± 0.002 0.062 ± 0.006
Emer13 0.026 ± 0.001 0.054 ± 0.005
Inter-assay *
Cmic02
0.083 ± 0.024 0.173 ± 0.041
0.030 ± 0.008 0.062 ± 0.015
Cmic19 0.035 ± 0.010 0.074 ± 0.018
Emer05 0.026 ± 0.007 0.054 ± 0.013
Emer13 0.022 ± 0.006 0.047 ± 0.011
* Data represent the mean ± SD of one microplate in three independent experiments (N2a cells at 795, 797 and 798 P).
** Data represent the mean ± SD of three microplates in one experiment (N2a cells at 810 P).
Based on the “dry extract weight/fresh weight” (DEW/FW) ratio characterizing each fish sample
(Section 5.2), the LOD and LOQ of P-CTX3C in fish flesh were determined and expressed in ng of
P-CTX3C eq/g of fish flesh (Table 5) for further comparison with the EFSA and US Food and Drug
Administration (FDA) advisory level. Although LOD and LOQ of the CTX-like toxicity varied from one
fish to another (Table 5) due to differences in DEW/FW ratios, the Wilcoxon test showed no significant
differences between intra- and inter-assay data regardless of the fish sample and P-CTX3C used as
reference (Table S3). Hence, the mean LOD values were established at 0.031 ± 0.008 (CV = 25.4%) and
LOQ = 0.064 ± 0.016 (CV = 24.3%) ng P-CTX-3C eq/g of fish flesh.
Application of the CBA-N2a to the detection of VGSC activators in four fish samples gave
two distinct patterns as observed for VGSC activators (Figure S1). When exposed to increasing
concentrations of fish extracts (Figure 8a,b), no cytotoxic effects were observed in OV− and OV+
conditions for Cmic02 and Emer13. Conversely, sigmoidal dose-response curves with a negative slope
were obtained for Cmic19 and Emer05 fish samples in OV+ conditions (Figure 8a,b), whose ciguatoxicity


















































































Figure 8. Dose-response curves displayed by N2a cells when exposed to increasing concentrations
of fish dry extracts (LF90/10) of two herbivorous fishes (a) and two carnivorous fishes (b) after 19 h
exposure time in OV− (open symbols) and OV+ conditions 85.7/8.57 μM (solid symbols): Cmic02 (Δ/),
Cmic19 (♦/), Emer13 (/•) and Emer05 (/). Data represent the mean ± SD of one microplate in three
independent experiments (N2a cells at 795, 797 and 798 P), with each concentration run in triplicate.
The dotted vertical line corresponds to the maximum concentration of dry extract (MCE = 10,000 pg/μL)
for matrix interferences.
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The sigmoidal dose-response curves thus obtained for Cmic19 and Emer05 were fitted according
to the four parameter logistic regression (4PL) model showing high repeatability and reproducibility
for top absorbance and Hillslope, with CVs < 10% (Table 6). Absorbance values close to 0 were also
consistently obtained at the highest concentration of fish extract tested (Table 6).
The mean EC50 and EC80 values determined in pg of dry extract/μL for Cmic19 and Emer05
also showed a high repeatability with CVs between 5% and 11.2%, respectively, whereas a lower
reproducibility of these values was noticed with CVs between 12% and 21.6%, respectively (Table 6).
The Wilcoxon test also confirmed no significant differences between intra- and inter-assay data with
p-values of 0.7 and 0.2 for Emer05 and Cmic19, respectively. Hence, mean EC80 values were established
at 63.6 ± 12.4 and 108.5 ± 13.7 pg/μL for Cmic19 and Emer05, respectively, with mean EC50 values 1.6
and 1.9 higher than that of EC80 for Emer05 and Cmic19, respectively. Based on EC50 values, Cmic19
dry extract was 1.5-fold more potent than Emer05 dry extract (Table 6).













Intra-assay * Cmic19 1.064 ± 0.007 0.001 ± 0.004 71.2 ± 8 130.6 ± 11 −2.282 ± 0.132
Emer05 1.110 ± 0.014 0.003 ± 0.004 114.7 ± 10 184.4 ± 10 −2.927 ± 0.271
Inter-assay ** Cmic19 1.084 ± 0.062 −0.003 ± 0.002 55.9 ± 12.1 109.5 ± 21.1 −2.056 ± 0.073
Emer05 1.081 ± 0.101 0.000 ± 0.002 102.2 ± 15.9 171.3 ± 20.5 −2.675 ± 0.196
* Data represent the mean ± SD of three microplates in one experiment (N2a cells at 810 P). ** Data represent the
mean ± SD of one microplate in three independent experiments (N2a cells at 795, 797 and 798 P). *** OV+ conditions:
85.7/8.57 μM final concentrations.
In addition, the toxin contents in fish flesh were also estimated using the EC50 values determined
for toxin standard and fish extract (Table 7).
Overall, CTX-like composite toxicity data showed high repeatability and reproducibility with CVs
< 13% (Table 7). The Wilcoxon test showed no significant differences between intra- and inter-assays
for toxin contents with p-values of 0.3 and 0.6 for Emer05 and Cmic19, respectively. Hence, the mean
toxin content in Cmic19 and Emer05 was estimated at 6.66 ± 0.68 and 3.31 ± 0.35 ng P-CTX-3C eq/g
fish flesh, respectively, indicating Cmic19 was twice as toxic as Emer05.
Table 7. CTX-like composite toxicity estimation in two ciguatoxic fish samples using the
revisited CBA-N2a.
Variability Sample ID
ng P-CTX3C eq/g Fish Flesh
Mean ± SD CVs (%)
Intra-assay * Cmic19 6.63 ± 0.74 11.2
Emer05 3.37 ± 0.32 9.5
Inter-assay ** Cmic19 6.76 ± 0.57 8.4
Emer05 3.10 ± 0.40 13
* Data represent the mean ± SD of three microplates in one experiment (N2a cells at 810 P). ** Data represent the
mean ± SD of one microplate in three independent experiments (N2a cells at 795, 797 and 798 P).
3. Discussion
Having sensitive and specific detection methods available to protect consumers against poisoning
risks due to seafood contaminated with marine biotoxins is a key component of food security monitoring
programs worldwide [1,5]. However, in the absence of duly validated reference methods, many marine
biotoxins are still unregulated [5]. This is the case for instance for CTXs, neurotoxins active on VGSCs
that are implicated in ciguatera poisoning [5]. Among the many detection tests currently available for
the detection of this group of compounds and, more widely, of toxins acting on voltage-gated sodium
channels [8,99], the neuroblastoma cell-based assay or CBA-N2a appears as a very sensitive, specific
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functional assay [3,12]. However, the numerous protocols found in the literature highlight the lack of a
consensus standardized protocol for CBA-N2a. It should be noted that the same observation applies
to other analytical methods used for CTXs determination in biological samples such as LC-MS/MS
and references therein, [99–101]. In this context, the present work aimed at revisiting several key
parameters of the CBA-N2a as a step towards the standardized and reliable detection of two groups
of toxins frequently involved in toxic outbreaks, namely VGSC activators (e.g., CTXs, PbTxs) and
inhibitors (e.g., STX, dc-STX).
3.1. Revisit of the CBA-N2a
Overall, six key parameters of the CBA-N2a were revisited.
The first parameter was the cell layer density reached in microplate wells following a 22 to 26 h
growth period at 37 ◦C, as assessed by measuring the absorbance values of the cell layer. The growth
curve of the N2a cell line used in this study was established, demonstrating that the maximum number
of cells that can be supported in 0.32 cm2 wells could not exceed ≈ 100,000 cells. Our data also showed
that seeding microplates at 50,000 cells/well allowed reaching this high cell density after ≈ 22 h of
culture, with 100% confluence of cell layer in wells, consistent with results obtained in previous
studies [59,77]. Obtaining maximum confluence with cells in late log growth phase ensures optimal
absorbance data [23]. In the literature, however, a cell layer confluence > 90% was reportedly reached
using different cell seeding densities, e.g., 10,000 cells/well [63], 30,000 cells/well [64,73] and 100,000
cells/well [19,20,47,48]. Some authors reported higher cell seeding densities of 250,000 cells/well [57,71],
but such assay conditions do not appear physically or physiologically relevant. Actually, our results
suggest that it is not the cell seeding density in itself that matters when seeking to achieve an optimal
implementation of cell layer in culture microplates, and that this parameter should be adjusted to
both the growth rate of the N2a cell line and the culture conditions used in the different laboratories.
Therefore, growth experiments should be conducted in each laboratory in order to characterize the
growth pattern of the cell line(s) in use.
The second parameter examined in this study was the MTT incubation time for cell viability
assessment [19]. Here, the MTT assay was standardized using an optimal wavelength of 570 nm and
an incubation time of 45 min, allowing to obtain reproducible absorbance values ≥ 1 when a maximum
density of adherent cells is reached in wells after 26 h of growth, i.e., ≈ 100,000 cells/well. In all further
experiments, this condition which serves as an indicator of the good health conditions of N2a cells
before exposure to toxic extracts was referred to as the “initial cell viability”, and was assessed by
implementing a RCV control microplate. Moreover, setting the initial cell viability to an absorbance
value ≥ 1 (=baseline viability) allowed us to establish a full sigmoidal dose-response curve derived
from testing an eight points serial dilution of the toxin standard/sample. Any subsequent drop in
cell viability following O/V treatment and toxin exposure, could then be most likely attributed to the
specific effect of toxin standard/biological sample, and not from non optimal culture conditions or
oversensitivity of cells.
Regarding the selection of a wavelength at 570 nm, our results are in agreement with previous
work showing that the peak absorbance of MTT formazan precipitate is classically observed at 562 nm
with shoulders at 512 and 587 nm [29]. Wavelengths within this range have been used in a number of
studies, [36,42,50,64,67,87,90], and were generally associated with MTT incubation time around 30 min.
However, wavelengths outside this range were also tested, resulting in a weaker optical signal [29]
consistent with the fact that the use of lower [45,76,84,85] or higher wavelengths [57,61,79,93] often
required longer MTT incubation times (>60 min).
The third parameter analyzed was the final viability of N2a cells under OV− conditions, following
an additional culture period of 19 h, overnight. Indeed, the N2a growth curve previously established
showed that a loss in N2a cell viability is likely to occur at this stage when a high cell density is reached.
To prevent this, a complete renewal of the used growth medium with a 2% FBS culture medium was
found sufficient to stabilize cell viability throughout the CBA-N2a, as evidenced by absorbance data
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that were consistently found ≥1 in COV− control wells. This operation appears all the more relevant
since MTT assay does not actually measure the number of viable cells or their growth, but the activity
of an integrated set of enzyme linked to cell metabolism [24]. The necessity of this medium renewal
has been previously highlighted in many studies [34,49,51,56,71,79,80,87,93] although the benefits of
such a procedure were never clearly explained.
The fourth parameter revisited was the concentrations of Ouabain and Veratridine applied in
O/V treatment. In this study, we were able to determine two distinct ranges of O/V concentrations to
use depending on the group of toxins targeted in the CBA-N2a, i.e., VGSC activators and inhibitors.
For the specific detection of VGSC activators in which a loss in cell viability is sought, non-destructive
concentrations of O/V with respect to N2a cell viability ranging from 80/8 and 100/10 μM are
recommended in order to maintain a final cell viability in COV+ control close to the initial cell viability
of RCV control (absorbance values ≥ 1). Conversely, for the specific detection of VGSC inhibitors in
which a restoration of cell viability is sought, destructive concentrations of O/V ranging from 270/27 to
300/30 μM should be used in order to induce a residual cell viability in COV+ control corresponding
to approximately 10% (absorbance value of ≈ 0.1) of the initial cell viability measured in the RCV
control. Moreover, the ranges of these two types of O/V treatments seem to induce constant effects
on N2a cells although high passages were used and that these latter were distant from each other up
to 420 passages. However, passage specific effects were not tested directly in this study, and may
be the focus of future work. These findings are currently verified on the N2a cell line used in our
laboratory at lower number of cell passages. The 500/50 μM O/V treatment originally proposed by
Jellett [17] to detect STX was in fact chosen to induce “a lysis of many of the cells in 24 h incubation
time”. Such characteristics reinforce the idea that the CBA-N2a is a bioassay that is function-specific
rather than toxin-specific [102].
The use of 83/17 μM [50] or 100/10 μM [83] in O/V treatment has been reported in the literature for
the detection of PbTxs, although a 10–20% reduction in cell viability was observed. Similarly, a 100/10μM
O/V treatment is often selected for the detection of CTXs in Gambierdiscus spp. extracts [56,65,79,80,93]
and fish samples [54,55,57,71,74,80], although in many of these studies no information on whether
a renewal of the growth medium was applied prior to O/V treatment or on the efficiency of O/V
treatment was provided. Consistent with our results is the report of the use of a 300/30 μM O/V
treatment in previous studies aiming at detecting STX, which resulted in an 80% reduction in cell
viability [83,94]. Additionally, previous studies showed a reduction of cell viability of 40% and up to
69–92% without and following the renewal of the growth medium, respectively, under O/V treatment at
500/50 μM [34,96]. In the present study, an O/V treatment at 300/30 μM was sufficient to induce a 100%
reduction in cell viability, suggesting that the renewal of the medium was beneficial to cell physiology,
thus allowing to optimize the effect of O/V treatment. However, the extent to which reduction of FBS
in the culture medium from 5% to 2% following medium renewal might have rendered the cells more
sensitive to toxins remains to be tested in follow-up experiments. The direct addition of O/V treatment
in old culture medium following cell layer implementation in wells [19] should be avoided to ensure
appropriate preservation of cell viability and further O/V treatment efficiency.
The fifth parameter examined was the concentration of solvents used to resuspend toxin standard
solutions or dry extracts. This study showed that, for MeOH and DMSO, the highest final concentrations
should be 0.5% to avoid non-specific cytotoxic effects on N2a cell viability, which is ensured by a
dilution of at least 1:200 of the sample stock solutions. These possible solvent interferences were
addressed in various ways in previous studies, including working at a final solvent concentration
of 0.25–0.3% [11,87], performing an additional evaporation step before re-dissolution of toxins or
biological samples in RPMI medium [54,74,81,91,103], or adding 1% MeOH in controls wells to identify
any cytotoxic effects [64,73] or 5% MeOH known to induce no more than 20% of cytotoxicity on
cell lines [53].
The sixth and last parameter was the maximum amount of extract to expose to avoid potential
matrix effects (MCE) as compounds that often co-extract with the analyte(s) of interest can induce
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unspecific effects on N2a cell viability [81]. In this study, this value was determined at 10,000 pg of dry
extract/mL based on the LF90/10 dry extract weight (DEW) instead of the fresh tissue equivalent (FW)
used to prepare these extracts, given the significant differences often observed in the DEW/FW ratio of
biological samples. Interestingly, only one previous study has used this rationale and has calculated the
MCE based on lipid extracts [84]. It should be noted that MCE values are likely to vary according to the
nature of tissue analyzed (e.g., flesh, viscera, fin, etc.), the different trends in lipid and water contents in
tissue when sampled at different stages of the life history of a given fish species [104]. Moreover, MCE
also depends on the extraction protocols and extraction efficiency [46,57,73,105], as shown for CTXs for
which no reference consensus extraction protocol is available as yet [105]. Thus, until a standardized
universal protocol is made available, researchers conducting similar studies should necessarily perform
their own matrix assessments before applying CBA-N2a.
3.2. Performance of the Revisited CBA-N2a
The accuracy of the data provided by this revisited CBA-N2a, relies, in part, on the availability
of five viability controls, i.e., RCV, COV−, COV+, QCOV− and QCOV+ that were established
throughout the various stages of CBA-N2a in order to verify: (i) the initial (RCV control) and
final viability of N2a cells (COV− controls), (ii) the efficiency of O/V treatment (COV+ controls)
and (iii) the detection of the specific mode of action of VGSC activators vs. inhibitors (QCOV−
and QCOV+ controls). If the use of percentages is recurrent in most studies to express cell
viability results [7,8,32,33,36,37,43,46,53,59,62,63,66–68,70,73,74,76,81,83,85,87,88,90,91,95,97,103,106–112],
the originality of our revisited CBA-N2a is to recommend the use of absorbance data by establishing a
RCV control that characterizes the baseline viability of N2a cell layer prior to O/V treatment and toxin
exposure. This RCV control serves as a reference from which all other viability controls as well as viability
data of standard and samples depend. This RCV control could be considered as a common reference
across all laboratories employing this method.
As a result of this comprehensive revisit of the CBA-N2a, a practical guide with a step-by-step
protocol was defined (Supplementary Materials), that is accessible to both supervised beginners and
experienced users. It also provides useful decision limits when interpreting CBA-N2a data in the
framework of routine CBA-N2a based monitoring programs.
In this study, the sensitivity of the CBA-N2a was characterized by EC50 values found for
P-CTX3C at 1.7 ± 0.35 pg/mL, consistent with previously published values of 1.3 ± 0.06 pg/mL [46],
1.66 ± 0.16 pg/mL [64,73] and 1.44 ± 0.70 pg/mL [77,78]. However, quite different values can also be
found in the literature, e.g., 0.57 ± 0.11 pg/mL [90], 0.914 ± 0.127 pg/mL [36] and 3.10 ± 0.76 pg/mL [59].
These discrepancies can be attributed to different experimental conditions including different
concentrations of O/V treatment [73] or the use of MeOH as a sample vehicle for higher sensitivity [90].
The EC50 found for PbTx3 was 5.8 ± 0.9 ng/mL, which is lower than the previously published value of
65.60 ± 23 ng/mL [37].
When comparing the mean EC50 values of P-CTX3C to those obtained via other functional
assays, they were found 350-fold lower than those estimated via the radioactive receptor binding
assay (rRBA), i.e., 0.62± 0.16 ng/mL [113] and 0.61 ± 0.01 ng/mL [46], and the fluorescent
RBA, i.e., 0.66 ± 0.16 ng/mL [73], respectively. For PbTx3, EC50 values were 2-fold higher than
those derived from rRBA experiments (2.77 ± 1.09 ng/mL [37] and 2.06 ± 0.16 ng/mL [113]).
These discrepancies observed between functional assays can be explained by the fact that the activity
of these polyether toxins depends not only on their mode of action, and their affinity for specific
sodium channel isoforms [114], but also on their efficacy on other ion channels and references
therein, [37,115–117]. As for the detection of STX and dc-STX, the comparison of CBA-N2a results
obtained in this study with other functional assays was not possible since previous studies used
different units.
For VGSC inhibitors, STX and dc-STX displayed typical dose-response curves with positive
Hillslope in the presence of lethal 270/27 μM OV treatment giving EC50 values of 3 ± 0.5 and
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15.8 ± 3 ng/mL for STX and dc-STX, respectively. At the EC20, this revisited CBA-N2a could specifically
detect inhibition of VGSCs at 1 and 5 ng/mL for STX and dc-STX, respectively. This result is consistent
with a detection limit established at 2 ng/mL for STXs by Manger et al. [19].
This improved CBA-N2a was further applied to the detection of CTX-like toxicity in fish matrix,
giving mean LOD and LOQ values of 0.031 ± 0.008 and 0.064 ± 0.016 ng P-CTX3C eq/g fish flesh,
respectively. In order to compare these results with those obtained via analytical techniques such as
LC-MS/MS data, this LOD value was further expressed in P-CTX1B equivalent, taking into account a
toxicity equivalent factor (TEF) of 0.2 for P-CTX3C [118]. A LOD value of 0.0062 ng P-CTX1B eq/g.
was found below the recommended threshold of 0.01 ppb for P-CTX-1B [118,119], indicating that both
CBA-N2a and LC-MS/MS share similar level of sensitivity for the detection of P-CTXs [61,100,120–122].
However, chromatographic analyses remain unavoidable for the formal characterization of the different
structural analogs (toxin congeners) present in biological samples.
Based on EC50 data, the toxin content in four fish samples of known ciguatoxic status was further
checked via the CBA-N2a. Only two fish specimens, namely Chlorurus microrhinos (Cmic19) and
Epinephelus merra (Emer05) were found to contain 6.66 ± 0.68 and 3.31 ± 0.35 ng P-CTX-3C eq/g fish
flesh, respectively, corresponding to ≈ 1.34 and 0.65 ng P-CTX1B eq/g, which are 134- and 65- fold
above the advisory level recommended by both the US FDA and EFSA [118,119]. The composite
cytotoxicity detected in the Cmic19 Chlorurus microrhinos is in agreement with fRBA and LC-MS/MS
analyses, which confirmed the presence of six distinct P-CTX congeners in this fish [120]. Interestingly,
these toxicity data also confirmed that the overall toxicity of herbivorous fish (parrot-fish) can sometimes
surpass that of a carnivorous fish (grouper), although CTX toxin profiles occurring in individuals
with different trophic habits can differ significantly owing to the biotransformation processes that
occur along the food chain [120,123,124]. In addition to biotransformation, several other traits can
be responsible for the unique CTX toxin profiles of individual fish, including site-specificity, feeding
behavior and ontogenetic dietary shifts [61,123,125].
Several intra- and/or inter-assay comparisons of the revisited CBA-N2a were performed to assess
the coefficients of variations (CVs) obtained for key parameters of CBA-N2a dose-response curves,
and evaluate the repeatability and reproducibility of the method. Results indicate that for both VGSC
activators and inhibitors, EC50 values showed CVs ranging from 10% to 26%, which are considered
as acceptable values for functional tests. These results are congruent with previous studies showing
3.5 to 25% and 5 to 24.7% of CBA-N2a variability for intra and inter-assay, respectively [46,80,93,126].
A variability of up to 30% is generally admitted for other functional tests [127–129]. Additionally,
no significant differences were found for EC50 and EC80 values of P-CTX3C and PbTx3 standards
obtained from two non destructive O/V treatments run at distinct cell passages. Using different OV
concentrations selected in the range of 80/8–100/10 μM and different numbers of cell passage seem to
not impact the values of EC50 and EC80 in our study. For LOD and LOQ values, CVs below 29% were
obtained vs. CV of 13% for composite toxicity estimates in the two ciguatoxic fishes.
3.3. Advantages of the Modified Protocol
An advantage of the CBA-N2a is necessary material and reagents, as well as basic laboratory
equipments are readily (commercially) available.
Several opportunities to reduce reagents were identified at different steps of the test, e.g., using 5%
instead of 10% FBS culture medium for the seeding of N2a cells, renewing culture medium
with only 2% FBS growth medium as opposed to 5% or 10% FBS commonly used in many
studies [34,49,51,56,71,79,80,87,93], or working at lower O/V concentrations for O/V treatment than those
originally proposed [83]. Moreover, the direct addition of O/V solution into the renewed growth medium
also contributes to a better homogeneity of O/V deposit for increased repeatability and reproducibility,
and a reduction of variability sources by limiting the number of pipetting. Finally, this revisited
protocol allowed the use of reduced amounts of expensive toxin standards with e.g., only 80 pg of
P-CTX3C toxin standard required per microplate to establish a full dose-response curve.
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Another advantage of this improved test is its high modularity with respect to the specific
detection of a wide range of toxins acting on VGSCs, i.e., both VGSC activators and inhibitors, thanks
to the definition of O/V treatment conditions allowing the visualization of a drop in cell viability
vs. cell layer restoration, respectively. This protocol also offers the possibility to assay as many as
15 microplates in one experiment (in addition to the one used for RCV control) that can be used either
for the qualitative screening of 120 distinct samples at a single concentration (Figures S3 and S4), or the
composite toxicity analyses of 14 samples and one toxin standard tested at eight distinct concentrations
(Figures S5 and S6), depending on the laboratory research goals. For instance, the high throughput
screening approach would be more suitable in risk monitoring programs aiming at the random testing
of a high number of wild fish specimens, e.g., to confirm the bioaccumulation of CTXs in the marine
fauna and/or the emergence of CP in novel areas. The composite toxicity estimation would be preferred
when confirmatory analyses in fish products are required, e.g., to confirm the diagnosis of CP in patients,
or help link the CTX content in fish to the symptoms and/or severity of the poisoning. Alternatively,
using a two-tiered approach in monitoring programs is also feasible, i.e., perform rapid screening tests
on a whole batch of fish specimens, and then conduct composite toxicity estimations only on those
specimens found suspect or positive.
3.4. Limitations and Gaps of the Present Study
Despite the significant improvements described in the present study, the effects of several
parameters that were not tested here remain to be evaluated prior to the standardization and widespread
use of this method by different laboratories. For example, parameters inherent to slight differences
in N2a cell lines across laboratories due e.g., to mycoplasma infection of cell cultures [130,131],
cell passage numbers [132,133], desensitization treatment [134] or the use of different mammalian cell
lines [53,66,83,135] should be considered in follow-up studies, as they are likely to affect cell growth
rates and cell responses to toxins in this functional assay. Additional studies about the effects of
reagents, media exchange, media renewal, etc. are also needed. Likewise, the inclusion of a limited
number of fish in the matrix interference study presently limits the application of the method for
general detection of VGSC toxins in other matrices (e.g., screening of PbTxs and STXs in shellfish
samples). Another major issue is the current lack of a duly validated standardized extraction protocol
for the detection of CTXs [100,105]. To this respect, the MCE value determined here must not be
regarded as a universal dose as MCE closely depends not only on the extraction protocol used but also
on the nature of the extract being tested [105]. Therefore, laboratories would need to perform their
own matrix assessments prior to CBA-N2a studies.
4. Conclusions
Today, CBA-N2a is widely used for the detection of CTXs in a variety of biological
samples, other than fish, including Gambierdiscus cells [46,59,64,65,79,91,93,136], giant clams [59,137],
gastropods [77], sea urchins [46,78], lobsters and crabs [61], sharks [103] and even samples derived from
passive monitoring sampling devices [138–140], highlighting the benefit of incorporating this functional
assay into routine ciguatera risk monitoring programs for increased food security of populations
worldwide. However, due to the lack of a validated reference detection method, this toxin group is
still unregulated. Owing to the good performance of this revisited CBA-N2a, this improved method
could reasonably be regarded as a first step towards the implementation of a reference functional
detection test, provided its further validation through inter-laboratory studies. To this end, significant
progress needs to be achieved in addressing several other issues such as the current shortage of certified
standards and reference materials as well as the lack of consensus extraction protocols.
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5. Materials and Methods
5.1. Biological Material
5.1.1. Neuroblastoma Cell Line Culture
Mouse neuroblastoma (N2a) cell line (CCL-131) was purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA) (Table S4). The complete growth medium consisted of RPMI
medium 1640 with HEPES and without L-Glutamine, supplemented with 10% fetal bovine serum (FBS),
2 mM GlutaMAX, 1 mM sodium pyruvate, 50 μg/mL streptomycin with 50 units/mL penicillin and
2.5 μg/mL Amphotericin B. This cell line was routinely maintained at 37 ◦C in a 5% CO2 humidified
atmosphere by splitting cell culture by 1:10 (every two days) or 1:30 (every three days) by rinsing the
cell layer with Dulbecco’s Phosphate Buffered Saline without CaCl2 and MgCl2 (DPBS-1X), followed by
a dissociation step using 0.05% Trypsin-EDTA. The N2a cell line used in this study showed a stabilized
growth after 300 P. All experiments presented in this study were done using cell passages ranging
from 383 to 810 P.
All reagents are listed in Supplementary Materials (Table S5). N2a cell line was sub-cultured
in 25 cm2 or 75 cm2 tissue culture flasks (Nunc™ Easy-Flask, ThermoFisherScientific, Kamstrupvej,
Danemark), while 96-well (0.32 cm2/well) flat bottom microplates (Falcon®, Corning Brand, New York,
NY, USA) were used for CBA-N2a experiments. The list of equipments and materials are presented in
Supplementary Materials (Table S6).
5.1.2. Reagents and Toxin Standards
Ouabain octahydrate (O3125), Veratridine (V5754), MTT, DMSO and MeOH are listed in
Supplementary Materials (Table S4). Aqueous stock solutions of Ouabain and Veratridine were
prepared at 20 mM in pure water and 5 mM in pH2 pure water, respectively.
Four toxin standards were used to characterize the mode of action of two toxin families using
the CBA-N2a (Table S4): (i) two VGSC activators for which certified reference material is not
available as yet, i.e., Pacific ciguatoxin P-CTX3C obtained from the bank of standards of Institut
Louis Malardé [77,78,141] and brevetoxin PbTx3 (ref. L8902) purchased from Latoxan (Valence,
France). Stock solutions of P-CTX3C and PbTx3 were prepared in DMSO at 20 ng/mL and 100 μg/mL,
respectively. Non volatile DMSO solvent was chosen to ensure stable toxin concentrations over long
periods of storage; (ii) two VGSC inhibitors for which certified reference materials were purchased
from the National Research Council Canada (NRCC, Halifax, NS, Canada), i.e., saxitoxin STX
(ref. CRM-STX-f) supplied at a concentration of 66.3 μM in aqueous hydrochloric acid 3 mM and
decarbamoylsaxitoxin dc-STX (ref. CRM-dc-STX-b) supplied at a concentration of 65 μM in aqueous
hydrochloric acid 3 mM. Concentrations of the STX and dc-STX standard solutions correspond to 24.7
and 21.4 μg/mL, respectively.
5.1.3. Fish Samples
The four fish samples tested in this study were collected from two ciguatera-endemic areas of
French Polynesia, namely Tikehau Island (Tuamotu Archipelago) and Mangareva Island (Gambier
Archipelago), and conditioned in the form of fillets kept at −20 ◦C until further CTX extraction.
For some of them, their toxicity was also previously characterized by means of the fluorescent Receptor
Binding Assay (fRBA) and/or Liquid Chromatography coupled with Tandem Mass Spectrometry
(LC-MS/MS) [73,120]. Table 8 details their geographic origin, species, trophic status, as well as
ciguatoxic status.
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Table 8. List of fish samples tested for the revisited CBA-N2a.
Genus Species Feeding Type Site Sample fRBA ** LC-MS/MS
Chlorurus microrhinos Herbivorous
Tikehau Cmic02 NT * NT *
Mangareva Cmic19 7.04 [73] six P-CTXs [120]
Epinephelus merra Carnivorous
Mangareva Emer05 4.4 ± 1.1 *** NT *
Mangareva Emer13 NT * NT *
* NT: not tested; ** Fluorescent RBA expressed in ng P-CTX-3C eq/g fish flesh; *** Unpublished data.
5.2. Extraction Procedure
Fish fillets were carefully homogenized in a blender (Groupe SEB, Lourdes, France) waste disposal
unit for 1–2 min [113]. For each fish sample, a portion of 10 g was processed following the protocol
described in Darius et al. 2018 [77]. Briefly, a liquid/liquid partition was applied followed by a
purification step using Sep-Pak C18 cartridges (360 mg sorbent per cartridge; Waters®, Saint-Quentin,
France) leading to three distinct liposoluble fractions, i.e., LF70/30, LF90/10 and LF100. Fractions
LF90/10 likely to contain CTXs were further dried in a SpeedVac concentrator (ThermoFisherScientific,
Waltham, MA, USA) and weighed with a Sartorius Micro balance (model MC 410 S, Sartorius, Göttingen,
Germany) with a reading accuracy of 0.1 mg (Table 9). The resulting dry extracts were resuspended in
pure methanol at a concentration of 10 mg/mL and kept at −20 ◦C until further CBA-N2a analysis.
Prior to dosing by N2a cells, fish extracts were brought to room temperature.
Table 9. Comparison of LF90/10 dry extract weights prepared from 10 g (fresh weight) of fish samples
tested with CBA-N2a.





Cmic02 37 926 10 3.6
Cmic19 45 2230 10 4.3
Emer05 22 185 10 3.1
Emer13 18 80 10 2.7
5.3. Neuroblastoma Cell-Based Assay (CBA-N2a)
5.3.1. Characterization of N2a Cell Growth and Initial Viability
The initial viability of N2a cells is a function of the cell density reached in wells after 26 h growth,
their physiological state and the time allocated for the metabolization of MTT by viable cells.
First, in order to determine the maximum cell density supported by each of the wells (representing
a surface of 0.32 cm2) of 96-well Falcon® microplates, the growth curve of the N2a cell line used in this
study was examined over a period of 4 days. For more convenience, growth experiment was conducted
in 25 cm2 culture flasks. Twelve culture flasks were seeded with 335,000 cells resuspended in 11 mL 10%
FBS culture medium solution, and left to incubate for 22 h as described in Section 5.1.1. Cell densities
were then monitored by sacrificing one flask every 6 h starting from 22 to 76 h. The two last flasks were
sacrificed at 85 and 100 h, respectively. Cell enumeration was achieved by manual counts (n = 10/flask)
using KOVA Glasstic slides (Hycor), and the results plotted against time. Cell density data were
normalized to a surface of 0.32 cm2 and used as a proxy of cell densities in 96-well microplates: e.g., using
this rationale, the initial cell density in a 96-well microplate was estimated at 4288 cells per well.
Second, the initial viability of N2a cells was examined under two different % FBS (5% and 10% in
culture medium) and six different MTT incubation times (15–65 min). Cell numbers before seeding
were determined from n = 5 counts performed on an aliquot of the cell stock suspension and apply for
all further experiments. To this end, twelve microplates (six microplates per % FBS) were seeded with
200 μL of ten different cell seeding densities ranging from 10,000 to 100,000 cells/well (n = 6 wells per
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cell density). After 26 h growth, cell viability was assessed via the MTT assay conducted by sacrificing
one microplate at 15 min and the remaining every 10 min. MTT and DMSO conditions were used as
originally described [19]. The MTT protocol followed the one described in Darius et al. [77]. Briefly,
after removing the culture medium from the microplate, the 60 inner wells were filled with 60 μL of
MTT solution at 0.83 mg/mL prepared in 2% FBS culture medium. After MTT incubation at 37 ◦C in a
5% CO2 incubator, the wells were emptied and the 60 inner wells and 12 outer wells (rows 1 and 12)
were filled with 100 μL of DMSO. Following cell layer lysis with DMSO and manual homogenization,
absorbance data were measured at 570 nm using an iMark™ microplate reader (Biorad, Marnes la
Coquette, France). All viability data were expressed in absorbance data.
5.3.2. Characterization of N2a Cell Final Viability in the Absence and under O/V Treatment
Ouabain and Veratridine (O/V) treatment is required for the successful detection by CBA-N2a
of toxins active on VGSCs. The N2a cell final viability, i.e., in the absence of O/V treatment (OV−
conditions) or following O/V treatment (OV+ conditions) was characterized as follows.
To characterize the final viability of N2a cells in OV− conditions, six microplates were seeded
with 200 μL of a 5% FBS culture medium at ten different cell densities ranging from 10,000 to 100,000
cells/well (n = 6 wells per cell density) and left to grow for 26 h. One microplate, defined as the
RCV control, was used to check the initial viability of N2a cells after 26 h growth and measured
by MTT assay, while the five remaining microplates were treated as follows: culture medium was
discarded under sterile conditions by overturning, and wells were dried by tapping each microplate
on an ethanol-sterilized absorbent paper to remove any residual liquid. The 60 inner wells of the
five microplates then received 200 μL/well of growth medium supplemented with 1%, 2%, 3%, 4% or
5% FBS, respectively, while the peripheral wells received the same volume of sterile distilled water.
Culture microplates were further incubated overnight (Section 5.1.1) for an additional 19 h. Cell final
viability was assessed using the MTT assay after 45 min incubation with MTT.
To characterize the final viability of N2a cells in OV+ conditions, two microplates were seeded
with 200 μL/well of a 5% FBS culture medium at an initial cell density of 50,000 ± 10,000 cells/well,
and left to grow for 26 h. After cell layer settlement, one microplate served as RCV control and
measured by MTT assay. For the second one, 20 mM (O) and 5 mM (V) solutions were first diluted in
2% FBS culture medium to obtain a 360/36 μM O/V stock solution, which was further used to prepare
serial dilutions ranging from 340/34 to 20/2 μM (with a decrease of 20/2 μM between each dilution).
After removal of the used culture medium as previously described, each of the 60 inner wells received
200 μL/well of culture medium at nineteen distinct O/V concentrations ranging from 0/0 to 360/36 μM
(n = 3 wells per O/V treatment conditions, except for 0/0 μM condition for which n = 6). Peripheral
wells received the same volume of sterile distilled water. Culture plates were then incubated overnight
for 19 h. Cell final viability was assessed using the MTT assay after 45 min incubation with MTT.
Five independent experiments were performed.
5.3.3. Characterization of the Unspecific Effects of Solvent and Dry Extract on N2a Cell Viability
The effects on N2a cell viability of two solvents commonly used to resuspend toxin standards and
dry extracts, i.e., MeOH and DMSO, were examined in the absence vs. under non-destructive O/V
treatment conditions. In this experiment, the 60 inner wells of three 96-well microplates were seeded
with 200 μL/well of a 5% FBS culture medium at an initial cell density of 50,000 ± 10,000 cells/well,
and left to grow for 26 h. One microplate served as RCV control and was measured by MTT assay while
the two remaining ones were treated as follows: after the complete removal of the used culture medium
as previously described, the 30 inner wells on the upper half of the microplate received 200 μL/well
of a 2% FBS culture medium (OV− conditions), while the 30 inner wells on the bottom half of the
microplate received 200 μL/well of a 105/10.5 μM O/V treatment (OV+ conditions). In parallel, 100 μL
of eight-points serial dilution at 1:2 of each solvent were prepared in the same culture medium using a
U-bottom 96-well microtiter plate. Then, 10 μL of each solvent dilution were directly added in triplicate
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wells and tested under OV− conditions versus OV+ conditions (100/10 μM final concentrations). Hence,
the final concentrations tested ranged from 0.037 to 4.762%. Addition of 10 μL of 2% FBS culture
medium in triplicate wells under OV− and OV+ conditions (COV− and COV+ controls, respectively),
allowed to check final viability in solvent-free growth medium. Peripheral wells received the same
volume of sterile distilled water. Culture plates were left to incubate overnight for 19 h, and the cell
final viability determined using the MTT assay after 45 min incubation with MTT.
In order to determine the MCE of the four fish samples, increasing concentrations of fish extracts
were tested in OV− conditions only, as no activity on VGSCs is expected to occur in this condition of
treatment [81]. In most CBA-N2a studies however, these concentrations are established based on the
fresh tissue weight of biological samples. Here, the tested concentrations were estimated based on the
DEW instead, since dry extracts interact directly on cell layers and substantial differences in DEWs are
often observed between extracts prepared from a same amount of tissue sample. In order to determine
the MCE of the four fish samples used in this study, the 60 inner wells of three 96-well microplates were
seeded with 200 μL of a 5% FBS culture medium at an initial cell density of 50,000 ± 10,000 cells/well,
then left to grow for 26 h. One microplate served as RCV control and was measured by MTT assay,
while the two remaining ones were treated as follows: first, 5% FBS growth medium was renewed by
addition of 200 μL of a 2% FBS culture medium in wells. In parallel, a 1:10 dilution of the LF90/10
dry extract of four fish samples was prepared in 2% FBS culture medium using a U-bottom 96-well
microtiter plate, followed by a nine-points serial 1:2 dilution (v = 100 μL per concentration). Then, 10 μL
of each concentration was directly added in triplicate wells, leading to final dry extract concentrations
that ranged from 186 to 47,619 pg/μL, i.e., 0.517 to 132.3 μg fish flesh equivalent/μL for Cmic02, 0.433 to
110.7 μg/μL for Cmic19, 0.600 to 153.6 μg/μL for Emer05 and 0.689 to 176.3 μg/μL for Emer13. Two fish
samples were tested per plate. Controls wells (COV−) were also established by addition of 10 μL of
2% FBS culture medium in the absence of dry extract. Peripheral wells received the same volume of
sterile distilled water. Culture plates were left to incubate overnight for 19 h, and the cell final viability
determined using the MTT assay after 45 min incubation with MTT. Three independent experiments
were performed.
5.3.4. Detection of VGSCs Activators and Inhibitors by CBA-N2a
In this experiment, 60 inner wells of five 96-well microplates were seeded with 200 μL of a 5%
FBS culture medium at an initial cell density of 50,000 ± 10,000 cells/well, and left to grow for 26 h.
One microplate served as RCV control and was measured by MTT assay, while the four remaining
ones were treated as follows: first, the growth medium was renewed by the addition of 200 μL of 2%
FBS culture medium in OV− conditions (upper half of the microplate) versus 200 μL of culture medium
in OV+ conditions (bottom half). The initial O/V concentrations in wells were 105/10.5 and 284/28.4 μM
when detecting VGSC activators and VGSC inhibitors, respectively. Further, a nine-points serial 1:2
dilution of each toxin standard stock solution was prepared in 2% FBS culture medium (v = 100 μL per
concentration) using a U-bottom 96-well microtiter plate, then 10 μL of each toxin concentration were
directly added in triplicate under OV− and OV+ conditions (Section 5.3.3). The final concentrations
of toxins tested ranged from 0.074 to 19.048 fg/μL for P-CTX3C, 372 to 95,238 fg/μL for PbTx3, 368 to
94,095 fg/μL for STX and 1592 to 407,619 fg/μL for dc-STX. The final O/V concentrations in wells were
100/10 and 270/27 μM when detecting VGSC activators and VGSC inhibitors, respectively. Appropriate
controls in both conditions of O/V treatment, COV− and COV+, were established to verify the cell layer
viability and the effect of O/V treatment, respectively, in the absence of toxins (Figure S7). The resulting
full dose-response curves were used to characterize the response typical of a given standard toxin
and for further toxin quantification. For each toxin standard, one microplate in three independent
experiments was examined for the purpose of inter-assay variability comparison.
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5.3.5. Detection of VGSC Activators in Fish Samples by CBA-N2a
This experiment was conducted as previously described in Section 5.3.4, except that the initial
concentrations of O/V in wells was set to 90/9 μM. Toxin detection and quantification in biological matrix
of unknown varying toxicity require the implementation of additional quality check controls (QC) in
OV− and OV+ conditions, namely QCOV− and QCOV+, to check for the validity of further toxicity
results (Figure S2). Practically, in these controls, a known concentration of a VGSC activator is tested,
whose effect on N2a cell viability has been pre-established. The QCOV− and QCOV+ were established
by adding 10 μL of 0.1 μg /mL of PbTx3 in triplicate, to reach a final concentration of 4760 fg/μL of
PbTx3 in wells (PbTx3 was preferred to P-CTX3C as it is commercially available). An eight-points
serial 1:2 dilution of P-CTX3C and fish dry extracts were prepared (v = 100 μL per concentration)
using a U-bottom 96-well microtiter, then 10 μL of each concentration were directly added in triplicate
under OV− and OV+ conditions (85.7/8.57 μM final concentrations). Hence, the final concentrations
of P-CTX3C tested ranged from 0.099 to 12.70 fg/μL and from 74.4 to 9523.8 pg of dry extracts/μL
for Cmic02 and Emer13, 14.9 to 1904.8 pg of dry extracts/μL for Cmic19 and 18.6 to 2381 pg of dry
extracts/μL for Emer05. The full sigmoidal dose–response curves obtained for each toxin standard and
fish samples when tested in parallel in the same experiment were used to determine EC50 values and
infer toxin content in fish samples (Section 5.3.6). Three microplates in one experiment (n = 3) and
one microplate in three independent experiments (n = 3) were examined for the purpose of intra- and
inter-assay variability comparison, respectively.
Validation of the CBA-N2a results by means of appropriate viability controls are presented in
Supplementary Materials (Table S4).
5.3.6. Absorbance Data and Toxin Analysis
First, for each experimental plate, all raw absorbance data were corrected by deducting
the corresponding mean DMSO control absorbance data (n = 12) to obtain net absorbance data.
Dose-response curves were then established by plotting net absorbance values vs. pure toxins or dry
extract concentrations tested, using GraphPad Prism software version 8.1.2 (GraphPad, San Diego,
CA, USA) based on a four parameter logistic regression model (4PL) according to the following
equation:
Y = Bottom + (Top − Bottom/(1 + 10ˆ((Log(EC50) − Log(X)) ∗ Hillslope)) (2)
In which Y is the net absorbance data and X is the concentrations tested (fg/μL), and EC50 (fg/μL)
represents the effective concentration of dry extract inducing a viability half way (50%) between the
basal (Bottom) and the maximal (Top) values of the curve (EC50). This parameter is used to establish
the toxic potency of each toxin standard.
The EC80 and EC20 values of toxin standards were inferred from dose-response curves and
correspond to the effective concentration of dry extract inducing a viability 80% and 20% between the
basal (Bottom) and the maximal (Top) values of the curve, respectively.
The limit of detection (LOD) and quantification (LOQ) of the CTX-like toxicity in fish samples
were determined according to the following equations:
LOD = (EC80/MCE) (3)
LOQ = (EC50/MCE) (4)
where EC80 and EC50 are the values obtained for P-CTX3C toxin standard, with values expressed in ng
P-CTX3C eq/mg of dry extract.
For more convenience, LOD and LOQ values can be expressed in the same unit as the one used in
the advisory level recommended by the EFSA and US FDA. Calculations are based on the fresh weight
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of flesh tissue extracted (FW) and the corresponding dry extract weight (DEW) (Table 9), and use the
following equations:
LOD = (EC80/MCE) × (DEW/FW) (5)
LOQ = (EC50/MCE) × (DEW/FW) (6)
In which LOD and LOQ of CTXs in biological matrix are expressed in ng P-CTX3C eq/g fish flesh.
In the same way, quantification of the composite toxicity in fish dry extracts (T), expressed in ng
P-CTX3C eq/mg, was determined by comparing the EC50 values of P-CTX3C and fish dry extracts
determined in the same experiment, using the following equation:
T = EC50 of P-CTX3C/EC50 of dry extract (7)
The composite toxicity in biological samples (Q), expressed in ng P-CTX3C eq/g of fish flesh,
is determined using the following equation:
Q = T × (DEW/FW) (8)
5.3.7. Data Analyses
Variabilities of CBA-N2a data were examined using the mean ± SD of three microplates tested in
one experiment on the same day (intra-assay comparisons) or the mean ± SD of one microplate tested
in three independent experiments (inter-assay comparisons). Statistical analyses were performed by
means of the Wilcoxon test with significant differences considered at p-values < 0.05, using RStudio
software version 1.0.153 Version 1.0.153–© 2009-2017 (RStudio, Inc., Boston, MA, USA).
First, the intra- and inter-assay variabilities of the five viability controls (Table S7), RCV, COV−,
COV+, QCOV− and QCOV+ controls were assessed from inter-assay experiments conducted at
100/10 μM run at 662-663-666 cell passages and intra- and inter-assay experiments conducted at
85.7/8.57 μM run at 810 and 795-797-798 cell passages, respectively of CBA-N2a experiments presented
in Sections 2.4.2 and 2.4.3 and Table S1.
Second, the Wilcoxon test was applied to search for variability between EC80 and EC50 of P-CTX3C
and PbTx3 obtained from inter-assay experiments conducted at 100/10 μM and run at 662-663-666
cell passages, and intra- and inter-assay experiments conducted at 85.7/8.57 μM and run at 810 and
795-797-798 cell passages, respectively (Table 4, Table S2).
For intra- and inter assay comparison of LOD and LOQ values of the CTX-like toxicity in
fish dry extracts, three different P-CTX3C EC80 or EC50 values were compared to a unique MCE
value, i.e., 10,000 pg/μL applying for all fish samples. Then, three LOD and LOQ values were obtained
giving a mean ± SD with n = 3 for intra- and inter-assay for all fish samples (Table 5).
For intra- and inter assay comparison of LOD and LOQ values of the CTX-like toxicity in fish
flesh, one specific MCE value (converted from the DEW/FW ratio) was obtained for each fish sample.
Then, three different P-CTX3C EC80 or EC50 values were compared to a unique MCE value per fish
sample. In the same way, three LOD and LOQ values were obtained for each fish giving a mean ± SD
with n = 3 for intra- and inter-assays (Table 5). Additionally, the Wilcoxon test was successfully applied
to search for possible variability between LOD and LOQ values among the four fish samples (Table S3).
For intra-assay comparison of toxin content in fish sample, three different P-CTX3C EC50 values
obtained from n = 3 microplates were compared to three different fish EC50 values obtained from
n = 3 microplates of a given fish sample run the same day. Then, cross calculation (three different
P-CTX3C EC50 values x three different fish EC50 values) were done giving nine toxin content values
and a mean ± SD with n = 9 per fish sample (Table 7).
For inter-assay comparison of toxin content in fish sample, one P-CTX3C EC50 value was
compared to one fish EC50 value for each fish sample per independent experiment run at different
times. Then, three toxin content values were obtained from the three independent experiments giving
a mean ± SD with n = 3 for each fish sample (Table 7).
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Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/12/5/281/s1,
Figure S1: Examples of pictures obtained from the revisited CBA-N2a, Figure S2: Suggested layouts on a 96-wells
microplate at day 2 of the CBA-N2a, Figure S3: Detection (DL) and confirmation (CL) limits adopted in qualitative
screening analysis of samples tested for the presence of VGSC activators (under non-destructive O/V treatment),
Figure S4: Detection (DL) and confirmation (CL) limits adopted in qualitative screening analysis of samples tested
for the presence of VGSC inhibitors (under destructive O/V treatment), Figure S5: Typical dose-response curve
expected with a sample positive for VGSC activators, tested at eight distinct concentrations (C1–C8) adjusted to
fall below the MCE, Figure S6: Typical dose-response curve expected with a sample positive for VGSC inhibitors,
tested at eight distinct concentrations (C1–C8) adjusted to fall below the MCE, Table S1: Comparison between
assays of the absorbance data of five viability controls, Table S2: Comparison between assays of EC50 and EC80
values of P-CTX3C and PbTx3 standards under two non destructive O/V treatments (100/10 μM vs. 85.7/8.57
μM), Table S3: Comparison between assays of LOD and LOQ values (ng P-CTX3C equivalent/g fish flesh) under
non-destructive O/V treatment at 85.7/8.57 μM), Table S4: List of biological materials, Table S5: List of reagents,
Table S6: List of equipments and materials, Table S7: Expected results for viability controls to enable validation of
the assay.
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Abstract: Citreoviridin (CTV) in an inhibitor of mitochondrial ATPase that has been isolated
from molded yellow rice and linked to the human disease Shoshin-kakke (acute cardiac beriberi).
The disease results from a deficiency of thiamine, however, purified CTV can reproduce the symptoms
in experimental animals. The link between CTV and Shoshin-kakke has been difficult to resolve,
in part because cases of the disease are rare. In addition to rice, CTV has been found in maize,
pecan nuts, and wheat products. A method to screen for CTV and its geometric isomer, iso-CTV,
in commodities was developed, based upon the isolation of two novel monoclonal antibodies (mAb).
In an antigen-immobilized competitive enzyme-linked immunosorbent assay format (CI-ELISA),
the observed IC50s for CTV were 11 ng/mL and 18 ng/mL (mAbs 2-2 and 2-4, respectively). The assays
were relatively tolerant to methanol and acetonitrile, which allowed their application to the detection
of CTV in spiked polished white rice. For quantification, a standard mixture of CTV and iso-CTV was
used, along with matrix matched calibration. The dynamic range of the ELISA using mAb 2-4 was
equivalent to 0.23 to 2.22 mg/kg in rice. Recoveries over the range of 0.36 to 7.23 mg/kg averaged
97 ± 10%. The results suggest that the mAb 2-4-based immunoassay can be applied to the screening
of white rice for CTV. Both mAbs were also observed to significantly enhance the fluorescence of
the toxin.
Keywords: citreoviridin; antibody; immunoassay; rice
Key Contribution: Two monoclonal antibodies were produced and used to develop a screening
immunoassay for detecting the mycotoxin citreoviridin at relevant levels in white rice.
1. Introduction
In Japan in the years before World War I and continuing through the 1920s, there were human
illnesses associated with consumption of moldy, yellow, rice. The illness, classified at the time as
Shoshin-kakke (acute cardiac beriberi) decreased in incidence significantly around 1910, a fact attributed
to increased inspection of rice by Japanese authorities [1]. The disease was related to beriberi, now
known to be caused by thiamine deficiency. By 1930 Shoshin-kakke had almost completely disappeared
from Japan [1]. Subsequent investigations in Japan led to the differentiation of the broad category
of yellow-colored rice into five groups, of which four are caused by Penicillium spoilage and one by
Eurotium amstelodami [2]. The four caused by Penicillia are each associated with a different species
of fungus and a different causative agent. The type of yellow rice known as Ou-hen-mai is infested
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with Penicillium citreonigrum and has been associated with Shoshin-kakke. In 1964 the structure of the
mycotoxin believed to be the causative agent (citreoviridin, CTV) was reported [3]. Another type of
yellow rice is Citrinum yellow rice (Citrinum ou-hen-mai) where the causative fungus is P. citrinum and
the associated mycotoxin is citrinin. In 2006–2008 an outbreak of beriberi occurred in the Maranhão
state of Brazil. Despite the presence of a few samples contaminated with CTV, the cases appear to have
been predominantly a result of thiamine deficiency, as many were reversed following administration
of thiamine [4–6]. An excellent summary of the history of yellow rice and the classification of rice
infested with fungi was provided by Kushiro [2].
The connection of Shoshin-kakke to moldy rice has been confounded by the multiple types of
“yellow rice”, the low incidence of the disease in modern times, and the extent to which thiamine
deficiency is required to produce symptoms. In research conducted in the 1960s and early 1970s,
crude alcohol extracts of moldy rice were tested in 14 vertebrate species [1,7]. Symptoms included
paralysis of the legs, vomiting, convulsions, and respiratory arrest [7]. Purified CTV given to mice,
cats, and dogs reproduced these symptoms, with an LD50 of 20 mg/kg in mice [1]. Purified CTV given
to mice and rats was lethal, with LD50s ranging from 3.6 to 11 mg/kg [7]. Reproducing symptoms of
Shoshin-kakke with purified CTV was important for distinguishing intoxication due to consumption of
yellow rice, from disease caused directly by thiamine deficiency. As such, Shoshin-kakke is considered
to be a mycotoxicosis [2].
On the molecular level, CTV inhibits the mitochondrial adenosine triphosphatase (ATPase) [8,9].
When given to rats CTV altered the pattern of transketolase (EC 2.2.1.1) in liver, and in vitro experiments
suggested an anti-thiamine effect of the toxin [10]. A mechanism that involves the exacerbation or
causation of thiamine deficiency would be consistent with the involvement of CTV in Shoshin-kakke.
Recently, the toxicokinetics of CTV was determined in swine [11]. Results suggested that following oral
exposure, CTV was readily absorbed by swine, and slowly metabolized, with a half-life of 21 h [11].
CTV (Figure 1) is produced by a variety of fungi including P. citreonigrum, Aspergillus terreus, and
Eupenicillium ochrosalmoneum (actual identity P. ochrosalmoneum) [12–14]. The fungi that produce CTV
were summarized recently by Peterson et al. [15]. While it is known primarily for its association with
rice in Asia, CTV has been found in maize and pecan nuts in the United States [16,17]. It has also been
found in rice and wheat-based products in Brazil [18] and in grain dust in Belgium [19].
 
Figure 1. Structure of citreoviridin (CTV) and related compounds.
The structure of CTV was first determined in 1964 [3]. Many of the physical properties of CTV
were reported by Ueno and Ueno [7] and were summarized by Cole and Cox [20]. Purified CTV
is bright yellow and, in methanol, has absorption maxima in the ultraviolet at 383 nm (ε 44,925),
294 nm (ε 24,725), 285 nm (ε 23,343), 238 nm (ε 10,383), and 203 nm (ε 15,388) [21]. Similar absorption
maxima, but lower molar absorptivity coefficients were reported more recently, also in methanol:
387 nm (ε 31,590), 294 nm (ε 21,960), and 285 nm (ε 20,060) [13]. The latter also reported Fourier
78
Toxins 2019, 11, 630
transform infrared (FTIR), 1H-, and 13C-nuclear magnetic resonance (NMR) spectra of CTV. Early
reports established that CTV was fluorescent [7,22].
CTV has been extracted from commodities and fungal cultures with a variety of solvents,
including ethanol (used in the early toxicity testing), chloroform [13,17], dichloromethane [21] and
aqueous methanol [23–25]. Before 1988 most analytical methods for detecting CTV relied upon
thin-layer chromatography, however, in that year a normal phase liquid-chromatography method
with fluorescence detection (LC-FLD) was reported [21]. With a mobile phase of ethyl acetate-hexane
(3+1) the fluorescence was detected at 480 nm using an excitation of 388 nm. More recently, normal
phase LC-FLD was used to detect CTV in rice [4]. CTV has also been measured using reverse phase
LC with photodiode array detection (LC-PDA) [13]. Several laboratories have reported reverse phase
LC-tandem mass spectrometry (LC-MS/MS) methods [13]. The molecular ion in positive mode was
observed at m/z 403.2, with the main fragments at m/z 315 and 139 [13,18]. Detailed mass spectra were
reported by Rebuffat et al. [26].
The total synthesis of CTV gave a product that upon exposure to ambient light yielded a mixture
of two major components. This led to the realization authentic CTV, which exists as the all-trans form,
undergoes photoisomerization, with the product termed “iso-CTV” [27]. The ratio of CTV:iso-CTV has
been reported as 7:3 [28] and 3:2 [4,27]. Handling the purified CTV only under red light minimized
the isomerization, however handling the toxin under typical laboratory ambient light resulted in
the mixture reaching a photostable state within only 1 to 9 h [27]. Even when stored under frozen
conditions and protected from light, CTV has been reported to isomerize [13]. As such it should be
considered that, under typical laboratory conditions, preparations of “citreoviridin” will likely exist as
mixtures that at equilibrium have ratios of CTV:iso-CTV ranging from 1.5:1 to 2.3:1.
Antibodies against CTV have been reported previously. These included polyclonal antibodies [23],
a monoclonal antibody (mAb) [24], and a single chain variable fragment (scFv) antibody [25]. While
these represented important efforts, the sensitivities of the immunoassays allowed for improvement.
In this report we undertook to develop monoclonal antibodies for the detection of CTV, to improve
immunoassays for CTV, and to apply such immunoassays to spiked white rice. In an attempt to yield
improved antibodies, CTV-protein conjugates were prepared using a different approach from that
described previously. Following the development of the mAbs, an interesting effect of the antibodies
on the fluorescence of CTV was observed and was likewise studied.
2. Results and Discussion
2.1. Antibody Development, and Tolerance to Solvents
Because of its low molecular weight, CTV was first conjugated to bovine serum albumin (BSA)
prior to immunization of mice. To facilitate the identification of CTV-binding antibodies, an ovalbumin
(OVA) conjugate was also prepared and used as the immobilized antigen in an indirect competitive
enzyme-linked immunosorbent assay (CI-ELISA). Previous attempts to produce CTV antibodies either
oxidized the hydroxy groups on CTV and then linked them to proteins [23], or formed hemisuccinate
derivatives that were then linked to the proteins [24]. Both routes involved linkage through the hydroxy
groups of CTV. In our attempt, the linkage was also made through the hydroxy groups, but using a
carbodiimide-based chemistry that did not involve oxidation of the hydroxy groups first or require
the introduction of a long linker group. When reacted with hydroxy groups, the reagent used, 1,
1′-carbonyldiimidazole, forms a carbamate linkage with primary amines of the proteins, adding only
one carbon to the length of the linkage [29]. The BSA conjugate (CTV-BSA3) was administered to 10
mice and their sera was evaluated for binding to the OVA conjugate (CTV-OVA2) and for response to
free CTV. Two of the sera showed binding to the immobilized antigen (CTV-OVA2) and were selected
for sacrifice and splenocyte fusions. No viable products were collected from the first fusion, while the
second fusion yielded only five products. Of the five, three were able to bind free CTV. Attempts to
subclone these three yielded two stable cell lines designated herein as “2-2” and “2-4”. Antibodies
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produced by these two cell lines were evaluated in a CI-ELISA format for their sensitivity towards free
CTV, cross-reactivity towards small molecules with similar structures, tolerance to solvents, and ability
to detect CTV in spiked rice.
The antibodies were relatively sensitive to CTV in buffer (0.1% OVA-phosphate buffered saline
(PBS)), with IC50s in the range of 11 to 18 ng/mL. The analytical standard used to determine the IC50s
contained predominantly CTV, with a small proportion of iso-CTV (7%, Figure 2A).
 
Figure 2. Liquid chromatography-tandem mass spectrometry (LC-MS) traces of protonated CTV and
iso-CTV (m/z = 403.2). (A) The analytical standard used for establishing the response of the competitive
enzyme-linked immunosorbent assays (CI-ELISAs) under various solvent conditions (93% CTV, 7%
iso-CTV). (B) The standard mixture used for examining cross-reactivity to iso-CTV and for spiking rice
samples (64% CTV, 36% iso-CTV).
Three compounds having structures that resembled portions of CTV were examined for cross
reactivity, including 4,6-dimethyl-α-pyrone (DMP), iso-dehydracetic acid (IDHA), and L-(+)-threose
(Figure 1). DMP and IDHA have some similarity to the lactone portion of CTV. L-(+)-threose has some
similarity to portions of the substituted furan of CTV. Neither IDHA nor L-(+)-threose were recognized
by either of the mAbs, even at levels as high as 500 μg/mL, indicating a cross-reactivity of less than
0.004%. There was a slight inhibition with DMP at 500 μg/mL, indicating a slight cross reaction on the
order of 0.04%. Obtaining IC50 data for DMP would have required concentrations above the solubility
limit for this compound in the test buffer, hence the upper limit on the cross-reactivity. Of course,
the most interesting compound to test for cross-reactivity was iso-CTV. This material was not available
commercially as an analytical standard, likely because of the photoconversion between iso-CTV and
CTV. However, some insights were obtained by comparing responses of standard curves prepared with
a small proportion of iso-CTV (7%, Figure 2A) to those prepared with a higher proportion of iso-CTV
(36%) (Figure 2B). The comparison was made by accounting for the total of the CTV and iso-CTV
present. As indicated in Figures S1 and S2, when the total of CTV and iso-CTV was accounted for,
the calibration curves obtained with both mixtures were nearly superimposable, with nearly identical
IC50s. Put another way, if the calibration curves were not corrected for the presence of the iso-CTV,
the preparation in Figure 2B (high iso-CTV) gave a much better ELISA response than the preparation in
Figure 2A (low iso-CTV). The strong similarities between the two curves, when iso-CTV was accounted
for, provided indirect evidence that the antibodies also recognize iso-CTV. Unfortunately, the absence
of a relatively pure iso-CTV standard prevented us from establishing this directly.
Citreoviridin is relatively hydrophobic, with a predicted Log P of 3.04, compared to 2.68 for
toluene and 3.94 for n-hexane [30]. Because of this, the conditions to extract CTV and iso-CTV from
commodities use organic solvents or aqueous mixtures of organic solvents. For this reason, it was
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important to determine the impact of solvent concentration upon the CI-ELISAs of the two antibodies.
Both antibodies demonstrated good tolerance to methanol and poorer tolerance to acetonitrile (Table 1).
There was not a significant impact of methanol until the concentration used to prepare the standards
reached 30% (v/v). At that point, the solubility of the OVA in the test buffer began to fail, and the
variability amongst replicates worsened. The proteins began to precipitate at a lower concentration
with acetonitrile (20%), which limited the concentration tested here to 15%. For the best results
the methanol concentration should be kept at or below 20% and the acetonitrile concentration at or
below 10%.
Table 1. Effects of methanol and acetonitrile on the CI-ELISAs based upon mAbs 2-2 and 2-4.
Solvent Concentration a
IC50 for CTV (ng/mL)
Replicates b
mAb 2-2 mAb 2-4
Buffer c - 11.1 ± 3.2 17.9 ± 5.6 8
Methanol
10% 14.8 ± 1.2 20.4 ± 0.5 4
15% 13.7 ± 1.2 21.7 ± 4.6 6
20% 15.2 ± 1.6 21.0 ± 1.1 4
30% 24.9 ± 14.6 36.9 ± 12.5 4
Acetonitrile
5% 13.3 ± 2.1 20.7 ± 1.1 4
10% 18.7 ± 3.3 29.2 ± 4.6 4
15% 29.6 ± 2.5 43.4 ± 4.2 4
a Concentration of solvent in which the CTV standards were prepared (percentage, v/v). The concentration of
solvent in the competition mixture is half of this value. b Number of replicate plates used in the statistic. c 0.1%
ovalbumin-phosphate buffered saline (OVA-PBS).
As noted previously, the mAbs 2-2 and 2-4 are not the first antibodies that have been applied to
immunoassays for CTV detection. The development of mouse polyclonal antibodies (pAb), mouse
mAbs, and a single chain variable fragment (scFv) antibody were reported by researchers at the Fujian
Agricuture and Forestry University [23–25]. These are the only known reports of CTV antibodies,
and the response of the mAbs 2-2 and 2-4 compared well to them, with lower IC50s and working ranges
(Table 2).
Table 2. Immunoassays for CTV.
Type of Antibody IC50 for CTV (ng/mL)
Dynamic Range (IC20 to IC80)
(ng/mL)
Citation
pAb 560 Not specified [23]
mAb 161 11–2370 [24]
scFv 120 25–562 [25]
mAb 11 3–29 this work, mAb 2-2
mAb 18 5–42 this work, mAb 2-4
2.2. Application of mAb 2-4 Competitive Enzyme-Linked Immunosorbent Assay (CI-ELISA) to Spiked Rice
CTV has been extracted from commodities using a wide range of solvents, from pure
dichloromethane to 5% methanol [13,17,23–25]. To ensure compatibility with the ELISAs, a mixture of
80% methanol/20% water was used for the extractions reported here. The extracts were filtered and
diluted 1:8 yielding test solutions containing 10% methanol, a level within the range that was found to
be acceptable in the solvent-tolerance tests (Table 1). Yellow rice has typically been described as rice
that has molded following dehulling and polishing. For this reason, the rice used for the recovery
experiments was polished, dehulled, white rice. Because it was also expected that yellow rice samples
would likely have been exposed to ambient lighting, and CTV is known to form an equilibrium with
iso-CTV, a spiking solution was chosen that contained both CTV and significant iso-CTV (Figure 2B).
Previous literature indicated that under ambient lighting CTV and iso-CTV reach an equilibrium with
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a ratio of approximately 1.5:1 to 2.3:1 CTV:iso-CTV. In the recovery studies reported here, the ratio of
CTV:iso-CTV was 1.8:1. Rice was spiked with this mixture over the range of 0.36 to 7.24 mg/kg “total”
(CTV + iso-CTV). Matrix matched calibration with the same stock solution was used to quantify the
concentrations of total CTV + iso-CTV in the spiked rice.
While mAb 2-2 was the more sensitive of the two antibodies, in terms of IC50s (Table 1, Figure S2),
it also tended to give greater variability in response when toxin was absent (data not shown). For this
reason, mAb 2-4 was selected as the basis of the screening assay for rice. Performance characteristics




Figure 3. Calibration curve in rice matrix. The standard used for this curve contained a mixture of CTV
and iso-CTV in the ratio of 1.8:1. Data are the mean values from 6 replicate plates with mAb 2-4. Error
bars are ± 1 standard deviation (SD). The midpoint was 21.7 ng/mL, equivalent to 694 μg/kg in rice.
The LOD, calculated as the response three standard deviations below the response of the toxin-free
samples, was estimated to be 0.13 mg/kg. The IC20 and IC80 were used to establish the dynamic range of
0.23 to 2.22 mg/kg. To improve quantification, spiked samples that contained greater than 2 mg/kg were
additionally diluted to keep the resulting signals within the dynamic range. The recoveries observed
were excellent (Table 3). From 30 samples covering the range of five spiking levels, the recoveries
averaged 96.7% with individual recoveries that ranged from 74.0% to 118.8%. The relative standard
deviation was 10.2%. We were not able to obtain any naturally contaminated samples of yellow rice
that would permit evaluation beyond our recovery studies. CTV has been found at levels of up to
254 μg/kg in rice bran [4] which is at the lower end of the dynamic range, and in maize kernels at
up to 2790 μg/kg [16], which is above the dynamic range of the mAb 2-4 CI-ELISA. Currently there
are no regulatory levels established for CTV in commodities or foods, which makes determining
a target level at which the assay should perform difficult. However, the data from oral toxicity
testing provide a context for what levels may be important in foods. Recently a neurogenesis model
was described wherein maternal mice were exposed to CTV through the diet from gestation day 6
through postnatal day 21. Male offspring were analyzed for effects on hippocampal neurogenesis.
The no-observed-adverse-effect level was determined to be 1 mg/kg [31]. This level fits within the
dynamic range for the CI-ELISA (0.23 to 2.22 mg/kg). Because of this, it appears that the CI-ELISA
would be applicable to the screening of CTV and iso-CTV at levels that are toxicologically relevant.
Previous immunoassays for CTV have also reported good recoveries from rice and corn. In those
experiments, the extraction solution was either 5% methanol (for rice powder) [23], or 10% to 20%
methanol (for corn) [24,25]. Unfortunately, in all three cases the authors reported the spiking levels
in units of “μg/mL”, rather than in units related to the mass of the food (i.e., μg/kg or mg/kg). The
units of μg/mL suggested that perhaps these referred to the spiking levels in liquid extracts, rather
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than to spiking levels in the solid food, a point that is unclear in the manuscripts. Because of this
uncertainty, it is unclear what the real spiking ranges were in the previous work. Despite this, results
from all three articles suggest recoveries were good, with average recoveries of 90% [24] 84–90% [25]
and 70.5–95% [23]. Given the greater IC50s for the previously reported antibodies (Table 2), it is likely
that, on a weight basis, the spiking levels were generally higher than reported here.








(% ± 1 SD) a
Number of
Replicates b
0.23 0.13 0.36 91.9 ± 14.3 6
0.46 0.26 0.72 89.6 ± 7.8 6
0.93 0.52 1.45 97.9 ± 3.2 6
1.86 1.03 2.89 106.2 ± 8.7 6
4.65 2.58 7.23 97.7 ± 7.1 6
Average (all): 96.7 ± 10.2 30
a Mean recovery ± one standard deviation (SD). b Number of rice samples that were spiked.
2.3. Effects of mAbs on the Fluorescence of Citreoviridin (CTV)
Molecular oxygen is known to quench most fluorophores [32]. Local environments that exclude
molecular oxygen, for example the binding of a fluorophore within a protein, can increase fluorescence
by reducing the inhibition caused by molecular oxygen. The previous sections have established that the
mAbs selectively bound CTV. Therefore, we examined whether the fluorescence of CTV was influenced
by the presence of mAbs or BSA. The concentrations of CTV and protein chosen for these experiments
(1.25 and 2.0 μM, respectively) were selected so as to minimize interference from the fluorescence from
the proteins themselves. The results demonstrated that the CTV mAbs significantly enhanced the
fluorescence of CTV in aqueous systems (Figure 4).
Figure 4. Effects of two CTV mAbs, bovine serum albumin (BSA), and a control mAb on the fluorescence
of CTV. (A) Emission spectra with excitation at 420 nm. (B) Excitation spectra with emission at 570 nm.
The concentration of CTV was 1.25 μM, while the concentrations of the proteins were 2.0 μM. The black
and red lines represent CTV incubated with mAb 2-2 and mAb 2-4, respectively. The pink line represents
the control of CTV incubated with an anti-deoxynivalenol mouse mAb (mAb 1-6.2.6). The green line
represents the control of CTV in buffer without added mAb or BSA.
Both the excitation and emission of CTV were manifest as broad peaks. The excitation maximum
was 420 nm and the emission maximum 570 nm (Figure 4). BSA also enhanced the fluorescence
of CTV slightly. The concentrations of the proteins used in our experiments were relatively low.
For immunoglobulin Gs 2.0 μM equates to approximately 0.3 g/L, while for BSA it equates to
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approximately 0.13 g/L. For comparison, the reference range for human serum albumin in blood is
35–50 g/L (approximately 525 to 750 μM), which is substantially higher. At those levels we suspect
that the binding of CTV would also be increased significantly, although quantifying this effect would
require separating out the fluorescence of the CTV from the previously reported fluorescence of the
serum albumin [33]. With regard to the antibodies, the enhancement of CTV fluorescence was seen
at levels at which the fluorescence of the antibody did not interfere (e.g., Figure 4). This observation
could potentially be used to determine the strength of the binding interaction, something that we
have only approximated here through competitive immunoassay. The effect might also be used to
establish a fluorescence-based immunoassay for CTV, analogous to systems that have been reported
for ochratoxin A and zearalenone [34].
3. Conclusions
Two mAbs that recognize CTV were developed and applied in CI-ELISAs to the detection of CTV
and iso-CTV. With CTV in buffer, the assays were of good sensitivity, with IC50s of 11 ng/mL (mAb 2-2)
and 18 ng/mL (mAb 2-4). Assays based upon both mAbs were relatively tolerant to methanol and
acetonitrile. For best results, it is recommended to keep the methanol concentration at or below 20%
and the acetonitrile concentration at or below 10%. One of the mAbs (2-4) was applied to the detection
of CTV and iso-CTV in spiked rice. Using matrix-matched calibration and a mixed CTV/iso-CTV
standard, the dynamic range was equivalent to 0.23 to 2.22 mg/kg in rice. Recoveries were excellent,
averaging 97 ± 10% over the range of 0.36 to 7.23 mg/kg. The developed mAbs and CI-ELISAs will be
useful for the screening of CTV and iso-CTV in white rice. In addition, it was observed that both mAbs
significantly enhanced the fluorescence of CTV, a phenomenon that may be useful in future efforts to
determine the affinity of the antibodies for the toxin.
4. Materials and Methods
4.1. Materials
Except where noted otherwise, deionized water (Nanopure II, Thermo Scientific, Waltham,
MA, USA) was used in the preparation of all reagents. The primary analytical standard of CTV
was produced by Hayashi Pure Chemical Ind., Ltd. (Osaka, Japan). For spiking of rice samples,
a standard material containing both CTV and iso-CTV prepared at the USDA-NCAUR (Peoria, IL,
USA) was used [21]. Acetonitrile and methanol were HPLC grade and were purchased from Fisher
Scientific (Hampton, NH, USA), as was polyvinyl alcohol (PVA). 1-1′carbonyldiimidazole (CDI),
4,6-dimethyl-2-oxo-2H-pyran-5-carboxylic acid (IDHA), 4,6-dimethyl-α-pyrone (DMP), and threose
were purchased from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals were reagent grade or
better and purchased from major suppliers.
4.2. Liquid Chromatography-Photodiode Array-Mass Spectrometry (LC-PDA-MS) of CTV Stock Solutions
Two concentrated stock solutions containing predominantly CTV were prepared and analyzed by
liquid chromatography-photodiode array-mass spectrometry (LC-PDA-MS) to determine relative purity.
The first of the materials was prepared commercially and was used as the primary analytical standard.
The second was prepared from material isolated by the late Robert Stubblefield at USDA-NCAUR
(Peoria, IL, USA) and had been stored for many years at −20 ◦C. The latter was used to study
the potential cross-reactivity of iso-CTV and was used to spike rice samples. A stock solution of
the analytical standard was prepared in acetonitrile and a portion was diluted in methanol to a
concentration of approximately 10 μg/mL. The ultraviolet–visible (UV–Vis) absorption spectrum was
obtained using an Evolution 201 UV-Visible spectrometer (Thermo Scientific, Waltham, MA, USA).
The absorbance at 383 nm was used to determine the concentration of total CTV and iso-CTV based
upon the molar extinction coefficient of 44,000 [20]. A stock solution of the material used for spiking
rice was prepared at nominally 0.6 mg/mL in acetone. The concentrations of CTV and iso-CTV in the
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spiking material were determined following LC-PDA-MS and were based upon the aforementioned
analytical standard.
The LC instrument was a Dionex Ultimate 3000 system (ThermoFisher, Waltham, MA, USA).
The column was a Kinetex 1.7 μ XB-C18, 100 Å, 100 × 3.0 mm, with a C18 Security Guard Ultra column
(Phenomenex, Torrance, CA, USA) maintained at 30 ◦C. The mobile phase consisted of (A) acetonitrile,
and (B) a mixture of 8% acetonitrile in water containing 0.25% acetic acid, with pH adjusted to 4 with
ammonium hydroxide. The gradient began as 80% B for 4 min, then 65% B for 9 min. At 13 min the
initial condition of 80% B was reinstated and the column was allowed to equilibrate for 7 min before
injecting the next sample. For injection, the standards were diluted to 2 μg/mL. Injection volume
was 20 μL. Flow rate was 0.7 mL/min, of which approximately 0.4 mL/min was directed to the PDA
detector and 0.3 mL/min to the MS. The MS was a model QDa single quadrupole instrument (Waters
Corp., Milford, MA, USA) operated in positive ion mode under the following parameters. Single ion
monitoring at m/z = 403.2, cone voltage 6.0 V, probe temperature 425 ◦C, detector gain 1, capillary
voltage 1.5 kV, sampling frequency 8 Hz. Under these conditions, CTV eluted at 7.8 min. At 8.5 min a
second peak, with the same absorption spectrum as CTV eluted. In previous literature this peak has
been termed iso-CTV, a convention also used here. Because no standards for iso-CTV were available
the concentration of iso-CTV was calculated relative to that of the CTV analytical standard under the
assumption that the ionization efficiencies for the two isomers were the same.
4.3. Preparation of CTV–Protein Conjugates
Purified CTV was linked to two proteins. One was used as a soluble antigen for immunizing
mice and the other was used as an immobilized antigen in indirect ELISAs. The immobilized antigen,
CTV-OVA2, was prepared as follows. All reactions were performed under conditions of reduced
ambient lighting. CTV (5 mg) was dissolved in 0.25 mL acetone and 50 mg CDI was added and held at
ambient temperature for 1 h. Twenty μL of water was added followed by 3.4 mL of OVA solution
(50 mg OVA in 0.1 M NaHCO3 buffer, pH 8.6). The mixture was shielded from light and stirred for
28 h at 4 ◦C. The product, CTV-OVA2, was dialyzed extensively against NaHCO3 and phosphate
buffers, using a 14 kDa membrane and culminating with 0.1 M PBS. The conjugate was diluted to a
concentration of 2 mg/mL, freeze-dried, and stored at −80 ◦C until use. The immunogen, CTV-BSA3,
was prepared in a similar fashion. However, instead of OVA the protein was BSA with a short ethylene
diamine (EDA) linker attached. The preparation of EDA-BSA has been reported elsewhere [35].
4.4. Immunization of Animals and Isolation of mAb-Producing Clones
Immunization of mice, splenocyte fusions, cloning operations and antibody production were
conducted at Envigo (Madison, WI, USA). Screening of sera and of fusion products were conducted
at USDA-NCAUR (Peoria, IL, USA). All animal procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) of Envigo. Work was performed according to protocols
421-09a – Polyclonal Antibody Production and Hybridoma Development (approved 14 December 2018)
and 638-18 Monoclonal Antibody Production (approved 14 December 2018). These protocols were
developed in accordance with guidelines established by the U.S. National Institutes of Health- Office
of Laboratory Animal Welfare. Ten female Balb/C mice were given a primary immunization of 100 μg
CTV-BSA3 using the same procedures as described previously for production of paxilline antibodies [36].
Mouse antisera and hybridoma culture supernatant solutions were tested by competitive indirect
ELISA (CI-ELISA). In initial experiments 0.1 mL of CTV-OVA2 (10 μg/mL in 0.05 M sodium phosphate
buffer, pH 7.2), was incubated in wells of polystyrene microtiter plates overnight at 4 ◦C. The plates
were washed twice with 0.32 mL Tween-PBS (0.02% v/v Tween-20 in 0.01 M PBS, pH 7.2) and blocked
with 0.32 mL of PVA-PBS (1% w/v PVA in 0.01 M PBS) for 2 h at ambient temperature. Test solutions
were prepared by mixing equal volumes of toxin standard solution (or control solution) and antiserum
(alternatively, culture supernatant) diluted in BSA-PBS (1% w/v BSA in 0.01 M PBS) in the wells of a
polypropylene microtiter plate (Corning Inc., Corning, NY, USA). The test plate containing immobilized
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antigen was washed twice with Tween-PBS and 0.1 mL of test solution was transferred to each well
and incubated for 30 min at ambient temperature. The plate was then washed three times and 0.1 mL
of a 1:2000 dilution of goat anti-mouse peroxidase conjugate was added. After incubating at ambient
temperature for 30 min the plate was washed four times and the substrate o-phenylenediamine (OPD)
was added. Preparation of the substrate is described elsewhere [36]. After 5 min 0.1 mL of 1 N
hydrochloric acid was added to stop the reaction. Color development was determined by measuring
the absorbance at 490 nm using a Synergy Neo microplate reader (Bio-Tek, Winooski, VT, USA).
From the 10 mice two were selected to undergo splenocyte fusion. The animals were sacrificed
and the spleens aseptically removed. The splenocytes were chemically fused with NS-1 myeloma cells
using polyethylene glycol then plated in HAT selection media. After 10 days, cultures were isolated
and screened for anti-CTV activity using the CI-ELISA described earlier in this section. The first fusion
yielded only a single product, which did not recognize free CTV. The second fusion also yielded a
low number of products (5) of which three recognized free CTV. From these three products two clones
were subsequently isolated, expanded, and used to produce larger amounts of antibody for evaluation.
The cell lines were designated 2-2.2.2.8 (herein referred to as “2-2”) and 2-4.3.5.1.2.1.4 (herein referred
to as “2-4”). Ascites fluid from mice administered these cell lines was partially purified by ammonium
sulfate precipitation using procedures described previously [37], then dialyzed against 0.1 M PBS
and freeze-dried. The protein content was determined using the BCA Protein Assay (Thermo Fisher,
Waltham, MA, USA).
4.5. Effects of Methanol and Acetonitrile on Two CTV mAbs
The impact of methanol and acetonitrile on the CI-ELISAs with mAbs 2-2 and 2-4 was determined
by incorporating the solvents at concentrations from 5% to 30% (v/v) in the diluent used to prepare
the calibration curves. The analytical CTV stock solution (i.e., 93% CTV, 7% iso-CTV) was used for
these experiments. CI-ELISAs were performed essentially as in Section 4.4, with a lower concentration
of CTV-OVA2 immobilized (4 μg/mL). Preliminary experiments indicated that using mAb 2-2 at a
concentration of 12 μg/mL or mAb 2-4 at a concentration of 4.9 μg/mL were sufficient to give color
development of approximately 1 absorbance unit with a 5 min substrate incubation. As described
in Section 4.4 the antibodies (in 0.1% OVA-PBS) were mixed with the toxin/solvent combinations
1+1 before transferring them to the test plates containing immobilized CTV-OVA2. Note that at 30%
methanol, the OVA was very poorly soluble and with 20% acetonitrile it was insoluble. For these
reasons the highest solvent concentrations tested were 30% methanol and 15% acetonitrile. Tests were
conducted with 4 to 8 replicate microtiter plates. Each CTV concentration level was represented by
4 wells on the plate. To obtain the most accurate comparisons, the two antibodies were compared
side-by-side on the same plates. Standards were prepared over the range of 0.2 to 1000 ng/mL.
Absorbance of all samples (i.e., “B”) were normalized to those of the toxin-free controls (i.e., “Bo”)
using the equation (B/Bo) × 100%. Calibration curves based upon the transformed data were obtained
using a logistic dose-response model and curve fitting software (TableCurve curve 2D, Systat Software
Inc., Richmond, CA, USA). Fitted curves were used to calculate the concentrations required to inhibit
color development by 50% (IC50s).
4.6. Spiking and Extraction of Rice Samples
Polished long-grain white rice was kindly supplied by Susan P. McCormick (USDA-ARS-NCAUR).
The rice had been milled so the husk, bran, and germ were removed. The rice was ground in a coffee
mill to produce a powder similar in consistency to flour. Ten g of ground rice were spiked with a
mixture of CTV and iso-CTV. The spiking solution contained a total of 144.7 μg/mL in methanol,
of which 93 μg/mL was CTV and 51.7 μg/mL was iso-CTV. The volumes, amounts, and corresponding
levels of CTV and iso-CTV in the rice are summarized in Table 4. Six replicate samples were produced
at each spiking level. Samples were kept overnight at ambient temperature to permit the solvent in the
spiking solution to evaporate. Samples were extracted with 40 mL of 80% (v/v) methanol/water by
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shaking for 2 h on a Burrell model 75 wrist-action shaker (Burrell Corporation, Pittsburgh, PA, USA)
for 2 h at ambient temperature. The mixture was filtered through a Whatman 2V filter (Whatman
plc, Maidstone, UK). The filtrate was diluted 1+7 (v/v) with a solution of 1% OVA in 10 mM PBS.
The resulting diluted extracts contained 0.03125 g equivalents of rice/mL. Unspiked, control, rice was
likewise extracted, diluted, and the diluted extract was used to prepare matrix-matched calibration
curves for use in the CI-ELISA experiments.






















25 2.33 1.29 0.233 0.129 0.362
50 4.65 2.58 0.465 0.258 0.723
100 9.30 5.17 0.930 0.517 1.447
200 18.60 10.34 1.861 1.034 2.894
500 46.50 25.85 4.652 2.585 7.235
4.7. CI-ELISA of Rice Samples
Samples of rice spiked with a mixture of CTV and iso-CTV in the ratio of 1.8:1 were compared to
calibration curves prepared using the same spiking mixture. The standards were prepared by diluting
the stock solution in a control rice extract consisting of 0.03125 g equivalents of rice/mL (Section 4.6).
As this was a 1:8 dilution of an 80% methanol extract of rice, the diluted extract also contained
10% methanol. The concentrations of the standards, represented as the sum of CTV and iso-CTV,
ranged from 1.45 ng/mL to 2894 ng/mL. Because the matrix consisted of 0.03125 g equivalents/mL,
the calibration curve covered the range from 0.046 to 93 mg/kg rice. To improve quantification,
the spiked samples that contained greater than 2 mg/kg were diluted further to keep the resulting
signals within the dynamic range of 80% to 20% of the maximal signals (i.e., between the IC20 and
IC80). The LOD of the assay in rice matrix was calculated by measuring the standard deviation of the
unspiked (toxin-free) controls and calculating the CTV concentration required to observe a signal 3
standard deviations from the mean of the controls.
4.8. Effects of mAbs and Bovine Serum Albumin (BSA) on CTV Fluorescence
Preliminary experiments indicated that the mAbs could influence the fluorescence of CTV in
aqueous buffer. To examine this further, mixtures of mAb or BSA were combined with CTV in aqueous
buffer (10 mM PBS, pH 7.2). The final concentrations of mAb (or BSA) and CTV were 2.0 μM and
1.25 μM, respectively. The volumes of test solutions were 0.32 mL. Excitation and emission spectra were
collected using a Neo microplate reader (BioTek, Winooski, VT, USA). Emission scans were collected
using an excitation of 420 nm, with emission monitored over the range of 450 to 700 nm in 1 nm
increments. Excitation scans were collected using an emission of 570 nm, with excitation provided
over the range of 360 to 500 nm in 1 nm increments. Both excitation and emission data were collected
with the top optics of the instrument and the following parameters: gain 150, normal reading speed,
optics positioned 4.50 mm above the sample, and temperature 20.5 ◦C. Data from triplicate plates were
averaged and imported into TableCurve. Spectra were smoothed using Savitzky–Golay filtering.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/11/11/630/s1,
Figure S1: Effect of iso-CTV on the calibration curve in diluted rice matrix using mAb 2-4, Figure S2: Effect of
iso-CTV on the calibration curve in diluted rice matrix using mAb 2-2.
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Abstract: Amatoxins (AMAs) are lethal toxins found in a variety of mushroom species. Detection
methods are needed to determine the occurrence of AMAs in mushroom species suspected
in mushroom poisonings. In this manuscript, we report the generation of novel monoclonal
antibodies (mAbs, AMA9G3 and AMA9C12) and the development of a competitive, enzyme-linked
immunosorbent assay (cELISA) that is sensitive at 1 ng mL−1 and shows selectivity for α-amanitin
(α-AMA) and γ-amanitin (γ-AMA), and less for β-amanitin (β-AMA). In order to decrease the overall
time needed for analysis, the extraction procedure for mushrooms was also simplified. A rapid
(1 min) extraction procedure of AMAs using solvents as simple as water alone was successfully
demonstrated using Amanita mushrooms. Together, the extraction method and the mAb-based ELISA
represent a simple and rapid method that readily detects AMAs extracted from mushroom samples.
Keywords: amatoxins; amanitins; immunoassay; monoclonal antibodies; ELISA; death cap mushrooms
Key Contribution: Highly sensitive and selective monoclonal antibodies were developed to detect
amatoxins. A rapid and simple extraction of amatoxins from mushroom specimens was demonstrated.
1. Introduction
There are thousands of reported mushroom poisonings occurring worldwide each year [1–5]. The
most severe cases are from amatoxin (AMA)-containing mushrooms. AMA-containing mushrooms
include a few species from the genera Amanita, Galerina, and Lepiota. The principle toxins responsible
for the poisonings are the bicyclic octapeptides known as AMAs, most notably α-amanitin (α-AMA)
and β-amanitin (β-AMA), and possibly γ-amanitin (γ-AMA) (Figure 1). In mice, the LD50 for α-AMA
is 0.1 mg kg−1 [6] and, to humans, a dose of 0.3 mg kg−1 is severely toxic [7]. AMAs are potent
inhibitors of RNA polymerase II, with bioactivity resistant to heat, cold, or acid inactivation. The
typical distributions of α-AMA, β-AMA, and γ-AMA in a Death cap (Amanita phalloides) mushroom
are approximately 43%, 43% and 14%, respectively [8,9]. A single dried mushroom typically contains
around 1–2 mg g−1 of α-AMA [8,10,11].
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Figure 1. Chemical structures of the amatoxin variants examined in this paper, (a) molecular structure
of amanitin, (b) R-group designations for each variant.
The most common method for the detection of AMAs extracted from mushrooms is liquid
chromatography (LC), coupled with UV detection or mass spectrometry (MS) [8,12–14]. Although these
methods are sensitive and provide a high resolution of individual analytes, they are time-consuming
and require expensive, laboratory-based instrumentation and highly trained personnel to interpret
the results. In contrast, immunoassays are faster, can be field portable, and require less sophisticated
instrumentation. The only commercially available antibody-based assay for AMA detection for research
purposes is the Bühlmann assay [15]. This assay relies on a polyclonal antibody (pAb), which is a
limited supply. Once the supply of antibody is depleted, the assay will have to be reevaluated for
sensitivity and selectivity using a newly produced pAb. Since monoclonal antibodies (mAbs) are
produced by a hybridoma cell line derived from a single cell, they overcome this supply limitation
and have little or no batch-to-batch variability. Similarly, recombinant antibodies can be produced in
large quantities, while preserving the monoclonality of the binding domain. Assays utilizing mAbs or
recombinant antibodies are thus more desirable for long-term consistency and can be scaled-up for test
kit manufacture. To our knowledge, only a few mAbs to AMAs have been described, and only one has
been used for analytical detection [16–18].
Regardless of the method used to detect the toxin, extraction of the AMA is required before
identification. Over the years, the extraction procedure has been streamlined from 24 h [8,10,19]
to one hour [12,14,16,20]. Most of these methods have utilized an extraction solution consisting of
methanol, acid, and water. Results from a latter study using a one hour extraction reported levels
of α-AMA to be 0.88–1.33 mg g−1 dry weight [12], while earlier studies using the 24 hour extraction
reported comparable levels of 0.75–2.8 mg g−1 dry weight [8,10] for the same species. Despite potential
differences in the ages of mushrooms studied, these consistencies across studies suggest that extraction
efficiency is not compromised with shortened extraction times. In addition, the historical methods use a
combination of methanol, acid, and water to facilitate AMA extraction. Antibody-based immunoassays
are often not compatible with large amounts of organic solvents or acidic solutions. Given the water
solubility of AMAs, we hypothesized that a water-based AMA extraction would be sufficient for
immunoassay detection.
The aim of this study was to utilize our previously reported immunogen, a periodate-oxidized
form of α-AMA conjugated to the keyhole limpet hemocyanin (PERI-AMA-KLH) [20], to generate
mouse mAbs. Then, we sought to use those mAbs to develop a sensitive and selective immunoassay for
AMA detection from mushrooms. In this report, we describe and characterize novel anti-AMA mAbs
and detail their performance in an indirect competitive inhibition enzyme-linked immunosorbent
assay (cELISA). We compare the performance of this immunoassay for the detection of AMAs from
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mushrooms using difference extraction solutions. A sensitive detection assay for AMAs, combined
with a rapid and simple toxin extraction method, would be a highly useful tool for the determination
of AMA presence in wild mushrooms.
2. Results
2.1. Monoclonal Antibody Production
Mouse mAbs to AMAs were generated using the immunogen PERI-AMA-KLH [20]. Following the
screening of the fusion plates, there were 14 positive cultures (optical density> 0.7), of which 12 cultures
exhibited substantial signal reduction (optical density decreased by 0.5 or greater) in the presence
of 100 ng mL−1 α-AMA in cELISA (Figure 2). Only two (9C12 and 9G3) of these grew stably, and
were cloned multiple times until every well of the cell culture plate with cell growth elicited a positive
indirect ELISA response to the coating antigen, a periodate-oxidized form of α-AMA conjugated
to bovine serum albumin (PERI-AMA-BSA). The resulting mAbs were AMA9G3 (American Type
Culture Collection Accession number PTA-125922) and AMA9C12 (American Type Culture Collection
Accession number PTA-125923). Both mAbs were isotype IgG1-possessing kappa light chains.
Figure 2. Hybridoma clone supernatants screened by indirect enzyme-linked immunosorbent assay
(ELISA) (black bars) and by indirect competitive ELISA (gray bars). The cELISAs were completed
using 100 ng mL−1 of α-amanitin as the competing analyte.
2.2. Cross-Reactivity and Sensitivity
In order to determine how effective the assay would be in selectively detecting AMAs, a panel of
cyclic peptides and smaller chemicals was tested. These included the bicyclic heptapeptides known as
phallotoxins (phalloidin and phallacidin) also produced by A. phalloides, chemical toxins (psilocybin,
muscimol, and ibotenic acid) produced by other mushrooms, and cyclic peptides (nodularin and
microcystin-LR) produced by cyanobacteria. Of these analytes tested, AMA9G3 was competitively
inhibited by all of the AMAs, α-AMA, β-AMA, and γ-AMA, while AMA9C12 was only competitively
inhibited by α-AMA and γ-AMA (Table 1 and Figure 3). Both mAbs did not bind to any of the other
compounds tested.
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Table 1. Cross-reactivity (%) of compounds found in associated mushrooms or structurally related compounds.












α-amanitin 1.57 ± 0.07 100 2.66 ± 0.18 100 100
β-amanitin 24.2 ± 6.2 6.5 >1000 <0.3 0.1
γ-amanitin 1.63 ± 0.21 96 2.3 ± 0.31 115 90
phalloidin >1000 <0.3 >1000 <0.3 Not detected
phallacidin >1000 <0.3 >1000 <0.3 Not detected
psilocybin >1000 <0.3 >1000 <0.3 Not determined
microcystin-LR >1000 <0.3 >1000 <0.3 Not determined
nodularin >1000 <0.3 >1000 <0.3 Not determined
ibotenic acid >1000 <0.3 >1000 <0.3 Not determined
muscimol >1000 <0.3 >1000 <0.3 Not determined
Figure 3. Standard cELISA inhibition curves for both monoclonal antibodies AMA9G3 (solid line)
and AMA9C12 (dashed line) against toxins α-amanitin (circles), β-amanitin (squares), and γ-amanitin
(triangles). R2 > 0.96 for the linear portion (including a minimum of three points) for every curve.
The standard curves for the binding of both mAbs to the α-AMA, β-AMA, and γ-AMA toxins
are shown in Figure 3. There is no reduction in signal response for AMA9C12 when tested against
different concentrations of β-AMA, whereas, for AMA9G3, all three of the toxins did competitively
inhibit at higher concentrations. The steepness of the curve indicated a small dynamic range for the
assay because of the dramatic signal change produced by very small changes in toxin concentration,
but simple sample dilutions could be performed to achieve a signal that fits within this range.
While both mAbs exhibited competitive inhibition from α-AMA and γ-AMA, AMA9G3 exhibited
slightly higher sensitivity, with an IC50 of 1.57 ng mL−1 for α-AMA (Table 1 and Figure 3). For
AMA9G3, the working range of detection (estimated as IC30 to IC80) of α-AMA is 0.7–3.1 ng mL−1, of
γ-AMA is 0.5–2.4 ng mL−1, and of β-AMA is 3.6–129.1 ng mL−1. A conservative estimate for the limit
of detection for α-AMA or γ-AMA with the AMA9G3 assay is 1 ng mL−1, accounting for the large
(30%) variation in signal at low to no concentrations of toxin. Because of the propensity for samples
(mushroom extracts) to contain all three AMAs, AMA9G3 was selected for use in the cELISAs for the
extraction studies.
2.3. Kinetic Measurements
For all three antibodies (two mAbs from this study and one rabbit pAb #58 from our previous
work), a final concentration of 10 nM was used in both the Equilibrium and Kinetics Injection studies.
Table 2 shows the affinity (Kd) and kinetic parameter (kon and koff) values obtained for each antibody
tested against α-AMA as the free ligand. Kd values of 10−10 M and lower indicate that these antibodies
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exhibit a high affinity for their target analyte (α-AMA). Given the similar affinity characteristics
between the mAbs and the pAb, the major advantage of the mAbs over the pAb is their ability to
produce a continuous supply of the same protein.
Table 2. Affinities (Kd) and kinetic parameters (kon and koff) for antibodies binding to α-amanitin
measured by KinExA.
Antibody Kd (M) kon (M−1 s−1) koff (s−1)
rabbit pAb 58 3.5 × 10−11 4.1 × 106 1.4 × 10−4
mAb AMA9G3 6.4 × 10−11 4.7 × 107 3.0 × 10−3
mAb AMA9C12 9.3 × 10−10 1.7 × 107 1.4 × 10−2
2.4. Mushroom Extraction
For the purposes of exploring the feasibility of performing simplified and rapid extractions, five
different extraction solutions were tested. The commonly employed extraction using methanol and
dilute acid was compared to extractions with more innocuous reagents, such as phosphates, tris, and
Tween-20. The extraction solutions were tested on three different mushroom species. Both A. phalloides
and A. ocreata are known to contain AMAs, while A. gemmata is known to not contain AMAs.
AMAs were detected by this mAb-based cELISA in both of the extracts for the species known to
contain AMAs (A. phalloides and A. ocreata) (Figure 4a,b). Detection is indicated by 100% inhibition at
dilutions up to and including a 9000-fold dilution of the extract (Figure 4a,b). With increasing dilutions,
it would be expected that the amount of inhibition would decrease as the AMA concentration decreases
in a dose-dependent manner. Indeed, at dilutions greater than 9000-fold, decreased inhibition was
observed for all extraction conditions.
Figure 4. Cont.
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Figure 4. Representative cELISA inhibition profiles illustrating the amount of inhibition from the tested
extraction conditions at varying dilutions of mushroom extracts obtained from (a) Amanita phalloides,
(b) A. ocreata, and (c) A. gemmata. The extraction conditions were as follows: (1) MeOH: methanol:
water: HCl for 1 h; (2) H2O: diH2O, 1 min, (3) PB: phosphate buffer, 1 min, (4) PBT: PB with Tween-20, 1
min, and (5) TBST: tris-buffered saline with Tween-20, 1 min.
There appeared to be very little difference between the different extraction conditions. The
methanol extractions had a slightly higher inhibition at 27,000-fold and 81,000-fold dilutions for
A. phalloides and the 27,000-fold dilution for A. ocreata. This may suggest that the methanol extractions
extracted more AMAs than the aqueous extractions, since more inhibition equates to more toxin.
However, the methanol extractions were carried out for 1 h, while the aqueous buffers were only carried
out for 1 min. So, we cannot conclude whether time or composition contributed to the slight differences
in extraction efficiency. However, because the differences were slight, we conclude that these aqueous
buffers, with only a 1 min shaking step, were highly effective methods for AMA extraction.
With competitive-type assays, the signal intensity is the greatest when the free toxin to be detected
is the lowest. In this case, low toxin levels are seen at the highest dilutions, and high signal intensities
exhibit the most variation. With the data plotted as percent inhibition, higher variation was seen at
higher dilutions (Figure 4). Thus, the background was estimated to be around 20–30% inhibition.
Extracts from the non-toxin containing mushroom A. gemmata (Figure 4c) were intentionally tested at
the more concentrated (e.g., 1- and 3-fold) dilutions, since no toxin was expected to be detected. The
strong distinction between samples that exhibit 100% inhibition (i.e., with AMAs) and those without
toxin demonstrated the ability of this mAb-based cELISA to selectively and sensitively detect AMAs
from mushroom extracts.
3. Discussion
In this work, we report the generation of new anti-AMA mAbs (AMA9G3 and AMA9C12) using
our previously synthesized immunogen (PERI-AMA-KLH) based on periodate oxidation of α-AMA.
Unlike early reports of generating AMA-conjugated immunogens that exhibit toxicity [21,22], this
immunogen did not cause any death in both mice (this study) or rabbits [20], corroborating the low
toxicity observed by other investigators [23].
These mAbs exhibited high selectivity for AMAs, but the selectivity within AMAs varied from
what was observed from our previously generated pAbs using the same immunogen [20]. The pAbs
detected α-AMA, β-AMA and γ-AMA within a narrow range of IC50 values (2–3 ng mL−1). Conversely,
both mAbs distinguish the AMAs differently, such that AMA9G3 detected α-AMA and γ-AMA (IC50
≈ 1.6 ng mL−1), and, to a lesser extent, β-AMA (IC50 = 24 ng mL−1), while AMA9C12 detected only
α-AMA and γ-AMA (IC50 = 2.3 and 2.7 ng mL−1, respectively). Similar to mAb AMA9C12, the
commercially available, pAb-based cELISA detected only α-AMA and γ-AMA, and not β-AMA [15].
Another mAb, generated using a different coupling strategy to generate an α-AMA immunogen,
produced mAbs with broad selectivity to α-AMA, β-AMA and γ-AMA (IC50 = 66, 97, and 163 ng
mL−1, respectively) [16]. A single chain variable fragment of a mAb, produced by this same group,
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also exhibited broad selectivity to α-AMA, β-AMA and γ-AMA (IC50 = 77, 115, and 199 ng mL−1,
respectively) [24].
Regarding total AMA extraction efficiency, the recovery obtained with all of these extraction
methods is reputable. Previously reported α-AMA concentrations were approximately 1–2 mg of toxin
per gram of dried mushroom [8,10,11], but this could vary depending on the location and age of the
specimen [11]. Nonetheless, given our extraction ratio of 1 mL per 0.1 g of dried tissue, we would
expect to recover 0.1–0.2 mg of α-AMA in 1 mL, as well as 0.1–0.2 mg of β-AMA and 0.05 mg of γ-AMA.
This equates to extracts containing 10,000–45,000 ng mL−1 for total AMAs, which greatly exceeds
our assay’s detection limit of 1 ng mL−1 for total AMAs. Furthermore, the detection of AMAs in the
27,000-fold dilution samples of these AMA-containing sample extracts provided evidence that we were
obtaining a high recovery of AMA. Other investigators performed a second extraction following a
1 h extraction (using an acetonitrile solution) and did not recover any detectable amounts of residual
toxin in the second extract [14]. While most of the AMAs appear to be easily extracted, further work is
needed to determine the recovery coefficient for the rapid extraction procedure.
Furthermore, none of these tissue samples were macerated prior to extraction for any of the
solutions tested. Maceration of dried mushroom samples increases exposure of the researcher to the
toxin-containing dust. In our previous work, and that of many others, the mushroom tissue was
ground to a powder [11–14,19,20,25]. In this study, however, we did not grind the samples and still
achieved sufficient toxin extraction, suitable for cELISA detection.
The sensitivity of our mAb-based cELISA permitted the detection of as little as 1 ng mL−1 of total
AMAs in simple, water-based extracts obtained from dried mushrooms known to contain AMAs. Most
LC methods achieve a detection limit of approximately 10 ng mL−1 for each individual AMA [8,14].
The amount of tissue required for an extraction can be as little as 50 mg for LC instrumental techniques,
whereas the antibody-based detection methods could conceivably utilize sub-μg amounts of material
using a simple, water-based extraction. The sensitivity, speed, and throughput of this mAb-based
immunoassay for the detection of AMAs provides a simplified strategy for the evaluation of these
toxins in wild mushrooms to characterize their occurrence and geographic distribution.
4. Materials and Methods
4.1. Immunization and Antibody Production
The Institutional Animal Care and Use Committee of the United States Department of Agriculture,
Western Regional Research Center approved the experimental procedures used in these studies
(protocol #16-1). Three 6-week-old female BALB/c mice were immunized by intraperitoneal injection
(i.p.) of 100 μL of a 1:1 Sigma Adjuvant System (Sigma-Aldrich, St. Louis, MO, USA) containing
50 μg of PERI-AMA-KLH [20]. Two subsequent booster immunizations were administered i.p. at
2-week intervals using 20 μg of PERI-AMA-KLH in Sigma Adjuvant System. Serum were collected one
week after the third immunization. Another two booster immunizations were performed four months
later, two weeks apart, and serum was collected one week after this round of immunizations. After
determining by indirect ELISA that the antibody response was still elevated to this target immunogen,
a final booster immunization containing 10 μg of PERI-AMA-KLH in saline was administered i.p., four
days prior to being euthanized and cell fusion.
4.2. ELISA Procedure
For serum antibody screening, black 96-well microtiter plates (Nunc, Thermo Fisher Scientific,
Waltham, MA, USA) were coated at 1 μg mL−1 with PERI-AMA-BSA for 1 h at 37 ◦C in carbonate
buffer (0.05 M carbonate-bicarbonate, pH 9.6). Then, the plates were blocked for 1 h at 37 ◦C with
3% non-fat dry milk in tris-buffered saline with 0.05% Tween-20 (TBST). After incubation for 1 h at
37 ◦C, TBST was removed and serum was loaded at a dilution of 1:100 in TBST and serially diluted.
After another incubation for 1 h at 37 ◦C, plates were washed three times with TBST. Plates were then
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loaded with a secondary horse radish peroxidase labeled goat-anti-mouse antibody (Sigma) at 1:5000
in TBST and incubated for 1 h at 37 ◦C. Plates were washed and loaded with SuperSignal West Pico
Chemiluminescent substrate (Fisher), incubated for 3 min, and then luminescent counts were recorded
on a Victor3 Multilabel Counter (PerkinElmer, Waltham, MA, USA).
4.3. Monoclonal Antibody Production and Screening
The cell fusion and expansion procedures were completed as previously described [26]. The
screening of the cell culture plates following cell fusion, in particular the use of an indirect cELISA,
was carried out as previously described with minor modifications [27]. The screening process was
the same, but the reagents used were changed. Briefly, wells of clear-bottom microtiter plates coated
with PERI-AMA-BSA were pre-loaded with 50 μL/well of either TBST for noncompetitive screening or
α-AMA at 100 ng mL−1 for competitive screening. Plates were incubated for 1 h at 37 ◦C, washed, and
then incubated with a secondary antibody, as described for the direct screening. After incubation and
washing, antibody activity was visualized using Enhanced K-Blue Substrate (Neogen, Lexington, KY,
USA) and read on a VersaMax Microplate Reader (Molecular Devices, San Jose, CA, USA).
Hybridomas from wells exhibiting a significant reaction to the presence of α-AMA (i.e., a reduction
in signal intensity) were selected for clonal expansion. Cells were cloned by limiting dilution, repeated
until every well with cell growth presented positive activity via ELISA. MAbs were purified from
the cell culture supernatant on a Protein G Sepharose affinity column (GE Healthcare Life Sciences,
Pittsburgh, PA, USA), eluted with 0.1 M glycine-HCl, pH 2.7. Purified protein was extensively dialyzed
against the phosphate buffered saline (PBS; 10 mM phosphate, 138 mM NaCl, 2.7 mM KCl, pH
7.4) and then stored at −20 ◦C until further use. Antibody protein concentrations were determined
on a NanoDrop Lite Spectrophotometer (Thermo). Antibody isotyping was completed using an
IsoStrip Mouse Monoclonal Antibody Isotyping Kit (Roche, Indianapolis, IN USA), following the
manufacturer’s protocol. Purified mAbs were titrated by indirect ELISA to determine the concentration
of the antibody at half of the maximal signal. This determined concentration was used as the working
concentration of the antibody for the cELISAs, to evaluate antibody cross-reactivity.
4.4. Antibody Characterization: Cross-Reactivity
Indirect cELISAs were completed using a panel of inhibitors to determine the selectivity of the
mAbs. The cELISA procedure was nearly the same as that described for the serum screening, except
for the addition of inhibitors (50 μL), which were mixed with 50 μL of the antibody solution during
the primary antibody incubation step. The inhibitors tested were α-AMA (≥90%, Enzo Life Sciences,
Farmingdale, NY, USA), β-AMA (≥90%, Enzo), γ-AMA (≥90%, Enzo), microcystin-LR (≥95%, Enzo),
nodularin (≥95%, Enzo), phalloidin (>90%, Enzo), phallacidin (≥85%, Sigma), pysilocybin (>99%,
Cerilliant, Round Rock, TX, USA), muscimol (>99%, Abcam, Cambridge, MA, USA), ibotenic acid
(>98%, Abcam). Each analyte stock was dissolved in dH2O, then serially diluted into TBST, starting
at the highest concentration of ,000 ng mL−1, and assessed in triplicate. Data were analyzed using
a 4-parameter logistic equation (GraphPad Prism 7 Software, La Jolla, CA, USA) to determine the
concentration of inhibition at half of the maximal signal (IC50). Cross-reactivity (%) was calculated as
follows: (IC50 α-AMA)/(IC50 test inhibitor) × 100.
4.5. Antibody Characterization: Kinetic Measurements
All KinExA experiments were performed on a KinExA 3200 with Autosampler (Sapidyne
Instruments, Boise, ID, USA) and data were analyzed using KinExA Pro software provided by
Sapidyne. Affinity values (Kd) utilized were their template protocol for an Equilibrium Experiment
and kinetic parameters were determined using the Kinetics Injection method. Flow rates and volumes
used were the default settings defined in the software.
Polymethylmethacrylate particles (aliquots of 200 mg, Syringa Labs, Boise, ID, USA) were
adsorption coated with 30 μg of BSA-AMA-PERI in 1 mL of carbonate buffer for 1 h at room
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temperature with end-over-end rotation. The particles were blocked with a solution of 1% BSA (Sigma)
in PBS for 1 h at room temperature with end-over-end rotation, and stored at 4 ◦C for no more than
one week before use. The diluent for all reagents was PBS containing 1% BSA. Three antibodies were
evaluated—two mouse mAbs (AMA9G3 and AMA9C12) generated from this study and one rabbit
pAB #58 generated from the previous study [20]. The secondary antibody used for the mouse mAb
experiments was DyLight650 labeled anti-mouse Ig (Fisher) (used at 0.5 μg mL−1) and the secondary
antibody used for the rabbit pAb experiments was AlexaFluor647 labeled anti-rabbit Ig (Jackson
Immunoresearch, West Grove, PA, USA) (used at 0.25 μg mL−1).
Signal test runs were completed on each antibody to determine the amount of antibody needed to
generate the appropriate signal change (1 Δv). Then, for the Equilibrium experiments, antibody was
prepared at 2× this concentration and then mixed with an equal volume of a solution containing α-AMA
diluted 2-fold, ranging from 300 ng mL−1 (326 nM) to 9.2 pg mL−1 (10 pM) of final concentrations,
including one sample with no α-AMA and one sample containing only diluent. For the Kinetics
Injection experiments, the same 2× antibody concentration was used, along with solutions containing
α-AMA diluted 2-fold, ranging from 920 ng mL−1 (1000 nM) to 1.8 ng mL−1 (2 nM). The Equilibrium
and Kinetics Injection experiments were completed in duplicate.
4.6. Mushroom Extraction
Whole mushroom specimens were identified, dried, and provided by expert mycologists. The
specimens included two that were known to contain AMAs, A. phalloides and A. ocreata, and one that
was known to not contain AMAs, but was from the same genus, A. gemmata. Small portions of the
specimens were weighed (~100–200 mg) and then placed into a 15 mL Falcon tube containing one of the
five extraction buffers: (1) methanol (methanol:water:0.01 N HCl, 5:4:4, v:v:v), (2) diH2O, (3) phosphate
buffer (PB; 0.1 M, pH 7.6), (4) PB with Tween-20 (PBT), or (5) TBST at a ratio of 1 mL per 100 mg tissue.
The samples that were extracted with the methanol buffer were shaken for 1 h at room temp and then
centrifuged at 1000× g for 10 min. Aliquots of the supernatant were drawn off, diluted in TBST as
necessary, and assessed by indirect cELISA. The samples in diH2O, PB, PBT, or TBST were briefly
shaken by hand for 1 min. Immediately after shaking, a 50 μL aliquot of the liquid phase was drawn
off, diluted in TBST as necessary, and assessed by indirect cELISA, as described earlier. At least two
individual mushrooms from each species were extracted, and extractions for each extraction condition
were completed in duplicate.
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Abstract: Globally, mushroom poisonings cause about 100 human deaths each year, with thousands
of people requiring medical assistance. Dogs are also susceptible to mushroom poisonings and
require medical assistance. Cyclopeptides, and more specifically amanitins (or amatoxins, here),
are the mushroom poison that causes the majority of these deaths. Current methods (predominantly
chromatographic, as well as antibody-based) of detecting amatoxins are time-consuming and require
expensive equipment. In this work, we demonstrate the utility of the lateral flow immunoassay
(LFIA) for the rapid detection of amatoxins in urine samples. The LFIA detects as little as 10 ng/mL
of α-amanitin (α-AMA) or γ-AMA, and 100 ng/mL of β-AMA in urine matrices. To demonstrate
application of this LFIA for urine analysis, this study examined fortified human urine samples and
urine collected from exposed dogs. Urine is sampled directly without the need for any pretreatment,
detection from urine is completed in 10 min, and the results are read by eye, without the need for
specialized equipment. Analysis of both fortified human urine samples and urine samples collected
from intoxicated dogs using the LFIA correlated well with liquid chromatography–mass spectrometry
(LC-MS) methods.
Keywords: lateral flow immunoassay; amatoxins; amanitins; point-of-care; mushroom poisoning
Key Contribution: The study demonstrates the utility of the lateral flow immunoassay for the rapid
detection of amatoxins in urine.
1. Introduction
Distinguishing toxic mushrooms from non-toxic ones is highly challenging, even for expert
mycologists. Techniques to properly identify a mushroom include detailed morphological examination
of the mushroom body, substrate identification, and knowledge of the location and the season.
The toxins often associated with lethal cases are cyclopeptides, and more specifically amanitins (most
commonly α-amanitin (α-AMA), β-AMA, and γ-AMA, collectively referred to as amatoxins) [1]
(Figure 1). Amatoxins are found in a few species of mushrooms from different genera, including
Amanita, Galerina, and Lepiota [2]. Amatoxins are highly resistant to degradation, and on the cellular
level they inhibit transcription by binding to RNA polymerase II. As little as 0.1 mg/kg body weight of
amatoxins may cause death [3,4], and this amount can be found in a single Amanita phalloides.
Toxins 2020, 12, 123; doi:10.3390/toxins12020123 www.mdpi.com/journal/toxins103
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Figure 1. Chemical structures of the amatoxin variants examined in this paper, (a) molecular structure
of the amanitin, (b) R-group designations for each variant.
Consumption of toxin-containing mushrooms can result in a range of symptoms, from mild
to life-threatening [5,6]. The presumptive diagnosis for amatoxin poisoning is based on a history
of consuming wild mushrooms (if known), presentation of delayed gastroenteritis, elevated liver
enzyme levels, and ruling out other gastrointestinal diseases or conditions [6]. To distinguish amatoxin
poisonings, the presence of an amatoxin in an intoxicated patient’s urine would provide a definitive
diagnosis. For dogs, obtaining a history of mushroom ingestion is rare, making diagnosis even more
challenging. There are only a few laboratories capable of testing biological specimens for amatoxins
to confirm human or animal exposures, and even when available, test results might not be available
soon enough to help guide treatment. Although there are no FDA-approved antidotes, early diagnosis,
aggressive immediate supportive care, and a range of potential therapies can potentially improve
patient outcomes [6–11].
For both humans and dogs, the first symptoms of amatoxin poisonings usually appear 6–24 h
after ingestion of an amatoxin-containing mushroom [6]. By this time, amatoxins have already
begun damaging the liver and kidneys. Based on toxicological studies, amatoxins disappear rapidly
from the serum, but are detectable in urine up to 4 days after ingestion [12–14]. In human urine,
toxin concentrations decreased over time, and the highest concentrations observed were 4820 ng/mL
for α-AMA and 7103 ng/mL for β-AMA [12]. Because of the relative ease of obtaining a urine sample,
and the longer duration of detectability of amatoxins in urine compared to serum, urine seems an
obvious sample matrix for performing rapid amatoxin analysis. Sensitive, rapid, and easy-to-perform
methods are needed to detect amatoxins for the early diagnosis of toxin poisoning [9,15,16].
Current methods of chemical detection of amatoxins in urine include liquid chromatography–mass
spectrometry (LC-MS) methods [17–23] and antibody-based enzyme-linked immunosorbent assays
(ELISAs) [24,25]. LC-MS methods require sample extraction and expensive equipment, while ELISA
methods require specialized equipment. Methods of both types typically take a few hours to complete.
Lateral flow immunoassay (LFIA) formats utilize some of the reagents used for ELISA, but the entire
test can be completed in minutes and requires no specialized equipment.
We have recently developed an LFIA for the detection of mushroom amatoxins [26]. As the
sensitivity of the LFIA allows it to detect as little as 10 ng/mL, we hypothesized that this test would
be useful for urine analysis in instances of mushroom poisonings. To test this hypothesis, we first
conducted analysis of urine samples that were fortified with toxins (blind to the analyst) based on
the reported concentrations of amatoxins identified in exposed individuals; and second, we used
the LFIA to detect toxins in the urine samples collected from poisoned dogs. The LFIA results were
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compared to the established LC-MS methods [17,20]. Based on these studies, we can begin identifying
the diagnostic utility of the LFIA for identifying amatoxin exposure.
2. Results and Discussion
2.1. Analytical Sensitivity of the LFIA and Interpretation of Results
Standard curves were obtained for the detection of α-AMA, β-AMA, and γ-AMA in a pooled urine
matrix (Figure 2). As this is a competitive binding assay, the test line signal intensity decreases with
the increase in toxin concentrations. The cut-off value for each individual amanitin was determined by
selecting the concentration where the test line almost completely disappears, which is equivalent to
a pixel intensity value of approximately 30. For α-AMA and γ-AMA, the cut-off value is 10 ng/mL,
while for β-AMA, the cut-off is 100 ng/mL. Although difficult to discern by eye, the limit of detection
(defined as three times the standard deviation of a sample without amatoxins) is 0.3 ng/mL for α-AMA
and γ-AMA and 1 ng/mL for β-AMA. To ensure consistent interpretation of the line intensity by eye,
the cut-off values determined in this study were used for the remainder of this study to determine the
diagnostic accuracy of the test for urine analysis.
(a) (b) 
Figure 2. Standard curves for the detection of amatoxins by the lateral flow immunoassay (LFIA) in
a pooled urine matrix. (a) A representative visual image of the LFIA test strips used for detecting
α-amanitin (α-AMA). (b) Digitized values for the test line intensity for the detection of α-AMA, β-AMA,
and γ-AMA. Data points represent the average of three replicates with error bars. T: test line, C:
control line.
The cut-off value for β-AMA when detected in urine resulted in a 20-fold more sensitive assay
cut-off value than our previous standard curve developed in phosphate-buffered saline (PBS) [26].
There was no change in sensitivity for α-AMA or γ-AMA when using urine or PBS as the matrix [26].
To test whether the β-AMA sensitivity differences were possibly due to the pH of the matrix,
we evaluated pH-adjusted PBS buffers ranging from 4.5 to 8 (Figure 3). Indeed, there was a positive
trend for the two concentrations of β-AMA tested (100 and 25 ng/mL), in which the test line intensity
increased with the increase in pH. This trend corroborated with the differences between the pH of
urine and that of PBS. The pH of the pooled urine matrix was 6.0, while the pH of PBS was 7.4.
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Figure 3. Test line intensities of the LFIA for solutions of β-amanitin in phosphate-buffered saline at
different pHs.
2.2. Detection of Amatoxins in Blind Fortified Human Urine Samples
We recapitulated a human exposure study by spiking unexposed human urine samples
with concentrations (45 to 4550 ng/mL) of amatoxins measured from actual food exposures [12].
Two modifications were made to the sample set: (1) we included γ-AMA along with α-AMA and
β-AMA, and (2) we utilized a mixture of single and pooled urine samples. LFIA analysis was conducted
as a blind test so that the LFIA readers would utilize only the LFIA as the detection method to see how
well they could identify amatoxin-containing urine samples. All samples were also validated using an
LC-MS/MS method [17] for confirmation. Figure 4 shows the nominal spiked concentrations along
with LFIA and LC-MS/MS results.
 
Figure 4. Design and results of experiments on amatoxin-fortified human urine samples. The toxin
concentrations shown are the nominal spiked amounts. LC-MS: liquid chromatography–mass
spectrometry, L: left, R: right.
In this sample set, the diagnostic efficiency of the LFIA for indicating when a sample contained
amatoxins and when it did not was outstanding (94.6%) (Table 1). Diagnostic sensitivity (true positive
rate) was 92.3% and specificity (true negative rate) was 100%. These diagnostic descriptor calculations
took into account the cut-off values determined for each analyte (i.e., 10 ng/mL for α-AMA and γ-AMA,
and 100 ng/mL for β-AMA). Overall, there were only three samples that were recorded as indeterminate
due to the difference in interpretation by two independent readers.
Using the cut-off values for each analyte compared to the nominal spike value resulted in a
designation of “false negative” for only five samples. A false negative result meant that the LFIA
reported a negative result, although the nominal concentration was greater than the cut-off value
that should have resulted in a positive detection result. All five false negative designations occurred
in samples that contained only β-AMA in the amount of 244–909 ng/mL (Figure 4). Of these five
incorrectly identified samples, three were from single urine samples, while the other two were from
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the pooled urine matrix. This error is plausibly due to the interpretation of a faint test line as the toxin
concentration approaches the cut-off value of the assay.
Interestingly, 7 samples fortified with only β-AMA in the range of 244–909 ng/mL tested positive
and were reported as true positive, since they matched the criteria of being above the assay’s cut-off
value. All the other samples fortified with only β-AMA below this range (i.e., 91 ng/mL or lower; n = 3)
tested negative, and the samples that were above this range (i.e., 4550 ng/mL; n = 4) tested positive, as
expected. Overall, inaccuracy of LFIA results is observed when only β-AMA is detected at a level
close to its cut-off value. For α-AMA and γ-AMA, the concentrations tested were all at least 4-fold
higher than the cut-off value, since these concentrations were those that were previously reported for
amatoxin poisoning cases, and thus are clinically relevant. Detecting low concentrations of β-AMA
may appear to be a limitation of this technology; however, α-AMA and β-AMA are almost always
found at comparable concentrations in mushrooms [27,28], and thus either analyte serves as a good
biomarker for determining amatoxin poisoning.
Table 1. Performance of LFIA for qualitative determination of the presence of amatoxins in blind
fortified urine samples and collected dog urine samples.
Diagnostic Parameter Fortified Human Urine a Intoxicated Dog Urine b
# of samples n = 96 c n = 38
True positive (TP) 60 8
True negative (TN) 28 22
False positive (FP) 0 0




a Compared to the LC-MS/MS method [17] for confirmation. b Compared to LC-MS/MS/MS method [20] for
confirmation. c 3 samples were not included in this analysis, because the LFIA results obtained by two independent
readers were ambiguous.
Most previous amatoxin exposure studies measured α-AMA and sometimes β-AMA, however
γ-AMA was often not included. Although the kinetics of γ-AMA are not well studied, we sought to
include it because it could conceivably be a diagnostic marker of amatoxin poisoning. The previously
described studies relying on immunoanalytical methods might also have been detecting γ-AMA,
because their reagents cross-reacted with this analyte [25]. Furthermore, the previously described
immunoanalytical methods were less sensitive to β-AMA [29], thus those tests would have also missed
the samples that this LFIA missed when only β-AMA was present in a urine sample.
The use of pooled and single urine samples was meant as a means to identify any potentially
interfering components found in urine. In the instances of inaccuracy mentioned above, no differences
were attributed to those samples being a single or a pooled urine sample. Furthermore, there were
no false positives observed in this amatoxin-fortified human urine study, which means that when a
sample had no amatoxins below the defined threshold concentration, it was interpreted correctly by
the LFIA. Together, these results underscore that no apparent urine components (natural or potentially
synthetic—urine samples were neither subjected to drug screening nor were they deemed free of drugs)
interfere with amatoxin detectability.
2.3. Detection of Amatoxins in Dog Urine Samples
Unfortunately, many dogs each year are poisoned by amatoxins due to their natural curiosity and
indiscriminate eating habits [30,31]. To evaluate this LFIA for diagnostic potential, we collaboratively
analyzed samples submitted to the California Animal Health and Food Safety Laboratory in Davis, CA,
USA (CAHFS Davis). Urine samples were qualitatively analyzed both by LFIA and LC-MS/MS/MS
methods [20] (Table 1). These samples were collected from the dogs presumed to have ingested
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amatoxin-containing mushrooms and from the dogs not suspected of mushroom poisoning (a mix of
healthy and sick dogs).
The LC-MS/MS/MS method only detects α-AMA. The LC-MS/MS/MS result reports “positive” if
the sample has detectable (above 1 ng/mL) amounts of α-AMA, reports “negative” when no amounts
are detected, and reports “trace” when a feature is detected with the correct retention time, molecular
weight, and fragmentation pattern, but the concentration is below 1 ng/mL.
As shown in Figure 5, the LFIA should and does indicate negative when the LC-MS/MS/MS
indicates trace (n = 7), since the limit of detection for the LC-MS/MS/MS is 1 ng/mL, which is 10-fold
lower than for the LFIA. Only one sample was found to be negative by the LFIA and positive by the
LC-MS/MS/MS. This particular sample had an estimated LC-MS/MS/MS concentration of 2 ng/mL,
which is below the LFIA’s cut-off limit (10 ng/mL), but above the threshold for positive for the
LC-MS/MS/MS (1 ng/mL). However, for the rest of the samples that had either detectable amounts of
α-AMA as determined by the LC-MS/MS/MS (i.e., true positive, n = 8) or non-detectable amounts of
α-AMA as determined by the LC-MS/MS/MS (i.e., true negative, n = 22), the LFIA correlates 100%
(Table 1). Based on this consistency, there seems to be no components in dog urine that interfere with
generating reliable results. Based on this dog urine sample set, the calculated values for diagnostic
sensitivity (50%), specificity (100%), and efficiency (78.9%) are provided in Table 1. This sample
set distribution is not the representative distribution of prevalence of the poisonings encountered
in the population, and so a larger sample size would help to determine diagnostic characteristics
more accurately.
Figure 5. Comparison of methods (LC-MS/MS/MS and LFIA) for determining the presence of amatoxins
in intoxicated dog urine samples (n = 38).
All detection methods have their benefits and limitations. LC-MS methods can provide a more
definitive analysis for the samples containing lower concentrations of amatoxins, but all samples (e.g.,
urine and mushrooms) require sample extraction before detection. This LFIA method is exceptionally
rapid (10 min), requires no sample extraction for urine, and the test is portable. In the mushroom
poisoning scenarios where the illness progresses rapidly, the LFIA described here is distinctively
appropriate for point-of-care urine testing. The speed of analysis and lack of requirement for trained
personnel and expensive instrumentation make this an ideal point-of-care method. Because there is
no clinical tool to determine amatoxin poisoning, this LFIA test should be further exploited given its
reliable diagnostic performance in this study.
3. Materials and Methods
3.1. Materials and Approvals
All the unexposed human urine samples were obtained from a commercial provider (Tennessee
Blood Services, Memphis, TN, USA) and pre-screened by the vendor in accordance with FDA
regulations, and thus no consent procedures were required for this project (IRB #201210385). All animal
urine samples were collected and submitted by the owners with their consent or by their veterinarians
to the California Animal Health and Food Safety Laboratory System, Davis, and thus did not require
the Institutional Animal Care and Use Committee review.
Monoclonal antibody (AMA9G3), hapten-protein conjugate (LB-AMA-BSA), and full LFIA test
strips were produced as described earlier [26,32,33]. The LFIA components are diagramed in Figure 6.
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The standards used were α-amanitin (α-AMA; ≥90%, Enzo Life Sciences, Farmingdale, NY, USA),
β-AMA (≥90%, Enzo), and γ-AMA (≥90%, Enzo).
 
Figure 6. Schematic diagram of the lateral flow strip components: (i) sample pad, (ii) conjugate pad,
(iii) nitrocellulose membrane, (iv) wicking pad, (T) test line, (C) control line. The arrow indicates the
flow direction.
3.2. Analytical Sensitivity of the LFIA
The sensitivity of the LFIA for α-AMA, β-AMA, and γ-AMA was determined using a pooled
urine matrix. The urine matrix for calibration curves was generated using 10 single urine samples
pooled together. All 10 single urine samples were tested separately as negative controls and confirmed
to not interfere with the read-out. Two-fold dilutions of the standards ranging from 0.08 to 2000 ng/mL
were made using the pooled urine as the diluent. Then, 100 μL of each concentration were applied
to the sample pad region of the test strip and tested in triplicate. The signal intensity of both the
control and test lines was resolved in 10 min. If no visible control line appeared on the test strip,
the test was determined to be invalid. Digital photographs of the test strips were obtained using a
Nikon SLR camera equipped with an LED ring light (B&H Foto and Electronics Corps, New York, NY,
USA) for even lighting. The images were analyzed using ImageJ software (NIH, Bethesda, MD, USA).
Images were contrast-enhanced (default setting of 0.3%), and boxes of consistent size were used to
integrate the test line’s pixel value. Pixel values were inverted by subtracting the measured value
from the maximum possible (i.e., 255). Data was plotted using GraphPad Prism 7 software (GraphPad
Software, San Diego, CA, USA) using a four-parameter logistic equation.
PBS solutions (10 mM phosphate, 138 mM NaCl, 2.7 mM KCl, pH 7.4) were adjusted to pH 4.5,
5.2, 6, 6.5, 7.4, and 8 by adding either 1 M NaOH or 1 M HCl. Each solution was then spiked with
β-AMA at 100 and 25 ng/mL. As described above, 100 μL of each solution were applied to the sample
pad region of the test strip, tested in triplicate, incubated for 10 min, photographed, and interpreted by
digital analysis.
3.3. Amatoxin-Fortified Human Urine Analysis
Single (n = 48) and pooled (n = 48) human urine samples (obtained under IRB #201210385) were
fortified (blind to the LFIA researchers) with varying amounts of α-AMA, β-AMA, and γ-AMA.
A 96-well microtiter plate was prepared by spiking urine with α-AMA, β-AMA, and γ-AMA at
concentrations ranging from 45 to 4550 ng/mL following earlier findings from exposed individuals [12].
The distribution of samples was intended to follow these findings such that 19 wells contained α-AMA
and β-AMA, 20 wells contained only α-AMA, 21 wells contained only β-AMA, 11 wells contained
α-AMA, β-AMA, and γ-AMA, and 25 wells contained no amatoxins. These spiked concentrations
were randomly distributed between the single and pooled urine matrices.
For analytical confirmation, all human urine samples were also analyzed following the previously
validated LC-MS/MS method used for human urine [17]. The LFIA method was performed by placing
100 μL of a urine sample directly onto the sample pad and waiting for approximately 10 min before
interpreting the line intensity of the test line. A visual qualitative reading of either YES(+) or NO(–)
(YES – no visible test line, NO – a visible test line) was performed by two individuals, and a digital
image of the strip was also acquired. If no control line appeared, then the test was determined to be
invalid. The LFIA’s cut-off values were set at 10 ng/mL for α-AMA and γ-AMA, and at 100 ng/mL for
109
Toxins 2020, 12, 123
β-AMA. If amatoxin concentrations exceeded these values, the result was to read positive (defined
as true positive), and if the amatoxin concentrations were below these cut-off values, the result was
to read negative (defined as true negative). On the basis of these studies, diagnostic sensitivity (true
positive rate), diagnostic specificity (true negative rate), and diagnostic efficiency of the LFIA results
were calculated using the following formulae:
False positive (FP) = LFIA positive, although the amatoxin concentration
was below the cut-off value
False negative (FN) = LFIA negative, although the amatoxin concentration
was above the cut-off value
Diagnostic sensitivity = TP/(TP + FN)
Diagnostic specificity = TN/(TN+ FP)
Single-study diagnostic efficiency = (TP + TN)/(TP
3.4. Collected Dog Urine Analysis for Amatoxins
Urine samples of the dogs with suspected amatoxin intoxication were submitted by their owners
or by their veterinarians. For analytical confirmation, dog urine samples were analyzed following the
previously validated LC-MS/MS/MS method used for dog urine [20]. The LFIA method was performed
as described previously for human urine samples by placing 100 μL of a urine sample directly onto the
sample pad and waiting for approximately 10 min before interpreting the line intensity of the test line.
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Abstract: Aflatoxin B1 (AFB1) is a secondary metabolite produced by some Aspergillus spp. fungi
affecting many crops and feed materials. Aflatoxin M1 (AFM1), the 4-hydroxylated metabolite of
AFB1, is the main AFB1-related compound present in milk, and it is categorized by the International
Agency for Research on Cancer (IARC) as a “group 1 human carcinogen”. The aim of this work was to
evaluate and compare the analytical performances of two commercial immunoassays widely applied
for the detection of AFM1 in milk, namely strip test immunoassay and enzyme linked immunosorbent
assay (ELISA). Assay validation included samples at AFM1 levels of 25, 50, 75 ng/kg and blank
samples (AFM1 < 0.5 ng/kg). With respect to a screening target concentration (STC) of 50 ng/kg the two
assays showed cut-off values of 37.7 ng/kg and 47.5 ng/kg for strip test and ELISA, respectively, a false
suspect rate for blanks <0.1% (for both assays) and a false negative rate for samples containing AFM1
at levels higher than STC, of 0.4% (for both assays). The intermediate precision (RSDip) was <32%
for the strip test and <15% for the ELISA. Method verification through long-term intra-laboratory
quality control (QC) measurements confirmed the results from the validation study. Furthermore,
a satisfactory correlation of the results obtained with both immunoassays and the AOAC Official
Method 2000.08 was obtained for the analysis of cow milk samples naturally contaminated with
AFM1 at levels within “not detected” (< 0.5 ng/kg) and 50 ng/kg. Finally, the extension of the scope of
the strip test method to goat and sheep milk was evaluated by applying the experimental design
foreseen in the EU regulation.
Keywords: Aflatoxin M1; milk; strip test immunoassay; ELISA; method validation
Key Contribution: The study provides insights about the process of evaluating and comparing the
performance profile of rapid methods currently applied for AFM1 screening in milk. Addressing
EU official guidelines, the fitness for purpose of strip test and ELISA based methods was evaluated,
including verification of method performances through long-term quality control measurements and
comparison with the AOAC reference method.
1. Introduction
Aflatoxins are mycotoxins found in four main chemical structures: aflatoxin B1 (AFB1), B2 (AFB2),
G1 (AFG1) and G2 (AFG2); they can occur in a wide range of crops, including the major staple cereals
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(e.g., maize), edible nuts and legumes and their products. The main fungal producers of aflatoxins are
Aspergillus flavus which produces mainly AFB1, AFB2 and Aspergillus parasiticus, which produces all
four forms. Contamination can occur before or after harvest or both. In general, AFB1 occurs at the
highest levels compared to the others, and is the most toxic and a potent carcinogen [1,2]. AFB1 is
converted into its hydroxylated metabolite (AFM1) by the liver enzymes of lactating animals [3].
This toxin, like the parent compound, has been categorized by the International Agency for Research
on Cancer (IARC) as a group 1 toxin, a human carcinogen [2]. Due to their carcinogenity, the aflatoxins
uptake through contaminated food consumption should be as low as possible, therefore the aflatoxin
legislation is intended to implement the ALARA principle (As Low As Reasonably Achievable) and no
threshold limit concerning the tolerable daily intake in humans has been established [4].
Evidences of aflatoxins carry over in milk, edible animal tissues and eggs have been reported,
however, among foods of animal origin, milk represents the main source of human exposure to AFM1,
which is the only mycotoxin which has regulatory limits in milk [4–6]. There is evidence of AFM1
occurrence in cow milk, but also in milk produced by other ruminants, such as buffalo, goat, sheep and
camel [5]. The occurrence of AFM1 has been reported in various locations worldwide. Overall, the
incidence of AFM1 in milk samples and milk products is relatively low in European countries, whereas
data from Asian countries like China, Thailand and Taiwan show AFM1 occurrence in up to 100% of
samples [7]. AFM1 is heat stable and processing or storage conditions are ineffective in reducing its
concentration in milk and milk products [8–10]. Several factors may affect the AFM1 contamination of
milk, such as environmental conditions, different farming and feeding practices, as well as the quality
and safety control systems put in place by food/feed business operators (FBO) [9,11]. The presence
of AFM1 in milk can be therefore considered as an indicator of maize chain vulnerability to fungal
contamination [12].
Nowadays, there is an increasing concern for the impact of climate changes (temperature,
humidity, rainfall and carbon dioxide production) on fungal behavior and consequently on aflatoxins
production [11]. The application of predictive models has already given an indication of the potential
increasing contamination by aflatoxins in Europe as consequence of climate changes [13]. Furthermore,
a recent study using a full chain modeling approach to predict the impacts of climate change on AFB1
production in maize and its consequences on AFM1 contamination in dairy cow’s milk, showed that,
in the investigated scenario (i.e., Ukrainian maize), AFM1 contamination in milk is expected to be
comparable or to increase in future climate scenarios [14]. Therefore, according to EFSA definition, the
presence of AFM1 in milk may be considered as an “emerging risk”, being a known risk for which an
increasing and unpredictable pattern of exposure risk is foreseen [15].
Approximately 60 countries have already established regulatory limits for AFM1 in milk and
dairy products [16]. In the EU, the maximum permitted levels for AFM1 have been set for consumable
milk (50 ng/kg) [17]. In addition, an alert threshold level of 40 ng/kg calling for action is considered
in some EU member states [18]. A maximum permitted level of 500 ng/kg of AFM1 in milk has been
established by the US-FDA (United States Food and Drug Administration) [19] and by the Codex
Alimentarius [20]. This is also the harmonized MERCOSUR limit applied in Latin America [16,21] and
in several Asian countries [16].
With the publication of the General Food Law (GFL) [22] the European Union has made a new
legal framework laying down the principles, obligations and definitions that apply in the field of
food safety. A general principle of the GFL is that FBOs have the primary responsibility for food and
feed safety. To this purpose, FBOs must implement a food safety management system, based on the
hazard analysis and critical control point (HACCP) principles. Regulatory limits therefore have a
strong impact on contracts and procedural guidelines in the dairy industry and, as consequence, on
the number of controls needed to verify milk compliance with maximum permitted levels, which may
affect production costs.
A wide range of methods for the detection of AFM1 in milk and dairy products is currently
available, however, achieving key analytical performances, such as sensitivity, precision and reliability,
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suitable to enforce regulatory limits in the low ng/kg range, is still quite challenging [23]. Screening
tests can play an important role within the safety monitoring, allowing rapid decision making and
interventions, also affecting the final price of food products. Nowadays, screening tests based
on immunochromatographic assays such as dipstick or lateral flow devices, and enzyme linked
immunosorbent assays (ELISA) represent the most common formats in the market [24–26]. To support
FBOs in selecting the most appropriate test in relation to the intended scope, internationally recognized
guidelines for screening test performance verification have been made available for instance by
the AOAC Research Institute (Performance Tested MethodsSM) and USDA-GIPSA (Performance
Verified Rapid Test), whereas at European level, such guidelines are set in the Commission Decision
657/2002/EC [27] and in the Commission Regulation 2014/519/UE [28], which is specifically devoted to
mycotoxin screening methods.
The aim of this work was to evaluate and compare the analytical performances of two commercial
immunoassays (strip test immunoassay and ELISA) widely applied for the detection of AFM1 in
milk. For this purpose, the Commission Regulation 2014/519/UE [28] was taken into consideration as
guidance document. Analytical performances, such as precision profile, cut-off value, false positive
and false negative rates were evaluated for each assay by single laboratory validation, whereas a
verification of the results from the validation study was performed based on long-term intra-laboratory
quality control (QC) data. Correlation of the results obtained with the rapid immunoassays and the
AOAC Official Method 2000.08 was evaluated for the analysis of naturally contaminated cow milk
samples. Finally, the extension of the scope of the strip test method to goat and sheep milk was
evaluated by applying the experimental design foreseen in the EU regulation [28].
2. Results and Discussion
The experimental design to evaluate analytical performances of strip test immunoassay and
ELISA comprised the following steps, which were carried out in parallel for the two assays: i) single
laboratory validation study to evaluate precision, cut-off value, false suspect and false negative rates
(milk samples fortified by AFM1 were used at this stage); ii) verification of cut-off and precision values
by long-term intra-laboratory QC study (a QC cow milk sample spiked at 50 ng/kg was used at this
stage); iii) evaluation of results correlation between rapid immunoassays and AOAC Official Method
2000.08 (a set of naturally contaminated cow milk samples was used for this purpose). Data obtained
for each step are described and discussed in the following.
2.1. Validation Results
Validation experiments were performed according to the experimental design described in
Section 4.6. The screening target concentration (STC) value was 50 ng/kg. Other tested mass fractions
values were: blank (AFM1 ≤ 0.5 ng/kg), 25 ng/kg (50% of the STC), 75 ng/kg (150% STC). The same
sample set was analyzed by the ELISA and the strip test. Results obtained from the 24 measurements
performed for each validation level were taken as basis for the calculation of validation parameters:
precision, cut-off value, false positive and false negative rate. The overall results of the statistical
assessment are shown in Table 1.
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Table 1. Analytical performances of the strip test immunoassay and enzyme linked immunosorbent
assay (ELISA), as resulted by validation experiments.
Test Sample Strip Test ELISA
Blank
(AFM1 ≤ 0.5 ng/kg)
Mean response (ng/kg) 4.2 8.2
RSDr (%)1 93 16
RSDip (%)2 140 33
False suspect rate (%) <0.1 <0.1
50% STC
(25 ng/kg)
Mean response (ng/kg) 23.2 30.7
RSDr (%) 26 5
RSDip (%) 32 5
False suspect rate (%) 3 <0.1
STC
(50 ng/kg)
Mean response (ng/kg) 53.1 57.9
RSDr (%) 12 5
RSDip (%) 17 10
150% STC
(75 ng/kg)
Mean response (ng/kg) 85.6 105
RSDr (%) 16 15
RSDip (%) 19 15
False negative rate (%) 0.4 0.1
Cut-off value (ng/kg) 37.7 47.5
1 RSDr relative standard deviation of the repeatability; 2 RSDip relative standard deviation for intermediate precision.
First, precision data were calculated for all tested concentrations. Specifically, RSDip (intermediate
precision) values of 32% (strip test) and 5% (ELISA) were obtained for samples contaminated at
25 ng/kg, values of 17% (strip test) and 10% (ELISA) at 50 ng/kg, 19% (strip test) and 15% (ELISA)
at 75 ng/kg. Repeatability values (RSDr) were lower than 26% in all cases. Comparable values were
obtained for the two tests at STC and above STC, whereas at 50% STC (25 ng/kg) lower intermediate
precision values where obtained for ELISA. This could be partially explained by the fact that ELISA
was working at a level five times higher than its limit of detection (LOD, 5 ng/kg, see Section 4.4),
whereas the strip test was working at its LOD (25 ng/kg see Section 4.3).
With respect to the blank samples, a high relative standard deviation of the strip test response was
observed. This could be mainly explained by the fact that for the strip test assay analytical signal values
below a certain fixed limit, which is set by the manufacturer, are reported as “zero concentration”,
whether that is true or not. This led to a high number of “zero concentration” values in blank samples
generating a high standard deviation. However, in the following, it will be shown that, notwithstanding
this high value, an acceptable low rate of false suspect results for the blank samples was obtained
anyway, due to the good separation of test responses for blank and contaminated samples.
Overall, the obtained precision values indicated an acceptable robustness of the two test methods,
also taking into consideration the very low target levels of AFM1 considered for validation.
Once intermediate precision data were available, it was possible to calculate the cut-off values.
According to European legislation [28], this value is defined as the response (AFM1 mass fraction)
obtained with the screening method, “above which the sample is classified as suspect”, with a false
negative rate of 5%. The calculated cut-off values were 37.7 ng/kg for the strip test and 47.5 ng/kg
for the ELISA test, respectively. In both cases, the assay sensitivity was considered satisfactory for
assessing milk contamination at levels encompassing the EU maximum limits.
116
Toxins 2020, 12, 270
Based on the cut-off values, the rate of false suspect results was estimated for samples containing
AFM1 below the STC. Specifically, for samples contaminated at 50% STC (25 ng/kg) the false suspect
rate was 3% for the strip test and < 0.1% for the ELISA test. Finally, the false negative rate for samples
contaminated at levels above the STC (75 ng/kg in the present case) resulted to be 0.4% for strip test and
0.1% for ELISA. In both cases, the acceptability criterion of maximum 5% false negative rate was met.
The overall results indicated satisfactory kits reliability in discriminating samples contaminated
at different AFM1 levels set in a very narrow working range (from ≤ 0.5 to 75 ng/kg), encompassing
EU regulatory limits.
In addition, the method fitness for purpose of evaluating milk contamination at the alert threshold
of 40 ng/kg was evaluated by analyzing 20 contaminated samples from two different farms. The obtained
average responses were 40.0 ng/kg for the strip test and 40.2 for the ELISA, with relative standard
deviation (RSDip) of 9.8% and 5.8%, respectively. The resulting cut-off levels were 33.2 ng/kg and
36.1 ng/kg. No false suspect samples resulted for blanks with respect to these cut-off values. These data
demonstrated the fitness for purpose of the two tested kits in evaluating compliance of milk samples
with respect to the alert threshold of 40 ng/kg.
2.2. Verification of Method Performances through Quality Control Data
Verification of method performances was carried out through long-term intra-laboratory QC
measurements over a period of 12 months (see Section 4.6). The results of the validation and the
verification study were compared in terms of precision, recovery rates and cut-off values, as shown
in Table 2. The cut-off values calculated by QC data matched very well with those obtained by
validation data. Moreover, the data from the validation study as well as from the QC exercise revealed
comparable values for the precision and the recovery rate, thus demonstrating sufficient ruggedness of
both methods over the time and different production lots.
Table 2. Verification of strip test and ELISA method performances though quality control (QC) data.
Method Performances Strip Test ELISA
Single Lab validation QC Single Lab validation QC
STC
(50 ng/kg)
Mean response (ng/kg) 53.1 53.5 57.9 52.8
Relative recovery rate (%) 106 107 116 106
RSDip (%) 1 17 12 10 9.2
Cut-off value (ng/kg) 37.7 42.7 47.5 44.7
1 RSDip relative standard deviation for intermediate precision.
2.3. Analysis of Naturally Contaminated Samples
The trueness of data generated by the two screening methods was evaluated by comparing them
with results obtained by the reference AOAC Official Method 2000.08 on a set of raw cow milk samples
naturally contaminated in the range n.d. (≤0.5 ng/kg) – 50 ng/kg AFM1.
Results are depicted in Figure 1. The two test kits performed in a similar way, and in both cases a
satisfactory correlation was observed, with results provided by the reference method (r = 0.923 and
slope = 0.84 for strip test vs HPLC and r = 0.924 and slope = 1.05 for ELISA vs HPLC). Irrespective of a
slight overestimation of the AFM1 content in some of the blank samples (HPLC result ≤ 0.5 ng/kg), both
immunoassays returned values lower than 14 ng/kg, confirming the absence of false suspect results.
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Figure 1. Correlation between results (AFM1 mass fraction, ng/kg) obtained by strip test or ELISA and
the HPLC analysis performed according to the AOAC Official Method 2000.08.
2.4. Extension of Scope of the Method to Other Commodities
Finally, the extension of the scope of the strip test method to goat and sheep milk was evaluated
by applying the experimental design foreseen in the EU regulation. The regulation foresees that
“as long as the new commodity belongs to a commodity group (“milk” in the present case) for
which an initial validation has already been performed, a minimum of 10 homogeneous negative
control and 10 homogeneous positive control (at STC) samples shall be analyzed under intermediate
precision conditions. The positive control samples shall all be above the cut-off value as calculated in
validation experiments.
For these purposes, first specific calibration curves (bar codes) were generated for strip test analysis
of raw goat and raw sheep milk. Then 10 blank (negative) samples and 10 samples contaminated
by AFM1 at 50 ng/kg were analyzed for each milk type. An additional sample set containing AFM1
at 25 ng/kg was also included. Results are reported in Figure 2. In both cases negative samples
were correctly classified as below the cut-off. No false suspect was reported. In addition, samples
contaminated at 50% STC (25 ng/kg) were all correctly classified as below the cut-off (Table 1) and no
false suspect was reported. All samples contaminated at 50 ng/kg (STC) were correctly classified above
the cut-off.
Figure 2. Results of strip test analysis of blank sheep and goat milk samples and samples contaminated
with 25 and 50 ng/kg AFM1.
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The obtained data showed the applicability of the strip test immunoassay to goat and sheep milk
provided that a specific calibration curve was used.
2.5. Fitness for Purpose of the Validated Immunoassays
Validation experiments returned, for both immunoassays, fit for purpose analytical performances
such as cut-off values (37.7 ng/kg and 47.5 ng/kg for strip test and ELISA respectively), false suspect
rate for blanks (<0.1% for both assays) and false negative rate (<0.4% (for both assays). Both assays
showed an intermediate precision at STC (50 ng/kg) <17% either in validation and QC measurements.
However, besides analytical performances, when choosing a method for rapid mycotoxin screening,
the concept of fitness for purpose also includes some practical parameters. Factors such as the time
needed for analysis, the skills or level of education of the user of the method and the place where
the analysis needs to be carried out are generally taken into consideration by the end users. A more
comprehensive comparison of performances of mycotoxin screening tests can be found in Lattanzio et
al. [29]. In the present case, the total analytical time for strip test assay was about 10 min and the use of
the incubator, as well as the portable reader, made it suitable for on farm use. The ELISA involved
more steps, a basic laboratory equipment and more time (approx 80 min). On the other hand, ELISA
tests allow to handle up to 48 samples simultaneously (including calibrants and QC samples), while
the strip test foresees only one sample per analysis/strip. ELISA can be therefore more efficient when
a large number of (sub)samples need to be analyzed in a short period of time. On the other hand,
when applied in routine by experienced technicians, strip testing can be stacked to process multiple
samples in a relatively short period of time, by processing 10 to 15 samples 1 min apart. Finally,
concerning method transferability to unskilled personnel, the strip test appears easier to be applied by
low experienced technicians, not only because the analytical protocol is less laborious, but also because
the automatic calibration via QR code uploading. In principle both platforms are potentially suitable
for multiplexing [30–32].
3. Conclusions
Analytical performances and fitness for purpose of two commercial immunoassays widely applied
for the detection of AFM1 in milk (strip test and ELISA) were evaluated, according to guidelines set in
Regulation 519/2014/EU. Both assays showed satisfactory performances in terms of precision, recovery
rates, false positive and false negative rates. In addition, the method performance profiles of the two
methods obtained in the validation study could be verified by long-term intra-laboratory QC data.
A good correlation between the results provided by the validated assays and the AOAC reference
method was observed when analyzing naturally contaminated samples. The extension of the scope of
the strip test method to goat and sheep milk was successfully evaluated by applying the experimental
design foreseen in the EU regulation.
4. Materials and Methods
4.1. Materials
Methanol and acetonitrile (HPLC grade) were purchased from Mallinckrodt Baker (Milan, Italy).
Ultrapure water was produced by using a Millipore Milli-Q system (Millipore, Bedford, MA, USA).
AflaM1 Test immunoaffinity columns were from VICAM (A Waters Business, Milford, MA, USA).
Paper Filters (Whatman 4) were obtained from Whatman International Ltd. (Maidstone, UK). Standard
aflatoxin M1 (acetonitrile solution 10 μg/mL) was purchased from Supelco (Bellefonte, PA, USA).
4.2. Milk Samples
Milk samples (cow, sheep, goat) were collected from farm bulk tanks from Italian farmers in the
time span 2018–2019. After collection samples were stored at 4 ◦C and analyzed within 48 h.
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Fortified milk samples to be used for validation (Section 4.6) were prepared as follows. A spiking
solution containing AFM1 at 1 μg/mL was prepared by diluting 10 times the standard AFM1 solution.
Then 25 μL of spiking solution were added to 50 mL of milk to prepare a mother solution at 500 ng/kg
AFM1. The mother solution was diluted by appropriate volumes of milk to obtain contaminated
samples at 75, 50, 40 and 25 ng/kg.
4.3. Strip Test Immunoassay
The strip test (AFLAM1-V™), incubator, and a photometric reader (Vertu Reader) were from
VICAM (A Waters Business, Milford, MA, USA). The strip test format is based on an indirect
competitive immunoassay. Line intensities developed on the strip membrane (test line and control
line) are measured using the photometric reader. The test response is the ratio between the signal
intensity of the test line and that of the control line and it is converted into toxin concentration through
a lot specific calibration curve.
Strip test analyses of milk samples were performed as follows. Two hundred microliters of cold
milk were pipetted into the reagent vial. After vortex mixing (3 times x 5 sec) the vial was placed into
the incubator set at 40 ◦C and the strip was inserted into it. The sample was allowed to migrate onto the
strip for to 10 min, then the strip was placed into the reader holder for result reading. The lot specific
calibration curve was uploaded onto the reader system by using the corresponding barcode provided
by the supplier. The calibration curve was generated by spiking uncontaminated milk (cow, sheep or
goat milk) at seven AFM1 levels over the range 0–800 ng/kg, performing triplicate measurements for
each calibration level. The limit of detection declared by the supplier was 25 ng/kg.
4.4. Enzyme Linked Immunosorbent Assay
The ELISA kit (I’Screen AflaM1) was from Eurofins Technologies (Budapest, Hungary). Calibration
standards, conjugate, antibody and substrate/chromogen solutions were provided in the kit. The plate
reader was Multiskan MS Plus MK II ELISA reader from Labsystems (Helsinki, Finland).
Samples were analyzed as follows. One hundred microliters of milk (or calibrant solution) were
transferred into the well and incubated for 45 min at room temperature. After discarding the liquid
by turning the plate upside down, the wells were filled completely with the working wash solution.
Then the liquid was poured out from wells and the remaining drops were removed by tapping the
microplate upside down against adsorbent paper. This washing sequence was repeated four times.
Then 100μL of AFM1-enzyme conjugate solution were added and incubated for 15 min. After discarding
the liquid, the wells were washed four times, according to the above described procedure. Then, 100
μL of substrate solution were added and incubated for 15 min for color development. Finally, 50 μL
of stop solution were added. Result were read measuring the absorbance at 450 nm. The limit of
detection declared by the supplier was 5 ng/kg.
4.5. Reference Method (AOAC Official Method 2000.08)
Screening for blank samples to be used for validation experiments and strip test calibration curve
generation, and analysis of naturally contaminated samples for method comparison purposes were
performed, according to the AOAC Official Method 2000.08, with minor modifications. Briefly, milk
samples (50 mL) were centrifuged at 2000× g to separate the fat. After discarding the upper thin fat
layer, the sample was filtered through paper filter. The filtered sample (25 mL) was passed through the
immunoaffinity column. The eluate was discarded and the column was washed twice with 10 mL
distilled water. The toxin was eluted by 2 × 1 mL methanol. The eluate was collected and dried
down under nitrogen stream. The residue was re-dissolved with 250 μL of a mixture water:acetonitrile
(75:25 by vol).
HPLC-FD analyses were performed on an Agilent 1100 Series chromatographic system (Agilent
Technologies, Palo Alto, CA, USA) equipped with a fluorometric detector (model 363), and the
ChemStation data software (Agilent Technologies). The analytical column was a Zorbax SB-C18 Rapid
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Resolution HT (4.6 mm × 50 mm, 1.8 μm) with corresponding in-line filter. The chromatographic
separation was performed by a gradient elution using water (solvent A) and acetonitrile (solvent
B). The flow rate of the mobile phase was 1 mL/min. The injection volume was 50 μL. The column
was kept at a temperature of 40 ◦C; the excitation wavelength was set at 365 nm and the emission
wavelength was set at 435 nm. The detection limit was 0.5 ng/kg.
4.6. Validation Design and Verification Study via Qualitity Control (QC) Measurements
The single laboratory validation study was designed to fulfil the specifications established in
Commision Regulation (EU) 519/2014, in terms of minimum sample set and minimum number of
validation levels.
Measurements were distributed in two different days (instead of 5 as suggested in the regulation,
due to the limited stability of milk samples). Milk samples were from three different farms. In addition,
each sample was analyzed in quadruplicate each day under repeatability conditions. The design
resulted in 12 independent analysis per day and 24 measurements in total per each validation level.
The screening target concentration (STC) was set at the EU maximum permitted level of 50 ng/kg.
The selected validation levels were four: blank (i.e., <0.5 ng/kg), and samples spiked by 25 ng/kg
(50% STC), 50 ng/kg (STC), 75 ng/kg (150% STC) of AFM1. An additional sample set containing AFM1
at 40 ng/kg was included to evaluate the fitness for purpose of the two tested methods in high risk
periods when it is recommended to set the alert threshold (STC) at 40 ng/kg [18].
The results of analysis were then subjected to statistical assessment to calculate validation
parameters as described in the following.
Verification of method performances was carried out through long-term intra-laboratory QC
measurements. For both assays, 50 measurements of the QC material, i.e., raw cow milk spiked at STC
(50 ng/kg), were spread over a period of 12 months. Moreover, 4 different kit lots were used for the
strip test and 6 different lots for the ELISA test, thus including additional factors in the verification
study, which may have an impact on the result of analysis. Finally, the results of these analysis were
taken as a basis for the calculation of the cut-off values, precision and recovery rates.
4.6.1. Precision
To evaluate the precision profile of the method, data generated each validation level were subjected
to analysis of variance (ANOVA). When applying this model, as defined by ISO 5725 [33], the measured
test response Yijk (the AFM1 mass fraction in the present case) is defined as the true value (TV) plus the
contribution of 3 components:
Yijk = TV + Di +Mij +Rijk (1)
where Di is the between-day variability, Mij is the between-matrix (milk batches from different farms)
variability, and Rijk is the within-day variability. The within-day variability gives the precision
under repeatability conditions, whereas the sum of all components gives the intermediate precision.
The statistical assessment was done with the software package MINITABTM Statistical Software for
Windows (Version 15).
4.6.2. Cut-Off Value
The measured levels (ng/kg) of samples containing AFM1 at STC were taken as basis for the
calculation of the cut-off value. According to Regulation 519/2014/EU the following equation was used:
Cut o f f = RSTC − tvalue(0.05) × SDSTC (2)
where the RSTC is the mean level of AFM1 (ng/kg) calculated from all 24 experiments performed on
samples containing AFM1 at STC, SDSTC is the corresponding standard deviation of intermediate
precision as defined in the previous paragraph, and tvalue(0.05) is the one tailed t value for a rate of
false negative results of 5%.
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4.6.3. False Suspect and False Negative Rate
Using the cut-off value and the results from the analysis of negative samples the rate of false
suspect results was estimated by first calculating the t-value as follows:
tvalue =
(




where meanneg is the mean value of the results obtained from the 24 experiments on the negative
samples and SDneg is the corresponding standard deviation of intermediate precision.
From the obtained t-value, based on the degrees of freedom calculated from the number of
experiments (23 in the present case), the false suspect rate results (probability) for a one tailed
distribution was calculated using the spread sheet function “TDIST” from Microsoft Excel.
The false suspect rate for samples containing AFM1 at 50% STC was calculated by applying the
same procedure using the mean value of the results obtained from the 25 experiments on samples
containing AFM1 at 50% STC and the relevant standard deviation of intermediate precision.
Finally, the false negative rate for samples containing AFM1 at levels above the STC was estimated
by calculating the t value as specified here:
tvalue =
(mean>STC − cuto f f )
SD>STC
(4)
where mean>STC is the mean value of the results obtained from the experiments on the samples
containing the analyte above the STC, cut-off is the value established as above, and SD>STC is the
corresponding standard deviation of the intermediate precision. The probability corresponding to the
calculated t value with a one-tailed distribution gives the rate of false negative results for the samples
containing the analyte at levels higher than STC.
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Abstract: Toxin detection is an important issue in numerous fields, such as agriculture/food safety,
environmental monitoring, and homeland security. During the past two decades, nanotechnology has
been extensively used to develop various biosensors for achieving fast, sensitive, selective and on-site
analysis of toxins. In particular, the two dimensional layered (2D) nanomaterials (such as graphene
and transition metal dichalcogenides (TMDs)) and their nanocomposites have been employed as label
and/or biosensing transducers to construct electrochemical biosensors for cost-effective detection
of toxins with high sensitivity and specificity. This is because the 2D nanomaterials have good
electrical conductivity and a large surface area with plenty of active groups for conjugating 2D
nanomaterials with the antibodies and/or aptamers of the targeted toxins. Herein, we summarize
recent developments in the application of 2D nanomaterial-based electrochemical biosensors for
detecting toxins with a particular focus on microbial toxins including bacterial toxins, fungal
toxins and algal toxins. The integration of 2D nanomaterials with some existing antibody/aptamer
technologies into electrochemical biosensors has led to an unprecedented impact on improving
the assaying performance of microbial toxins, and has shown great promise in public health and
environmental protection.
Keywords: two dimensional layered nanomaterials; electrochemical biosensors; microbial toxin
detection; antibodies; aptamers
Key Contribution: This review updates the construction strategies of electrochemical biosensors
such as immunosensors and aptasensors for cost-effective determination of microbial toxins with
high sensitivity given by rapidly developing two dimensional layered (2D) nanomaterial-based
labels and substrates. We summarize the roles of 2D nanomaterials and their nanocomposites
in the configuration of electrochemical biosensors, as well as the advantages they provide to the
analyses, and address the major challenges and perspectives of these electrochemical biosensors for
future commercialization.
1. Introduction
Two-dimensional layered (2D) nanomaterial (e.g., graphene and its derivatives, transition metal
dichalcogenides (TMDs) and other layered nanosheets)-based electrochemical signal amplifications
have great potential for improving both the sensitivity and selectivity of electrochemical biosensors
because of their unique physical, chemical, and electrical properties [1–21]. Graphene is a single
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layer of densely packed carbon atoms with a benzene-ring structure, and is the first known 2D
layered nanomaterial [22]. The unique properties of graphene, including its exceptional mechanical
strength [23], extremely large surface area (2630 m2/g) [24], very high thermal conductivity in
the range of ∼3080–5150 W mK−1 [25], high conductivity [26], good charge carrier mobility [27],
and wide potential window [28], endow it with great applicability in the development of biosensors,
and, in particular, electrochemical biosensors [1–5,12,22–24,29]. In addition, based on the molar
ratio of carbon to oxygen (C/O), graphene can be roughly divided into two categories, graphene
oxide (GO) or reduced graphene oxide (rGO). It is demonstrated that rGO has better electrical
conductivity than GO. Because pure graphene lacks an intrinsic band gap and is limited by chemical
modification, there is an increasing interest in synthesizing graphene derivatives/nanocomposites
and graphene-like 2D nanomaterials. Among the graphene-like 2D nanomaterials, TMDs (e.g.,
molybdenum disulfide (MoS2) and molybdenum selenide (MoSe2)) show excellent physicochemical
properties and remarkable biocompatibility, and also have significant attraction for the fabrication
of electrochemical (bio)sensors [6,7,9,14,21,29]. Driven by their unprecedented properties, massive
synthetic methods/protocols have been developed for preparing 2D nanomaterials and 2D nanomaterial
composites, which involves both physical strategies and chemical approaches, such as dry
mechanical exfoliation (e.g., Scotch tape), chemical (e.g., solution-based exfoliation, graphite oxide
exfoliation/reduction) and/or electrochemical (oxidation/reduction and exfoliation) processes, chemical
vapor deposition (CVD), chemical synthesis, thermal decomposition of SiC wafers and unzipping carbon
nanotubes [26,30–43]. In this review, we will not describe the detailed synthetic methods/protocols
mentioned above for synthesis of 2D nanomaterials, however, we suggest reading several recently
published comprehensive review articles [40–45]. These methods of 2D nanomaterial preparation
produce different forms of nanomaterials with a diversity of properties including mechanical, optical,
electrical, chemical and biological properties. These diverse properties make 2D nanomaterials suitable
for an extensive range of applications, such as drug delivery, in vitro and in vivo imaging, tissue
engineering, biosensor construction, and energy conversion and storage [39,43,46]. For biosensor
applications, 2D nanomaterials should be extensively characterized because their properties strongly
dependent on their characteristics such as thickness or number of layers, morphology, chemical
structure and surface functional groups.
Microbial toxins are the general term for a class of substances covering a broad range from
small molecules to biomacromolecules (e.g., peptides and proteins), which are produced by living
organisms including bacteria, fungus and algae [47–53]. They are widespread throughout the
whole world, threatening the health and/or life of humans and livestock, and affecting domestic
and international trade. For instance, aflatoxin B1 (AFB1, a kind of mycotoxin produced by fungi)
has been defined as a group I carcinogen by the World Health Organization (WHO) [53]. Some
microbial toxins can generate acute poisonous effects even at very low doses, and the co-occurrence
of microbial toxins in nature may cause significantly additive and/or synergistic toxicity. In order
to efficiently avoid potential hazards on public health and safety, it is important to precisely and
reliably determine the toxins in practical samples from different sources. Liquid chromatography-based
methods including high-performance liquid chromatography (HPLC) and high-performance liquid
chromatography-tandem mass spectrometry (HPLC/MS/MS) are the gold standards for accurate analysis
of toxins [54–59]. Although the HPLC-based methods have high reliability and accuracy, they typically
require expensive laboratory facilities and instruments, complex pre-treatment processing of the sample
and well-trained operators. These drawbacks strongly limit the application of HPLC-based methods in
on-site detections of toxin. Various sensing systems such as surface plasmon resonance (SPR) biosensors,
electrochemical biosensors, fluorescence biosensors, colorimetric assays, competitive enzyme-linked
immunosorbent assay (ELISAs) and microfluidic immunoassay have been developed for analysis of
toxins from different sources including clinical samples, foods, water and feeds [60–66]. Among these
biosensing systems, electrochemical biosensors and biotransducers are more attractive because they
offer several advantages such as high sensitivity, operational simplicity, relatively low cost, easily
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miniaturization and suitable on-site analysis [8,11–19,67–69]. These advantages make electrochemical
biosensors/transducers of microbial toxins powerful tools in many areas including food, environmental
and medical monitoring, disease diagnosis and anti-terrorism security. Owing to the large surface
areas and excellent conductivities, the integration of 2D nanomaterials (e.g., graphene and TMDs) and
their nanocomposites with electrochemical transducers has great potential to enhance the analytical
performance of electrochemical biosensors for detection of toxins [8,11–19]. For example, since its birth,
multiple research initiatives on graphene applied to electroanalytical chemistry have been launched
worldwide, and analysts have been developing a plethora of different graphene-based electrochemical
sensing platforms for detection of various targets including microbial toxins. Typically, these
electrochemical biosensors comprise a graphene and/or a graphene derivative/nanocomposite-modified
electrode as an electrochemical signal transduction element, and a biological recognition element (e.g.,
antibodies, aptamer and microbial cells). The signal from the biological recognition event is converted
to a quantifiable electrical signal because the biological target is normally in close contact with the
electrochemical signal transduction element through physical or chemical interactions (e.g., electrostatic
interactions, π-π interactions and covalent bonds). Because of their unique properties (e.g., large
surface area and good conductivity), the detection performance of an electrochemical biosensor can be
significantly improved by using the graphene and/or a graphene derivative/nanocomposite. Therefore,
the scope of application of 2D nanomaterial-based electrochemical biosensors has been constantly
expanding in the field of toxin detection. Some of these studies have been reviewed elsewhere
with a focus on the fabrication and toxin detection of graphene-based electrochemical biosensors
or as subclassifications in more generalized overviews of the nanomaterial-based electrochemical
biosensors [8,11–19]. In this review, we will focus on the recent development of GO/rGO and/or
MoS2/MoSe2-based electrochemical biosensors for the determination of various microbial toxins, such as
bacterial toxins, fungal toxins and algal toxins, highlighting some of their current achievements, technical
challenges/limitations and the future directions by means of a set of selected recent publications.
2. Detection of Bacterial Toxins
2.1. Botulinum Neurotoxins
The Botulinum neurotoxins (BoNTs), which are produced by Clostridium botulinum, an anaerobic
bacterium, are among the most toxic of all naturally occurring substances [70–72]. Based on their
molecular structures, BoNTs are categorized into seven serotypes (from A to G). They inhibit
acetylcholine release from presynaptic nerve terminals at the neuro-muscular junction in both the
central and peripheral nervous systems through cleavage of soluble N-ethylmaleimide-sensitive factor
attachment protein receptors (SNAREs), resulting in flaccid muscle paralysis. BoNTs can cause the
deadly disease, botulism, with a median lethal dose (LD50) of 1 ng per kg bodyweight. Foods are
easily contaminated by Clostridium botulinum during processing. Various (impedimetric, voltammetric
and amperometric) electrochemical biosensors have been fabricated for BoNT detection [73–76].
In particular, electrochemical biosensors can achieve detection of this toxin in a fast and meticulous way,
and they also provide a robust and cost-effective approach for real-time monitoring of BoNTs. Recently,
2D nanomaterial-based electrochemical biosensors have been applied to sensitively detect BoNTs
in various samples including foods. For instance, Narayanan et al. constructed an electrochemical
immunosensor of the BoNT serotype E (BoNT/E) by using graphene nanosheets–aryldiazonium
salts as transducers [74]. The as-proposed immunosensor shows a low limit of detection (LOD,
5 pg mL−1) and can be employed for rapid detection of BoNT/E with a total analysis time of 65 min.
Chan et al. fabricated an electrochemical biosensor for ultrasensitive detection of BoNT serotype
A light chain (BoNT-LcA) through immobilization of the SNAP-25-GFP (synaptosomal associated
protein 25-green fluorescent protein) peptide substrate on the rGO modified gold electrode via
a pyrenebutyric acid (PA) linker (as shown in Figure 1) [75]. In this case, PA was immobilized
on the rGO surface through π-π stacking. Subsequently, SNAP-25-GFP peptide reacted with PA
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via N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride/N-hydroxysulfosuccinimide
(EDC/Sulfo-NHS) activation. After specific cleavage of SNAP-25-GFP by BoNT-LcA, the steric
hindrance and electrostatic repulsion of SNAP-25-GFP decreased, resulting in an increase in the
electrochemical signal. The amount of BoNT-LcA can be detected through the change of peak
current of the electrochemical redox probe (ferricyanide, [Fe(CN)6]3−/4−(1:1)) by the differential pulse
voltammetry (DPV) measurement. The as-fabricated electrochemical biosensor provides a relatively
wide linear range (1 pg mL−1 to 1 ng mL−1) and a relatively low LOD (8.6 pg mL−1) for detection of
BoNT-LcA because the rGO modified Au (rGO/Au) electrode provides a robust and biocompatible
platform with improved electron transfer capability and a large surface area for peptide immobilization.
The feasibility of the as-fabricated biosensor is demonstrated by detection of BoNT-LcA in spiked
milk samples. Afkhami et al. developed a gold nanoparticle-graphene-chitosan (Au NPs-Gr-Cs)
nanocomposite-based impedimetric immunosensor for the detection of BoNT serotype A (BoNT/A) [76].
The Au NPs-Gr-Cs nanocomposite was used for the amplification of the electrochemical signal, and
monoclonal anti-BoNT/A antibodies were conjugated on the Au NPs-Gr-Cs nanocomposite modified
glassy carbon electrode (GCE). In the presence of BoNT/A, the immunocomplex formed on the
as-prepared electrode surface, which acts as the inert electron and mass transfer blocking layer.
Therefore, the diffusion of [Fe(CN)6]3−/4− is hindered, resulting in a decrease of the peak current.
The Au NPs-Gr-Cs nanocomposite-based impedimetric immunosensor has an excellent linear range
(from 0.27 to 268 pg mL−1) with a LOD of 0.11 pg mL−1, and is very suitable for routine analysis of
BoNT/A in different matrices, such as serum and milk.
 
Figure 1. Schematic representation of the detection principle of the rGO based electrochemical
biosensors (adapted from Chan et al. 2015 [75], Copyright 2015 Elsevier B.V. and reproduced with
permission).
2.2. Clostridium difficile Toxin B
Clostridium difficile toxin A (Tcd A, 308 kDa) and toxin B (Tcd B, 270 kDa) are co-produced by
Clostridium difficile (C. difficile). Tcd A is an enterotoxin responsible for tissue damage, while Tcd B
is referred to as a potent cytotoxin [77–81]. In particular, the rapid and sensitive detection of Tcd B
is very helpful for early diagnosis and efficient therapy because Tcd B is critical for virulence and
is found in all clinically isolated pathogenic strains [79–85]. Using the advantages of GO, including
the large surface area and good conductivity, Fang et al. developed a simple sandwich-assay type
electrochemical immunosensor for improving the Tcd B detection sensitivity by using GO as a scaffold
for the enhanced loading of horseradish peroxidase (HRP) and HRP-labeled secondary Tcd B antibody
(as shown in Figure 2) [84]. The LOD (0.7 pg mL−1) of the sandwich-assay type electrochemical
immunosensor is much lower than those of other current techniques including ELISA. In addition,
the as-prepared electrochemical immunosensor was successfully employed to detect Tcd B in practical
samples (e.g., real human stool), demonstrating that the immunosensor has promising potential in
clinical applications.
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Figure 2. Schematic representation of the immunosensor array preparation and detection strategy by
sandwich-type immunoassay of Tcd B. Here, Tcd B means C. difficile toxin B, BSA means bovine serum
albumin, anti-Tcd B means anti-Tcd B antibody, HRP means horseradish peroxidase, HRP-Ab2 means
HRP-labeled second anti-Tcd B antibody, GA means glutaraldehyde, CS means chitosan, PB means
Prussian blue, MWCNTs means multi-walled carbon nanotube, GO means graphene oxide, and GCE
means glassy carbon electrode (adapted from Fang et al. 2014 [84], Copyright 2013 Elsevier B.V. and
reproduced with permission).
2.3. Staphylococcal Enterotoxin B
Among the toxins secreted by Staphylococcus aureus, the staphylococcal enterotoxin B (SEB)
shows superantigenic properties in nature. SEB exposure can result in immunosuppression and
serious food poisoning [86,87]. Therefore, it is important to develop a cost-effective, easy-to-use,
rapid and sensitive method for real-time monitoring of a low concentration (less than 20 ng kg−1
(i.e., LD50 value)) of SEB in foods. Several graphene-based electrochemical biosensors have been
developed for real-time detection of SEB in foods with a high sensitivity [88–91]. For instance,
Sharma et al. reported on an electrochemical biosensor based on a rGO-chitosan-AuNPs-capturing
antibody (rGR-Ch-AuNPs-CAb)-modified GCE for detecting SEB [88]. The rGR-Ch-AuNPs-CAb
modified GCE shows remarkable detecting performance because it has a flat two-dimensional
configuration and large surface area with plenty of active sites (i.e., functional groups). Using the
as-proposed rGR-Ch-AuNPs-CAb-based electrochemical biosensor, 5 ng mL−1 SEB can be easily
detected within 35 min, which is much lower than the LD50 value of SEB. Very recently, Nodoushan et
al. fabricated an electrochemical aptasensor for SEB detection by using a rGO and gold nano-urchins
(AuNUs)-modified screen printed carbon electrode (SPCE) (as shown in Figure 3) [91]. The aptamer of
SEB was attached on the electrode surface through hybridization with the immobilized single-stranded
DNA probe on the surface of the AuNUs. Hematoxylin was used as the electrochemical signal
generator. In the presence of SEB, the aptamer released from the electrode surface, resulting in an
increase in the peak current of hematoxylin. Benefiting from the high conductivity of rGO and high
surface area of AuNUs, a wide linear range from 5.0 to 500.0 fmol L−1 was achieved and the LOD
was calculated as 0.21 fmol L−1. There is no significant difference between the results given by the
commercial ELISA kit and the electrochemical aptasensor. In particular, the aptasensor shows better
recovery rates and lower standard deviation than those of the commercial ELISA kit, which could be
employed as a point-of-care (POC) device for assessing food samples.
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Figure 3. Schematic representation of the fabrication process of the SEB aptasensor by using rGO and
AuNU-modified screen printed carbon electrodes (SPCEs) (adapted from Nodoushan et al. 2019 [91],
Copyright 2018 Elsevier B.V. and reproduced with permission).
3. Detection of Fungal Toxins
3.1. Aflatoxins
Aflatoxins are a widespread group of food toxins that are produced by Aspergillus flavus and
Aspergillus parasiticus [92–95]. There are four main types of aflatoxins: B1, B2, G1, and G2, which
are based on their fluorescence characteristics under UV light (blue or green) excitation and relative
chromatographic mobility in thin-layer chromatography. Among the aflatoxins, AFB1 is considered
the most toxic aflatoxin, and can cause cancers, such as hepatocellular carcinoma. Various 2D
nanomaterial-based electrochemical biosensors have been constructed for detecting AFB1 in various
matrixes [96–113]. Srivastava et al. have developed a series of functionalized GO nanocomposite-based
electrochemical biosensors for profiling AFB1 in foods since they developed the first rGO-based
AFB1 immunosensor through the covalent conjugation of the monoclonal anti-AFB1 antibodies onto
an rGO modified indium tin oxide (ITO) electrode in 2013 [96–99]. Among these electrochemical
biosensors, the functionalized GO/rGO-based nanocomposites are employed in different roles, such as
catalysts, electroactive probes and immobilization platforms for improving the biosensing performance.
For instance, benefiting from the highly crystalline properties of the rGO-Ni NPs sheets (Ni nanoparticle
decorated rGO sheets) along with the excellent electro-catalytic properties, the rGO-Ni NPs-ITO-based
AFB1 immunosensor exhibits high sensitivity (129.6 mA ng−1 mL cm−2), long term stability (up to
6 weeks) and low LOD (0.16 ng mL−1) [99]. Photoelectrochemical (PEC) biosensors have attracted
great attention in the biological analytical field as the PEC method can obtain high sensitivity without
expensive equipment. Recently, Hao et al. developed a dual channel self-reference PEC biosensor
for detecting AFB1 through immobilization of the AFB1 aptamer onto cadmium telluride (CdTe) and
the CdTe-GO modified ITO electrode (as shown in Figure 4) [104]. In this case, CdTe and CdTe-GO
were used to generate an anodic photocurrent and cathodic photocurrent, respectively. The AFB1
aptamer was immobilized on the PEC active materials, CdTe and CdTe-GO, through a covalent
reaction or physical absorption, respectively. In the presence of AFB1, the aptamer is released from the
CdTe-GO surface, resulting in the recovery of the cathodic photocurrent, while the aptamer forms an
aptamer-AFB1 complex on the CdTe surface, and the anodic photocurrent decreases further. Compared
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to traditional PEC biosensors, the CdTe/CdTe-GO-based dual channel self-reference PEC biosensor
can provide better precision and reliability, which is promising for detection of AFB1 in complex
matrixes. Very recently, Peng et al. developed an AFB1 electrochemical aptasensor based on tetrahedral
DNA nanostructures (TDNs) immobilized on three dimensionally ordered macroporous MoS2-AuNPs
hybrids (3DOM MoS2-AuNPs) [107]. 3DOM MoS2-AuNPs can enhance the immobilization amount of
TDNs and facilitate the movement of the electrons between the electrode surface and the redox probe.
In combination with a HRP functionalized magnetic signal amplifier, the aptasensor achieves a good
linear range (from 0.1 fg mL−1 to 0.1 μg mL−1) and a LOD of 0.01 fg mL−1, which can be employed to
detect AFB1 in grain products such as rice and wheat powder samples.
 
Figure 4. Schematic representation of the construction of the self-reference photoelectrochemical (PEC)
biosensor for the detection of AFB1 (adapted from Hao et al. 2017 [104], Copyright 2017 American
Chemical Society and reproduced with permission).
3.2. Ochratoxin
Ochratoxin A (OTA) is the major mycotoxin of the ochratoxin group, which are produced
primarily by fungi (e.g., Aspergillus ochraceus, Penicillium verrucosum and Aspergillus niger) [114–117].
OTA has strong nephrotoxicity, and is the main etiological agent responsible for human Balkan
endemic nephropathy (BEN) and associated urinary tract tumors. In addition, high concentrations
of OTA has certain hepatotoxicity. During the last 5 years, several 2D nanomaterial-based
electrochemical biosensors including immunosensors and aptasensors have also been developed for
sensing OTA [118–131]. For instance, a series of aptasensors based on rGO-AuNP nanocomposites have
been constructed by Wang’s group [118–120]. The rGO-AuNP nanocomposites have well-dispersity
and controllable surface coverage of AuNPs on the rGO sheet, which can be employed as an excellent
signal amplified platform for an impedimetric aptasensor and/or an efficient nanocarrier for the CdTe
QD (cadmium telluride quantum dot)-based amperometric aptasensor. As a typical example, a label
free electrochemical aptasensor was successfully fabricated for ultrasensitive detection of OTA through
using the CdTe QDs modified graphene/AuNPs nanocomposite (GAu/CdTe) as a signal amplifier.
The as-proposed label-free amperometric aptasensor exhibits a wide linear range from 0.2 pg mL−1
to 4 ng mL−1 and a low LOD (0.07 pg mL−1), which has great potential in various applications, such
as food safety monitoring and clinical diagnosis [120]. Bulbul et al. developed a non-enzymatic
nanocatalyst-based amperometric aptasensor for OTA detection through immobilization of the OTA
aptamer on the GO-modified electrode and the electro-oxidation of a nanoceria (nCe) tag [121]. In this
case, GO was used as an electrode material for facilitating the electron transport and enhancing the
electrochemical response because it has high conductivity and peroxidase-like activity. In particular, the
synergistic effect between the catalase activity of nCe and the peroxidase like activity of GO increases
the OTA detection sensitivity significantly. The LOD of as-proposed amperometric aptasensor is
calculated to be 0.1 nmol L−1, which is below the European Union regulatory limits of OTA (such as
5 μg kg−1 in raw cereal grains, 3 μg kg−1 in products derived from cereals, and 2 μg kg−1 in grape juice).
The analytical reliability of the amperometric aptasensor has been demonstrated by the detection of
OTA in spiked corn samples. Recently, Wang et al. constructed a ratiometric electrochemical aptasensor
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for OTA detection through assembly of a methylene blue (MB)-modified OTA aptamer (MB-aptamer)
on the MoS2 nanosheet/AuNP (MoS2-AuNP) nanocomposite-decorated gold electrode through the
host-guest recognition of β-cyclodextrin (β-CD) (as shown in Figure 5) [128]. After interaction with
OTA, the MB-aptamer was disassembled because of G-quadruplex formation, leading to a decrease
in the peak current of MB. Whereas the free ferrocenecarboxylic acid was recognized by β-CD
and produced signals in the current, resulting in the “ratiometric” effect. With the combination of
high electrocatalytic activity of MoS2-AuNP nanocomposites and the recognition capability of β-CD,
the as-proposed ratiometric electrochemical aptasensor possesses satisfactory superiority in terms of
detection range (from 0.1 nmol L−1 to 50 nmol L−1), sensitivity (a LOD of 0.06 nmol L−1), and accuracy
(6.5% of the relative standard deviation (RSD)). The practicability of the aptasensor was successfully
demonstrated by detecting OTA in red wine samples.
 
Figure 5. Schematic representation of the fabrication of the ratiometric electrochemical aptasensor for
OTA detection based on nanocomposites of gold nanoparticle and MoS2 nanosheets with β-CD-SH
(thiolated β-CD) (adapted from Wang et al. 2018 [128], Copyright 2018 Elsevier Ltd. and reproduced
with permission).
3.3. Mycotoxins Produced by Fusarium
The 2D nanomaterial-based electrochemical biosensors have also been developed for detecting
other mycotoxins produced by Fusarium including deoxynivalenol (DON), fumonisin 1 (FB1),
and zearalenone (ZEN) [132–137]. Shi et al. developed an aptasensor for sensitive FB1 detection by
using the dual amplification of AuNPs and graphene/thionine nanocomposites (GSTH) [132]. GSTH
served as electrochemical probes, which exhibit a strong electrochemical signal because the graphene
has excellent conductivity and a large surface area for immobilizing a large amount of thionine
molecules. The as-prepared aptasensor has a six orders of magnitude linear range with a LOD of
1 pg mL−1. Lu et al. fabricated an electrochemical immunosensor based on a graphene nanocomposite
for rapid and sensitive detection of two mycotoxins, DON and FB1 by using correspondent anti-toxin
antibodies (as shown in Figure 6) [134]. In this case, the disposable SPCE was used as a sensing
platform, which was modified by AuNPs and polypyrrole (PPy)-electrochemical rGO (PPy/ErGO)
nanocomposite film. The film exhibits effective anti-toxin antibody immobilization capacity, enhanced
electrical conductivity, and biocompatibility. The current signal of PPy/ErGO-SPCE is much better than
that of PPy/rGO-SPCE. Benefiting from the excellent electrochemical response and effective antibody
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immobilization, the immunosensor exhibits good sensitivity, with a LOD of 4.2 ng mL−1 for FB1
and 8.6 ng mL−1 for DON. The immunosensor can be used for simultaneous detection of multiple
co-contaminant mycotoxins individually in the practical samples (e.g., corn extracts) because it shows
low matrix interference even in co-existing toxin environments. Very recently, Jiang et al. constructed a
facile electrochemical immunosensor based on thin-layer MoS2 and thionin (MoS2-Thi) composites for
the sensitive and rapid detection of zearalenone (ZEA) in human biofluids (as shown in Figure 7) [136].
The as-prepared MoS2-Thi nanocomposites were employed as excellent electrochemical probes, as well
as an efficient anti-ZEA antibody loading platform because MoS2 retains the electrochemical activity of
Thi, and has a large surface area. The MoS2-Thi-based electrochemical immunosensor has good ZEA
detection performance including a wide linear range (0.01 to 50 ng mL−1), low LOD (0.005 ng mL−1
ZEA in both the plasma and urine), excellent selectivity, rapid responding time (20 min), acceptable
stability (retained more than 85% detection capability at 4 ◦C for 10 days) and good practicability
(detection of ZEA in real human biofluids).
 
Figure 6. (A) Schematic representation of fabrication of the immunosensor and (B) detection of mycotoxins
(adapted from Lu et al. 2016 [134], Copyright 2016 Elsevier Ltd. and reproduced with permission).
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Figure 7. Schematic representation of the electrochemical immunosensor based on MoS2-Thi composites
for the rapid detection of ZEA in biofluids (adapted from Jiang et al. 2019 [136], Copyright 2019 Elsevier
B.V. and reproduced with permission).
4. Detection of Algal Toxins
4.1. Microcystins
Microcystins (MCs), a group of toxins produced by a number of cyanobacteria species,
are monocyclic heptapeptides with the general structure cyclo(D)-Ala-X-(D)-erythro-b-methyl-
iso-Asp-Y-Adda-(D)-iso-Glu-N-meth-yldehydro-Ala (X and Y represent L-amino acids). They are the
most common cyano-toxins [138–142]. The unusual Adda amino acid, unique to MCs, is responsible
for the toxicity of the molecule. There are more than 100 known variants of MCs, which are
found in a wide variety of aquatic environments, in particular, eutrophic waters. Exposure to
MCs via consumption of poisoned drinking-water or eating contaminated fish can cause permanent
multiple organ injuries, developmental effects, reproductive effects and cancer. Therefore, it is
important to develop highly sensitive methods for on-site monitoring of MCs. In addition, as the
most potent congener, the Microcystin-LR (MC-LR) is commonly used to evaluate the toxicological
data on the effects of MCs. The maximum tolerance limit of MC-LR concentration is 1 μg L−1 in
different water sources by the WHO provisional guideline. Electrochemical biosensors, including 2D
nanomaterial-based amperometric immunosensors, impedimetric aptasensors, and PEC aptasensors,
have been extensively employed to detect MCs/MC-LR [143–159]. Li et al. have fabricated an
electrochemical immunosensor based on GO-AuNP nanocomposites for MC-LR detection in water
samples though layer-by-layer alternate electrodeposition of GO and chloroauric acid (HAuCl4) on the
GCE surface for 20 cycles [147]. The GO-AuNP-decorated GCE was then modified by the conducting
polymer (poly(2,5-di-(2-thienyl)-1-pyrrole-1-(p-benzoicacid)) and 1-iso-butyl-3-methylimidazolium
bis(tri-fluoromethane-sulfonyl) imide ionic liquid (IL). A polyclonal antibody of MC-LR was
immobilized on the electrode by the conventional EDC/NHS reaction. The GO-AuNP nanocomposites
enhance electron transfer of Fe(CN)6 3−/4− to the electrode while the IL acts as the stabilizer of the
antibody. The as-developed electrochemical immunosensor has good repeatability (e.g., RSD = 1.2%)
and long-term stability (e.g., retain 95% activity over a 20 weeks storage period), and can detect MC-LR
in water samples with a very low LOD of 3.7 × 10−17 mol L−1. Recently, He et al. synthesized a
kind of magnetic rGO nanocomposite (Fe3O4@PDA/RGO) for constructing a MC-LR electrochemical
immunosensor by using the hydrothermal treatment of Fe3O4 nanocluster@Polydopamine core@shell
nanoparticles (Fe3O4@PDA) with GO (as shown in Figure 8) [153]. Due to its surface area and easy
separation, the Fe3O4@PDA/RGO clearly enhances the antigen immobilization ability of the electrode.
Then, a secondary-antibody and circularization DNA template were conjugated on gold nanorods
(AuNRs) for recognizing the captured MC-LR-antibody pair on the Fe3O4@PDA/RGO-modified
electrode surface and rolling circle amplification. Because the rolling circle amplification strategy can
generate massive repeated DNA sequences, the signal of the immunosensor is greatly enhanced by
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hybridization of electrochemical active probes with the repeated DNA sequences. Under the optimal
conditions, the as-developed immunosensor has good detection performance including a wide linear
range (from 0.01 mg L−1 to 50 mg L−1) and a low LOD (0.007 mg L−1), which can be employed to
detect MC-LR in real samples (e.g., river water). A series of PEC aptasensor-based various GO/rGO
nanocomposites have been developed for sensitively detecting MC-LR since the PEC method has been
considered to be a more sensitive technique, ascribed to the combination of electrochemical and optical
techniques [149,151,157]. For instance, Du et al. developed a PEC aptasensing platform based on
AgI-nitrogen-doped graphene (AgI-NG) nanocomposites as photo-cathodes and a MC-LR aptamer
as the recognition unit [157]. The PEC aptasensor has a LOD of 3.7 × 10−17 mol L−1, which can be
employed to determine MC-LR in inaquatic products (e.g., fish extracts). As a graphene analogue,
the MoS2 nanosheet is also expected to serve as an excellent functional material for development
of electrochemical biosensors. As shown in Figure 9, Pang et al. constructed an enzyme-free
electrochemical immunosensor for detecting MC-LR based on a unique competitive detection scheme
using MoS2 nanosheets/BSA-stabilized gold nanocluster (MoS2/AuNCs) nanocomposites and Au
core/Pt shell nanoparticles (Au@PtNPs) [155]. Due to its large surface area and excellent biocompatibility,
the MoS2/AuNCs nanocomposite was employed as a platform for improving the biological activity
and immobilizing amount of antibody on the electrode surface. The as-developed enzyme-free
electrochemical immunosensor has good stability (e.g., 92% of the initial level remained after being
stored at 4 ◦C for four weeks), and exhibits a wide linear range of 1.0 ng L−1–1.0 mg L−1 with a LOD of
0.3 ng L−1. The practicability of the as-developed immunosensor has been demonstrated by detection
of MC-LR in various water samples including tap water, lake water, and river water. The MC-LR
amounts in these water samples detected by the immunosensor are consistent with those determined
by the conventional ELISA method. Very recently, Liu et al. developed an electrochemical aptasensor
for sensitive and selective determination of microcystin-LR by using a dual signal amplification system
consisting of a ternary nanocomposite and HRP [159]. The ternary nanocomposites were prepared
by depositing AuNPs on the MoS2 nanosheets covered with TiO2 nanobeads (TiONBs). The MoS2
nanosheet-modified TiONBs provide a large surface area for efficiently immobilizing AuNPs and
thiolated MC-LR aptamers. Due to the combination of good electron transfer and high catalytic
capability of the ternary composite, the aptasensor has a wide dynamic range from 0.005 to 30 nmol L−1
and a LOD of 0.002 nmol L−1.
 
Figure 8. Schematic representation of (A) the preparation of Ab2-AuNR-cirDNA, (B) the formation of
magnetic graphene composite, and (C) the construction process of the proposed MC-LR immunosensor
(adapted from He et al. 2017 [153], Copyright 2017 The Royal Society of Chemistry and reproduced
with permission).
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Figure 9. Schematic representation of the preparation and detection principle of the MC-LR immunosensor
(adapted from Pang et al. 2018 [155], Copyright 2018 Elsevier B.V. and reproduced with permission).
4.2. Cylindrospermopsin
Cylindrospermopsin (CYN), a tricyclic alkaloid with a molecular mass of 415 Da, is a common
cyanotoxin, and is produced by cyanobacteria including Cylindrospermopsis, Anabaena, Umezakia, and
Aphanizomenon [160–166]. Cylindrospermopsin can cause DNA/RNA strand breakage and promote
hepatotoxicity, cytoxicity, and genotoxicity through inhibiting protein translation and binding to
DNA. The Falconer recommends a tentative guideline value of 1 ug L−1 for cylindrospermopsin [166].
Recently, we fabricated a label-free impedimetric aptasensor based on a GO-thionine (TH-GO)
nanocomposite for detection of CYN by covalent binding of the amino-terminated aptamer of CYN
to TH-GO nanocomposite-modified GCE via glutaraldehyde (as shown in Figure 10) [167]. Using
[Fe(CN)6]4−/3− as an electrochemically active probe, CYN can be detected as low as 0.117 ng mL−1 in
water. The as-proposed aptasensor has been employed for detecting CYN in spiked lake water samples,
and satisfactory recoveries were obtained. With its superior performance characteristics combined
with long-term stability (it retained approximately 74.7% of its initial value after being stored at 4 ◦C for
30 days) and excellent reusability (RSD = 2.1% within 10 reacting cycles), the as-developed aptasensor
is a potential candidate for on-site CYN analysis.
Figure 10. Schematic representation of the label-free impedimetric aptasensor for detecting
cylindrospermopsin (adapted from Zhao et al. 2015 [167], Copyright 2015 The Royal Society of
Chemistry and reproduced with permission).
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4.3. Saxitoxins
As a group of carbamate alkaloid neurotoxins, saxitoxins (STXs) contain sixteen variants, which are
commonly associated with “red tides,” and found as a paralytic shellfish toxin. Australia has a drinking
water guideline of 3 μg L−1 of STX equivalence. Recently, Bratakou et al. constructed a miniaturized
potentiometric STX immunosensor on graphene nanosheets with incorporated lipid films and anti-STX
(the natural STX receptor) [168]. The potentiometric STX immunosensor can be easily miniaturized
because graphene nanosheets have a high surface area and good conductivity, and incorporate well with
the lipid bilayer membrane for immobilizing anti-STX antibody. The potentiometric STX immunosensor
exhibits several advantages such as a rapid response time (ca. 5–20 min), low LOD (1 nmol L−1) with
high sensitivity (ca. 60 mV/decade of toxin concentration), good reproducibility (maximum deviation
only 6.8%), reusability, high selectivity and long shelf life (> 1 month). The practicability of the method
was demonstrated by detecting STX in lake water and shellfish samples. This graphene nanosheets
with incorporated lipid films could be used to develop biosensors for monitoring other toxins.
4.4. Brevetoxin B
Brevetoxins (BTXs) are potent cyclic polyether neurotoxins, which are naturally produced by
the marine “red tide” dinoflagellate, Karenia brevis. BTX exposure can cause neurological shellfish
poisoning (NSP), which has increased in geographical distribution over the past decade [139]. As early
as 2012, Tang et al. constructed a magneto-controlled electrochemical immunosensor for sensitive
detection of brevetoxin B (BTX-2) in seafood by using guanine-assembled graphene nanoribbons
(GGNRs) as molecular tags on a home-made magnetic carbon paste electrode [169]. In this case,
the GGNRs were modified by bioconjugates of BSA with BTX-2 (BTX-2-BSA), while monoclonal mouse
anti-BTX-2 antibodies were covalently immobilized on the surface of magnetic beads for the capture
of BTX-2 through a competitive-type immunoassay format. The formed magnetic immunocomplex
was integrated on the electrode with an external magnet, followed by determination in pH 6.5
phosphate-buffered solution containing 2 μmol L−1 Ru(bpy)3Cl2. Compared with pure guanine-labeled
molecular tags, the GNR-labeled electrochemical immunoassays show a much wider linear range and
lower detection limit. Under optimal conditions, the electrochemical signals decreased by increasing
concentration of BTX-2 in the sample. The magneto-controlled immunosensing platform has a wide
dynamic range from 1.0 pg mL−1 to 10 ng mL−1 with a LOD of 1.0 pg mL−1 BTX-2. The analytical
reliability of the magneto-controlled electrochemical immunosensing platform is demonstrated by
the detection of BTX-2 in 12 spiked samples including S. constricta, M. senhousia and T. granosa.
The as-obtained results are consistent with those of traditional ELISA.
4.5. Okadaic Acid
The family of okadaic acid (OA) biotoxins consists of OA and its analogues dinophysistoxins
1, 2 and 3 (named as DTX-1, DTX-2 and DTX-3) [170]. As a by-product of harmful algal blooms
(HABs), OA originates from the algal genera Prorocentrum and Dynophysis. Eissa and Zourob
developed a direct competitive voltammetric immunosensor for the sensitive detection of OA based
on carboxyphenyl-functionalized graphene-modified SPCEs (GSPCEs) [171]. The anti-OA antibodies
were immobilized on the GSPE via carbodiimide chemistry, where OA and OA-ovalbumin (OA-OVA)
in solution compete for their binding to the immobilized antibody. Benefitting from the unique
electrochemical properties of graphene and the stability of the carboxyphenyl layer, the immunosensor
exhibits a linear response up to 5000 ng L−1 with a LOD of 19 pg mL−1. The immunosensor
was successfully applied for detecting OA in the spiked shellfish extracts, showing good recovery.
Very recently, Ramalingam et al. fabricated an electrochemical microfluidic biochip for detecting OA
by using phosphorene-gold (BP-Au) nanocomposite-modified SPCE (as shown in Figure 11) [172].
The as-synthesized BP-Au nanocomposite not only serves as a backbone to the aptamer sequence,
but also significantly enhances the electrochemical response of the aptasensor. DPV measurements
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revealed a LOD of 8 pmol L−1, while a linear range was found between 10 nmol L−1 to 250 nmol L−1.
The electrochemical aptasensor has excellent selectivity and can be employed to detect OA in fresh
mussel extracts. The results suggest that the microfluidic electrochemical aptasensor can be served as
an easy-to-use POC device for an on-field assay.
Figure 11. A microfluidic electrochemical aptasensor for the detection of okadaic acid: (A) graphic of the
fabricated PDMS microfluidic chip, and (B) schematic representation of the process of aptamer-based
sensing (adapted from Ramalingam et al. 2019 [172], Copyright 2019 Elsevier B.V. and reproduced with
permission).
5. Conclusions and Perspective
This review has summarized the recent progress in electrochemical biosensing systems for the
determination of various microbial toxins by using 2D nanomaterials and their nanocomposites
(hereinafter referred to 2D nanomaterials). The literature results demonstrate that the integration
of 2D nanomaterials into electrochemical biosensors has led to the significant enhancement of their
analytical efficiency, including a high sensitivity (e.g., very low LODs) with a wide linearity range over
several orders of magnitude, rapid assaying time, and simplified analytical procedures, and they are
also suitable for on-site monitoring. During the determination processes, 2D nanomaterials mainly
have two roles: as substrates for efficient immobilization of capturing biomolecules (e.g., anti-toxin
antibodies and aptamers) and high active electrochemical probes for signal amplification. Some 2D
nanomaterials have multifunctionality, and are capable of playing both of the above roles. Furthermore,
the 2D nanomaterial-based electrochemical aptasensors have been proven as reusable platforms for
detecting toxins.
Although the 2D nanomaterial-based electrochemical biosensors show great promise within
laboratory investigations, such as the detection of toxins in buffer solutions and/or toxin-spiked samples,
the technique remains relatively immature in development compared with standard toxin assaying tools
(e.g., HPLC and ELISA), and several technical challenges are still awaiting further investigation. (1) The
multiple electrode modification steps are normally required for increasing the recognition performance
of the immobilized aptamer or antibody, and reducing background signals. This phenomenon requires
manual and tedious work, which not only increases the preparation cost of biosensors, but also
leads to poor reproducibility of the results among laboratories. In order to simplify the biosensor
construction procedure, future research should increase the reaction efficiency of 2D nanomaterials
with biomolecules (such as an antibody and apatmer) and decrease unreacted activity groups on the
surface of 2D nanomaterials after biomolecule immobilization. Furthermore, development of automatic
methods for modification of 2D nanomaterials on the electrode surface may help to increase the
inter-laboratory reproducibility of biosensors. (2) The properties of 2D nanomaterials, including their
electrical conductivity, PEC conversion capability and biomolecule immobilization capacity, are strongly
dependent on their morphology, such as shape, size, purity, and defects. Therefore, 2D-nanomaterials
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should be fully characterized before biosensor fabrication. In further research, researchers are
strongly encouraged to establish the synthesis standard of 2D-nanomaterials in order to improve the
reproducibility of 2D nanomaterial-based electrochemical biosensors. In addition, the as-proposed
synthesis strategy should be easily employed to produce 2D-nanomaterials on a large-scale by simply
adjusting the synthesis conditions, such as increasing the amount of reactants. This factor is very
important for industrialization of the 2D nanomaterial-based electrochemical sensors. (3) To date,
one kind of 2D nanomaterial-based electrochemical biosensor is merely confined to determine a single
microbial toxin. Because of coexistence of various microbial toxins in nature, future research should
focus on development of a universal biosensor production technology for enabling rapid analysis of
various toxins. (4) In order to achieve large-scale application, in particular for on-site monitoring,
further efforts should be directed toward the development of 2D nanomaterial-based electrochemical
biosensors, which can be used to detect toxins in practical samples such as various agricultural, food
stuff, body fluids, and environmental sectors (e.g., lake water and sea water). The practicability of 2D
nanomaterial-based electrochemical biosensors could be improved through integration of the biosensor
with other techniques such as microfluidic devices and microarrays because miniaturization will help
to increase the detection throughput, e.g., recognize multiple elements simultaneously. (5) Currently,
aptamers and antibodies are mainly used for recognition of the toxins. In order to obtain high selectivity,
the key epitope residues of the aptamer and antibody should be unrestrained after immobilization on
the 2D nanomaterials. In addition, the molecular structures of the aptamer and antibody are sensitive
to the environmental conditions (such as temperature, ionic strength and interferences from sample
matrices). The high apparent affinity of the aptamer and/or antibody could be achieved through
immobilization of the aptamer and/or antibody by stereoselective reactions (e.g., chick chemistry,
DNA hybridization, biotin-avidin recognition). In addition, future research should aim to increase the
biocompatibility of 2D nanomaterials. Finally, we expect commercialization of 2D nanomaterial-based
electrochemical biosensors into practical procedures for detecting multiple toxins in practical samples
through efforts of researchers in different disciplines, which would give significant benefit to the public.
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